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This thesis details the synthesis of various libraries of silver(I)-N-heterocyclic 
carbenes (Ag(I)-NHCs) that are derived from natural and/or biologically relevant 
non-toxic precursors. The complexes have been evaluated as potential classes 
of chemotherapeutic agents. Furthermore, the use of polymers for 
encapsulating the Ag(I)-NHC complexes was investigated for drug-delivery, and 
a unique biological membrane has been used to examine the interaction of the 
complexes with a membrane monolayer.  
Ag(I)-NHC complexes derived from the xanthine precursors caffeine, 
theophylline and theobromine were evaluated for anticancer activity against 
eight cancerous cell lines, revealing IC50 values in the micromolar range. 
Hydrophobicity measurements revealed that a fine balance of steric bulk around 
the Ag-carbene bond and water solubility of the complex is required for the 
antiproliferative activity. Complexes derived from the antifungal compound 
clotrimazole were prepared. Various trends are discussed which relate 
cytotoxicity to hydrophobicity, N-substitution on the carbene ligand, 
counteranions, and substitution on the phenyl ring of clotrimazole. Selectivity 
ratios for these complexes were calculated which revealed that complexes with 
N-hydroxyethyl substituents on the ligand, which exhibit IC50 values similar to 
those obtained for cisplatin, had excellent selectivity. Water-soluble complexes 
bearing alcohol or carboxylic acid N-substituents on the ligand were prepared 
from biologically relevant precursors. Hydrophobicity measurements and in vitro 
cytotoxicity studies revealed similar hydrophobicity-cyctotoxicity trends to those 
obtained for the clotrimazole-derived complexes. Overall, the results indicate 
that intermediate lipophilicity is results in high antiproliferative activity. 
Encapsulation of the Ag(I)-NHC complexes inside polymers via different routes 
was investigated using non-toxic polyethylene glycol (PEG)-based polymers. 
Dynamic light scattering (DLS) and scanning electron microscopy (SEM) studies 
suggested successful encapsulation and/or coordination of the complexes with 
the particles. In some cases, it was found that the cytotoxicity of the complexes 
increased upon encapsulation with a polymer. Various Ag(I)-NHCs were 
screened using a unique biological sensor that detects the interaction of the 
complexes with a membrane monolayer. The results gave insight into the 
possible mechanism of action of the complexes through their ability to interact 
with biological membranes. Further development of this technique may provide 
a valuable pre-screen for drug molecules, prior to more costly and time-
consuming cell work. 
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Chapter 1                                                                       
Introduction 
1.1 Overview 
This thesis is focussed on the synthesis and in vitro anticancer activity of 
silver(I)-N heterocyclic carbene (Ag(I)-NHC) complexes, the use of polymers for 
the encapsulation of these complexes with the purpose of targeted delivery to 
cancerous cells, and the use of a novel biosensing device to detect the potential 
effects of Ag(I)-NHCs on a biological membrane. This chapter introduces the 
field of NHCs, with a focus on Ag(I)-NHCs, discussing biological applications 
and reviewing reported anticancer properties. 
 
1.2 Carbenes 
Carbenes are uncharged compounds with a divalent carbon atom that has only 
six electrons in its valence shell.1 Two of the electrons are uninvolved in bonding 
and can be assigned to two nonbonding orbitals. The carbon atom of a carbene 
can be either linear or bent, depending on the hybridisation at the carbenic 
centre.1, 2 A linear geometry indicates an sp-hybridised carbene centre with two 
nonbonding degenerate orbitals (px and py). The bent molecule breaks this 
degeneracy and the carbon atom adopts sp2-type hybridisation, with the py 
orbital remaining almost unchanged (it is usually called pπ), and the px orbital 
being stabilised since it acquires some s character (it is therefore called σ). Most 
carbenes are bent and their frontier orbitals are called σ and pπ , whilst the linear 
geometry is a rare case (Figure 1.1).2 
 
 
Figure 1.1: Correlation between bond angle and orbitals in a carbene2 
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Free carbenes are characteristically unstable due to their incomplete electron 
octet and coordinative unsaturation. Preparation of the first isolable carbene 
was reported by Bertrand and co-workers,3 by stabilisation through interactions 
with neighbouring phosphorus and silicon atoms. Inspired by the structures of 
metal-carbene complexes by Öfele4 and Wanzlick5, Arduengo6 succeeded in 
isolating the first free NHC. 1,3-Di(adamantyl)imidazol-2-ylidene was isolated 
through the deprotonation of an imidazolium salt bearing bulky adamantyl N-
substituents using NaH and catalytic amounts of the dimsyl anion (Scheme 
1.1).6 
 
Scheme 1.1: Synthesis of the first free N-heterocyclic carbene (NHC)6 
 
1.3 Metal-carbene bond 
Metal-carbenes are categorised into Fischer and Schrock carbenes. Fischer 
carbene complexes are compounds that have a heteroatom linked to the 
carbenic carbon, and are usually associated with a metal in a low oxidation 
state, π-acceptor ligands, and electrophilic character at the carbenic carbon. 
Schrock carbene complexes (also referred to as alkylidenes) are compounds 
with alkyl groups or hydrogen atoms adjacent to the carbene centre, and are 
usually associated with higher oxidation state metal atoms, a variety of ligands 
(usually free molecules that are not closed shell species), and nucleophilic 
character at the carbenic carbon.7  
 
1.3.1 Fischer carbenes 
Fischer carbene complexes such as aminocarbenes and alkoxycarbenes have 
a substantial energy gap between their singlet and triplet ground states and are 
therefore well-stabilised singlet carbenes.2 These compounds form a metal 
carbon bond by mutually exchanging electrons (donor–acceptor interaction) 
from singlet closed shell orbitals found in both the carbene and the metal.  The 
main interaction in this bond is the carbene-metal σ-donation (Figure 1.2). The 
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other interaction is the metal-carbene π-back donation, where the π-electrons 
are generally polarised toward the metal. This character is diminished by the 
stabilisation of the carbene through its donating α-groups.8, 9 The π-back 
donation from the metal in diaminocarbenes (including NHCs) is weak since the 
carbenic carbon is already stabilised by π-donation from its α-amino-groups. 
Fischer carbene complexes are electrophilic at the metal-carbon bond and are 
therefore susceptible to nucleophilic attack at the carbene centre.10, 11 The early 
synthesis of carbenes was first established by Skell in the 1950s, and they were 
introduced into inorganic and organometallic chemistry by Fischer and his 




Figure 1.2: Fischer carbene metal-carbon bond9 
 
1.3.2 Schrock carbenes 
Schrock carbenes such as dialkylcarbenes or alkylidenes have a small gap 
between their singlet and triplet ground states and are therefore weakly 
stabilised carbenes. Their metal-carbene bond is formed through the interaction 
of triplet orbitals of both the carbene and metal (Figure 1.3). Their metal-carbon 
bond is viewed as a double bond as the π-electrons are equally distributed 
between the carbon and the metal. They are nucleophilic at the carbene centre 




Figure 1.3: Schrock carbene metal-carbon bond9 
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1.4 N-Heterocyclic carbenes 
NHCs are heterocycles with a bent carbene centre and at least one adjacent 
nitrogen atom.2, 9 The σ-withdrawing effect (inductive) of the two α-amino 
substituents stabilises the sp2-hybridised σ orbital containing a lone pair of 
electrons. The α-amino lone pairs are meanwhile donated into the vacant p-
orbital (mesomeric effect), destabilising it. The electroneutrality at the carbene 








Transition metals-NHCs are used as catalysts in cross coupling reactions,16-21 
olefin metathesis22, 23 and  hydrogenation reactions24 among many other 
catalytic processes.1, 25, 26 Metal-NHCs are also used as substrates for the 
development of organometallic materials27-29 including polymers30 and 
photoactive materials.31 Medicinal applications of metal-NHCs include 
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Co-ordination of NHCs to transition metals is owed to their strong σ-donor 
ability. However, σ-donation is not the only orbital contribution in the metal-NHC 
bond, both d→π* (metal to NHC) back donation as well as π →d (NHC to metal) 
donation are also present (Figure 1.5).9, 34, 35 Since σ-donation is the major 
orbital contribution, the metal-NHC bond is depicted as a single rather than a 
double bond. NHCs are therefore strong σ-donors and weak π-acceptors, with 
coordination properties similar to those of phosphines to which they are usually 
compared to in the literature.36   
 
 
              
 
Figure 1.5: Three orbital contributions in M-NHC bond, NHC→M σ-donation, 
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1.6 Metal-NHCs as anticancer agents  
Since the discovery of cisplatin in 1965 (Figure 1.6),37 metallo-based drugs 
have gained significant attention for the treatment of cancer. Auranofin, a Au-
based anti-rheumatic drug, was recently reported effective against a cisplatin-
resistant ovarian cancer cell line.38 Metal-NHCs have shown potential as 
anticancer agents and are a fast growing field of research.39 Although Pt-
NHCs40-42 and Au-NHCs 43-54 have been the main focus in this area, Ag-NHCs 
are rapidly emerging.55 Ag-NHCs with anticancer properties possibly bind to the 
same biological targets as Au-NHCs, in particular  Se-containing enzymes e.g. 
Thioredoxin reductase (TrxR).56  Ru-NHCs,57-61 Pd-NHCs,62-64 and Cu-NHCs65 
have also been reported for their potential use as anticancer agents. 
 
                                  
                     Cisplatin                                           Auranofin 
 
Figure 1.6: Structures of cisplatin and auranofin 
1.6.1. Gold-NHCs as anticancer agents 
Barnard et al. reported Au(I)-bis(NHC) complexes that induce Ca2+ sensitive 
Mitochondrial Membrane Permeation  (MMP) causing mitochondrial swelling 
and subsequent cell death.66  Baker and co-workers reported simple cationic 
Au(I)-bis(NHC) (Au1, Figure 1.7) that also caused mitochondrial swelling, and 
correlated the antitumor activity to the lipophilicity (calculated as Log P) of the 
complexes.67 Hickey et al. studied cationic Au(I)-bis(NHC) complexes with the 
same general structure as Au1 that also target mitochondria by selectively 
binding to selenol-over thiol-containing proteins. This is reflected in one of the 
complexes which selectively inhibits 50% activity of TrxR (a selenoenzyme) at 
5 μM concentration while showing no effect on glutathione reductase (GR, a 
thiol based enzyme).56 Inhibition of TrxR leads to apoptosis of cancer cells, and 
as these complexes do not do not inhibit GR, normal cells are not affected.56 
Hovarth and co-workers suggested the  selective cytotoxicity towards cancerous 
cells of Au(I)-NHC complex Au2 is due to the incorporation of the ferrocene 
moiety.68 Recently, Bertrand et al. reported caffeine based Au(I)-NHC 
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complexes, including one neutral complex, Au3 and cationic Au(I)-bis(NHC) 
complexes, with the general structure Au4, (Figure 1.7). Although they were 
less active than cisplatin, one complex (R = H) was 2-fold more potent than 
cisplatin against the cancerous cell line A2780/R.69 Two Au(I)-NHC complexes, 
Au5 and Au6 (Figure 1.7), one containing 2,3,4,6-tetra-O-acetyl-1-thio-β-D-
pyranosatothiolato and the other a saccharin ligand, were reported as potential 
anticancer agents by Fremont et al.70 Tacke and co-workers more recently 
tested saccharine containing complexes Au7-Au9 against breast cancer cell 
line MCF-7, revealing higher potency compared to cisplatin.71  Lemke et al. 
reported two amino acid containing Au-NHC complexes, Au10 and Au11,  that 
show good antitumor activity compared to the non-amino acid derivatives.72  
 
Figure 1.7: Au-NHC complexes that display chemotherapeutic properties56, 68-
72 
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1.6.2 Platinum-NHCs as anticancer agents 
Skander et al. explored the anticancer activity of twelve Pt(II)-NHC complexes 
with the general structures Pt1-Pt5 (Figure 1.8).40 Most complexes were 
reported to be significantly more potent than cisplatin, and a few showed activity 
against cisplatin resistant cell lines.40 Sun and co-workers revealed the ability of 
cyclometalated Pt complexes to accumulate in the cytoplasm, with Pt6 showing 
200 fold higher affinity towards human carcinoma cell line HeLa than the non-
cancerous human lung fibroblast cell line CCD-19Lu .41 A library of amino Pt-
bis(NHC)s with general structure Pt7 that are all more potent than cisplatin 
against many cancerous cell lines (KB3-1, SK-OV3, OVCAR-8, MV-4-11, and 
A2780) were reported by Chtchigrovsky and co-workers.73 Caffeine-based Pt-
NHC, Pt8, reportedly exhibits antitumor properties.74 The mechanism of action 
of Pt-NHC complexes in general has been found to be similar to that of cisplatin, 
where the complex intercalates with the two strands of DNA, inhibiting DNA 
growth and inducing cell apoptosis. The difference in mechanism between Pt-
NHC complexes and Au-NHC complexes is illustrated in Figure 1.9,39 
displaying the accumulation of Au-NHC in the mitochondria, leading to 
mitochondrial disruption through inhibiting mitochondrial enzymes.  
 
Figure 1.8: Pt(II)-NHC complexes that display chemotherapeutic properties41, 
73, 74































Figure 1.9: Mechanisms of action of Au-NHCs and Pt-NHCs that lead to apoptosis.39 Au-NHCs (yellow circles) through 
mitochondrial accumulation (green route), and Pt-NHCs (white circles) through DNA binding (blue route)
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1.6.3 Palladium, ruthenium and copper-NHCs as anticancer agents 
Two Pd(II)-NHC complexes, Pd1 and Pd2 (Figure 1.10), were tested for 
antitumor activity.75 Pd2 showed potent anticancer activity against cervical 
cancer HeLa cells, being more potent than cisplatin, as well as its corresponding 
Au and Ag complexes. Haque et al. compared the anticancer activities of two 
Pd(II) NHC complexes, Pd3 and Pd4, to that of 5-fluorouracil (5-FU) and 
reported that only the trans geometry of these complexes exhibited 
cytotoxicity.76  
Various Ru(II)- and Ru(III)-NHC complexes have revealed promising anticancer 
properties.57, 58, 60, 61, 77, 78 For example, Oehninger et al. reported Ru(II)-NHC 
complex Ru1 to show good cytotoxicity, by reported inhibition of selenol 
containing enzymes such as TrxR.61 Tacke and co-workers also reported six 
Ru(II)-NHC complexes of general structures Ru2 and Ru3 that showed higher 
potency than their corresponding Au(I)-NHC complexes against Caki-1 and MCF-
7.65 Four Ru(II) Ƞ6 – arene imidazole complexes Ru1 and Ru4-Ru6 were reported 
to have anticancer properties, with complex Ru4 having 3 fold more toxicity 
towards cancer cells compared to non-cancerous cells.78 Gallori et al. report the 
DNA binding ability of NAMI-A Ru5, thus providing a potential mode of action to 
explain its potent cytotoxicity.57  Further investigation into complex Ru5 and Ru6 
revealed their ability to induce DNA unwinding, and revealed the role of Ru5 in 
selective metastatic cell targeting and binding to collagen.77 Two bis-imidazole 
DMSO containing complexes Ru7 and Ru8 displayed antiproliferative and 
antimetastatic activity by arresting the cell cycle in G0/G1 phase, thus inducing 
apoptosis.60 
Teyssot et al. investigated the anticancer properties of seven Cu(I)-NHC 
complexes including Cu1 and Cu2 and their saturated imidazole  analogues, 
which were all more potent (IC50 = 0.04 - 4.4 µM) than the activity of cisplatin (IC50 
= 10.4 µM)  against the breast cancer cell-line MCF-7.79 Tacke and co-workers 
reported the synthesis of ten biologically active symmetrically and non-
symmetrically p-benzyl substituted Cu(I)-NHC bromide complexes of general 
structure Cu3 and Cu4.80 The iso-propyl substituted Cu(I)-NHC complexes 
showed better cytotoxicity than the remainder of the complexes against both 
breast cancer cell-line MCF-7 and renal cancer cell-line Caki-1. One Cu(I)-NHC 
complex with iso-propyl and methoxy substitutents on the benzyl groups revealed 
superior cytotoxicity to cisplatin.  
 




Figure 1.10: Pd(II)- ,75, 76 Ru(II, III)- ,57, 58, 60, 61, 77, 78 and Cu(I)-NHC79, 80 
complexes that exhibit cytotoxic behaviour 




Various NHC-type ligands have been used to complex silver, including 
imidazolin-2- ylidene (A), benzimidazol-2-ylidenes (B), imidazolidin-2-ylidenes 
(C) tetrahydropyrimid-2-ylidenes (D), 1,2,4-triazolin-5-ylidenes (E) and 
imidazolin-4(5)-ylidenes (F) (Figure 1.11).81-88 Transmetalation reactions of 
NHCs from silver to other metals have been reported for the synthesis of a broad 
range of transition metals: Au(I), Cu(I), Cu(II), Ni(II), Pd(II), Pt(II), Rh(I), Rh(III), 
Ir(I), Ir(III), Ru(II), Ru(III), and Ru(IV).89 
           
 
Figure 1.11: NHCs that have been coordinated to silver81-88 
1.7.1 Preparation of silver(I)-NHCs 
The first Ag(I)-NHC complex to be structurally characterised was prepared by 
reaction of a free carbene with a silver salt.81 In 1997, the formation of a Ag(I)-
NHC complex formed by reaction of a triazolium salt with silver acetate was 
reported.82 The most popular current method for the preparation of Ag(I)-NHCs 
was reported in 1998 by Lin and Wang, using Ag2O as both the base and 
metallating reagent.83 Ag(I)-NHCs can be synthesised from imidazolium salts in 
several different ways, with four common methods highlighted below: 
1. Preparation of a free carbene followed by reaction with a silver salt e.g. silver 
triflate (Scheme 1.2).81, 90-92 
 
 
Scheme 1.2: Synthesis of Ag(I)-NHC by reacting a free carbene with a silver 
salt81 
CHAPTER 1                                                                  UNIVERSITY OF LEEDS                         
13 
 
2. Reaction of imidazolium salts with basic silver reagents in situ e.g. Ag2O, 
AgOAc, or Ag2CO3 (Scheme 1.3).82, 83, 85-88, 93, 94 
Silver oxide is the most commonly used basic metal to prepare NHCs, as the 
reaction time is relatively short and can be monitored by the uptake of the 
insoluble Ag2O. A range of solvents have been used with Ag2O in the synthesis 
of Ag-NHCs, including CH2Cl2, 1,2-(CH2)2Cl2, DMSO, (CH3)2CO, MeOH, MeCN, 
DMF, H2O and also solvent mixtures. Most of these reactions proceed at room 
temperature, however, it was found that silver oxide reactions with bulky 
imidazolium salts often require heating. This suggests that steric bulk around 
the imidazolium cation affects the ability of the silver oxide to effectively 
deprotonate the imidazolium salt. Molecular sieves were reportedly used in 
some such reactions as they speed up the rate of the reaction (H2O is 




Scheme 1.3: Synthesis of Ag(I)-NHC complexes by reaction of imidazolium 
salts with basic silver reagents A. Ag2O,83 B. AgOAc,75, 80 and C. Ag2CO394 
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3. Reaction of an imidazolium salt with a base in the presence of silver salt.83 
A method using a phase transfer catalyst to synthesise a Ag(I)-NHC from the 
benzimidazolium salt in the presence of AgBr is shown in Scheme 1.4. This 
provides the same products as the silver oxide route (Scheme 1.3A). However, 
this method did not work with other imidazolium salts.83, 94 
 
Scheme 1.4: Synthesis of Ag(I)-NHC by reacting imidazolium salt with a base 
in the presence of silver salt83 
4. Transmetallation from W-NHC on to silver.84  
The Ag(I)-NHC complexes synthesised from this method were moisture 
sensitive and quickly decomposed to the imidazolium salt when exposed to air. 
This method has been discarded due to the success of silver oxide.84, 110, 111  
One main purpose of synthesising Ag(I)-NHCs is to transfer the NHC ligand to 
other transition metals. Some metal-NHC complexes can be synthesised by 
deprotonation of the imidazolium salt using a strong base, and then reaction with 
the desired metal. However, many compounds do not metalate due to 
degradation under the required harsh conditions. As mentioned previously, Ag(I)-
NHC complexes has been successful at transferring to a variety of other metals 
(Scheme 1.5). Transmetallation reactions are generally carried out under aerobic 
conditions and can occur in the presence of water. Since synthesising Ag(I)-NHC 
complexes and transferring them to other transition metals is reasonably facile, 
this route is more commonly used than other routes which require anaerobic 
conditions.93, 101, 103, 106, 112-122  
  
Scheme 1.5: Transmetallation from Ag to A. Au and B. Pd114, 118, 123 
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1.7.2 History of silver in medicine 
For centuries, metallic silver was used as an antimicrobial agent to purify 
drinking water and used medicinally to cure ailments.124-130 Wounds and 
infectious diseases were treated with silver nitrate, even before the discovery of 
bacteria. Following the discovery of bacteria, silver nitrate was used to minimise 
bacterial growth on burns patients. Later on, dilute solutions of silver nitrate were 
dropped into the eyes of new-born babies to prevent conjunctivitis and other 
bacterial infections that might be contracted during birth. Silver sulfadiazine 
(Figure 1.12), discovered in the 1960s, was found to be more effective and safer 
than silver nitrate in treating burn wounds and is currently the most widely used 
remedy in American burn centres. Since silver-based therapeutics can be used 
for the treatment of burns, open wounds and chronic ulcers, the interest in 
developing silver-based NHCs from this area was initiated. Silver is considered 
nontoxic to mammalian cells within the determined exposure limits (0.01-0.1 
mg/m3),131, 132 due to however, silver compounds may cause skin discoloration, 
known as Argyria.133 Therefore, the ideal silver compound is one that slowly 
releases silver into the wound and traps it in the wound without discoloration, 
thus maintaining a constant source of antimicrobial agents to prevent re-
infection.89 Recently, the interest in silver as an antibacterial re-emerged in the 
form of silver nanoparticles,134-136 introduced in various forms, including silver-
based dressings, silver-coated textile fabrics and silver-coated medicinal 
devices such as nanogels and nanolotions.134, 137 The mechanism of action of 
silver as an antimicrobial, and the role of ‘Ag+ ions release’ is under debate, and 
in an attempt to resolve it, Liu et al. evaluated the release of Ag+ ions under 
aerobic and anaerobic conditions, concluding the release of Ag+ ions from 
nanoparticles occurs exclusively in the presence of oxygen (Scheme 1.6).138 
Further research is required to end the ongoing debate and to determine the 
role of silver in bacterial cells as well as cancerous cells. 
 
Figure 1.12: Structure of silver sulfadiazine 
 
4Ag(0) + O2 →  2Ag2O  →  4Ag+ + 2H2O 
Scheme 1.6: Release of Ag+ ions from nanoparticles under aerobic 
conditions138 
4H+ 
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1.7.3 Silver(I)-NHCs as antibacterial agents 
Currently, Ag(I)-NHC complexes are the most widely studied type of metal-
NHCs in the field of anti-infectives. Two pyridine-linked pincer Ag(I)-NHC 
complexes Ag1 and Ag2  (Figure 1.13) were found to be active against E. coli, 
S. aureus and P. aeruginosa, with minimum inhibitory concentration values 
lower than that of AgNO3.139 It is thought that the complexes slowly release Ag+ 
ions into the culture medium, however, the distribution of the bioavailable active 
species responsible for the antimicrobial properties is unknown. The 
encapsulation of Ag(I)-NHC complexes in nanoparticles or nanofibres has been 
reported.140-143 One example is Ag3 (Figure 1.13), which has been 
encapsulated into an electro-spun polymer and the antimicrobial properties of 
this polymer were studied.140 It was found that the encapsulation of Ag(I)-NHC 
complexes into fibre mats resulted in improved antimicrobial activity, faster kill 
rate, and increased bioavailability of the active silver species when compared 
to silver sulfadiazine or silver nitrate. However, the decomposition of the Ag(I)-
NHC complex not only releases cationic silver but also the imidazolium salt, 
which was found to be relatively toxic in this case.140-143 This highlights the 
importance of utilising non-toxic imidazolium salts as ligand precursors. 
 
       
 
Figure 1.13: Antibacterial pyridine-linked pincer Ag(I)-NHC complexes (Ag1, 
Ag2),139  and antimicrobial Ag(I)-NHC that has been encapsulated in 
nanoparticles(Ag3)140 
 
CHAPTER 1                                                                  UNIVERSITY OF LEEDS                         
17 
 
Biologically benign precursors such as the xanthine derivatives caffeine and 
theobromine, that are commonly found in the body, have been utilised for the 
synthesis of Ag4 and Ag5 (Figure 1.14).98 Complexes Ag4-Ag8 were effective 
against highly resistant opportunistic pathogens recovered from the respiratory 
tract of patients with cystic fibrosis as well as against E. coli J53.144-151 
Symmetric and non-symmetric Ag(I)-NHC complexes including Ag4-Ag8 were 
evaluated against both Gram-positive bacteria S. aureus and the Gram-negative 
bacteria E. coli. It was observed that the more lipophilic the compound is, the 
more it is able to penetrate the cell membrane effectively leading to better 
antibacterial activity.144-151 14 Halide containing Ag(I)-NHC complexes including  
Ag9-Ag11 were reported,152 and found to be active against E. coli, S. aureus 
and the resistant strains S.aureus NorA and S. aureus MRSA.152 
                                                                                                                                                                                                 
Figure 1.14: Ag(I)-NHC acetate complexes145, 146, 150 and halide-containing 
Ag(I)-NHC152 complexes that display antibacterial properties 
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1.8 Silver(I)-NHCs as anticancer agents 
The medicinal applications investigated for Ag(I)-NHC complexes has mainly 
involved their use as anti-infectives (section 1.7.3). However, more recently, a 
number of groups have reported cytotoxic effects of Ag(I)-NHCs against cancer 
cells. 79, 129, 146-150, 152-161 The mechanism of action of Ag(I)-NHC complexes in 
cancer remains unknown, however, their cellular targets appear to be similar to 
those of Au(I)-NHC complexes, i.e. target mitochondrial enzymes (Figure 1.9). 
This is possibly due to the affinity of both Ag and Au to sulfur-containing 
enzymes such as thioredoxin reductase and glutathione reductase which are 
overexpressed in cancerous cells. For example, TrxR, a sulfur-containing 
enzyme found in both the cytoplasm (TrxR1) and the mitochondria (TrxR2), has 
been reported to be inhibited by Ag(I)-NHC complex Ag12 (Figure 1.15).158 
Youngs and co-workers described the benefits of encapsulation of Ag(I)-NHC 
complexes into polymeric nanoparticles (NPs).129 Water-soluble complexes 
seemingly improved the encapsulation into nanoparticles (NPs) as the 
encapsulation is performed in water, therefore the higher the water-solubility of 
the complex the higher the encapsulation. The NPs were reported to provide 
good resistance against biological inactivation of the Ag(I)-NHC complex from 
sulphur containing enzymes such as glutathione reductase. The NPs also make 
use of  the ‘leaky’ blood vessels near the tumour, referred to as enhanced 
permeability and retention, or EPR effect of tumour tissue.129 The enhanced 
permeability part of the cancerous tissue EPR effect allows the entrance of 
macromolecules such as NPs, while the reduced retention through the 
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A series of mono- and binuclear Ag(I)-NHC complexes with different xylyl 
spacers have been synthesised and their anticancer activity reported (Figure 
1.16).153 Ag14-Ag16 showed good anticancer activity against human colorectal 
HT116, with IC50 values (Ag14 = 1.3µM, Ag15 = 1.1µM, Ag16 = 0.9µM) five 
times lower than 5-fluorouracil (5µM) while the value for complex Ag13 (5.4µM) 
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Two simple Ag(I)-NHCs Ag17 and Ag18 were synthesised (Figure 1.17), and 
their anticancer activities were tested on H460, a lung cancer cell line, revealing 
anticancer efficacies comparable to that of cisplatin.154 The cytotoxicity of Ag(I)-
NHC Ag19 was tested on 6 different human cancerous cell lines (KB: oral 
carcinoma, HL60: promyelocytic leukaemia, HL60R: resistant HL60, MCF-7: 
breast cancer, MCF-7R: resistant MCF-7, T47D: breast cancer), revealing 
higher cytotoxicity than cisplatin on all the cell lines.79 Ag19-Ag23 were 
evaluated against MCF-7, a breast cell line, to study the effect of the ligand. 
Increasing the stability of the ligand by either increasing the steric hindrance 
around the metal (Ag19 versus Ag21) or by decreasing its saturation (Ag19 
versus Ag20) increased the cytotoxicity ten-fold. Another observation was that 
having a large substituent on the imidazole ring (Ag23) exhibits lower IC50 than 
that of cisplatin (Table 1.1).79 This is possibly due to the bulkiness of the 
substituent, which may lead to a slow and prolonged release of Ag+ ions.  
 
Figure 1.17: Ag(I)-NHCs with reported anticancer activity against lung cancer 







Table 1.1: IC50 values of complexes Ag19-Ag23 against 
MCF-7 compared to cisplatin79 
Complex cisplatin Ag19 Ag20 Ag21 Ag22 Ag23 
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Three Ag(I)-NHC acetate complexes (Ag24-Ag26, Figure 1.18),145 silver 
nitrate, and silver acetate were reported to exhibit anticancer activity against the 
cancer cell lines OVCAR-3 (ovarian), MB157 (breast), and Hela (cervical). 
However, their anticancer activity was found to be less potent than cisplatin. All 
three complexes showed higher activity against the breast cancer cell line over 
the ovarian cell line.160 A series of monodentate, bidentate and macrocyclic 
cationic Ag(I)-bis(NHC) complexes Ag27-Ag30 were synthesised and their 
cytotoxicities tested against human breast adenocarcinoma MCF7 and the 
colon adenocarcinoma DLD1 cell lines. The complexes exhibited higher 




Figure 1.18: Ag(I)-NHC acetate, 160  and Ag(I)-bis(NHC) complexes155  with 
anticancer properties 
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A number of  Ag(I)-NHC complexes (general structures Ag31-Ag33, Figure 
1.19) displayed IC50 values similar to those obtained for analogous Au or Pt-
NHC complexes, and lower than those obtained for established cytotoxic drugs 
such as 5-fluorouracil.153-156, 160 Molecular studies revealed the ability of three 
complexes with general structure Ag34 to accumulate in the mitochondria and 
depolarise the mitochondrial membrane.159 This induces apoptosis through 
damage of the endoplasmic reticulum and cytosolic translocation of the 
apoptotic inducing factor (AIF) from the internal part of the mitochondrial 
membrane.159 Moreover, the potential of Ag32 to strongly inhibit TrxR activity 
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The cytotoxicity of Ag(I)-NHC acetate complexes Ag35 and Ag36 (Figure 1.20) 
were evaluated against the human cancerous renal-cell line Caki-1. Symmetric 
and asymmetric Ag(I)-NHC bromide complexes Ag37 and Ag38 were reported 
and their cytotoxicity evaluated against the human cancerous renal cell line 
Caki-1.  For Ag35, the complex R = H (IC50 = 13.5µM ± 2.0), showed superior 
anticancer activity to its corresponding R = Cl (IC50 = 68.3µM ± 1.0) complex, 
while for Ag38 , the complex R = H (3.3µM±0.4) revealed the highest cytotoxicity 
with IC50 value similar to that obtained for cisplatin (3.3µM), higher than its 
corresponding R = Bn (IC50 = 13.2µM ± 1.0)  and comparable to its Au(I) 
counterpart.149 These results show the importance of hydrophobic substituents 
such as benzyl groups in anticancer activity, however additional hydrophobic 
groups (e.g. Cl or Bn) leads to a decrease in cytotoxicity, and therefore 
suggesting that a balance in hydrophobic substituents is ideal for anticancer 
activity. Based on the success of previously reported benzimidazole-derived 
Ag(I)-NHCs as anticancer agents,146 two more were synthesised (general 
structure Ag39) by Haque et al.157 IC50 values of Ag39 (13.9-14.6µM) although 
higher, were comparable to those obtained for 5-fluorouracil (5µM) against HCT 
116 cell line. 
 
Figure 1.20: Ag(I)-NHC acetate complexes, symmetrically and 
unsymmetrically benzyl- or 4 cyanobenzyl-substituted bromo complexes and 
benzimidazole-derived Ag(I)-NHCs that exhibit anticancer activity157 
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Fourteen Ag(I)-NHC complexes, Ag11 and Ag40-Ag42 (Figure 1.21) were 
previously reported for their antibacterial properties against E. coli and S. 
aureus, and for their in vitro cytotoxicity against MRC5 cells, which are human 
noncancerous cells in rapid proliferation (secondary human lung fibroblasts).152 
Promising cytotoxicity against MRC5 cells in bactericidal concentrations 
encouraged Roland et al. to further investigate the anticancer activity of these 
complexes against different cancerous cell lines.159 Initially the complexes were 
tested against KB cells (human carcinoma of the nasopharynx) at two 
concentrations, 10 µM and 1 µM. The IC50 values of the 5 most active Ag(I)-
NHC complexes Ag11a, Ag11b, Ag40d, Ag41a and Ag41b were subsequently 
evaluated against KB cells, all showing superior cytotoxicity compared to 






                           
Figure 1.21: Ag(I)-NHC complexes evaluated for their anticancer activity 159 
Table 1.2: IC50 values (µM) of five Ag(I)-NHC complexes against KB cells159 
Complex Ag11a Ag11b Ag40d Ag41a Ag41b cisplatin 





a b c d 
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1.9 Project aims 
The aim of this project is to synthesise libraries of Ag(I)-NHC complexes from a 
variety of non-toxic, naturally-derived and/or biologically relevant ligand 
precursors. Examples of naturally-derived precursors include xanthine 
derivatives, caffeine, theophylline and theobromine, and amino acid L-alanine. 
An example of a biologically benign precursor is the non-toxic, imidazole-based 
antifungal compound clotrimazole. The cytotoxicity of the complexes against 
various cell lines will be evaluated using MTT-based assays, with the aim of 
establishing structure-activity relationships (SAR). Studies conducted on both 
cancerous and non-cancerous cell lines can give insight to the selectivity of 
these complexes. Hydrophobicity measurements will be conducted on the 
complexes to determine their Log P values, which will aid in the understanding 
of how they are likely to be distributed inside the body, since a Log P value is a 
measure of how the complex partitions between aqueous and organic layers.  
Drug delivery is a major concern in pharmaceuticals, however, it has been rarely 
been addressed for organometallic drugs. Therefore, developing carriers that 
can selectively deliver the Ag(I)-NHC complexes to cancerous cells will be a 
focus in this work. The use of polymers as carriers or delivery vehicles for the 
Ag(I)-NHC complexes will be investigated, with the aim being to acquire 
maximum potency with minimal toxicity. Either chemical conjugation of the 
Ag(I)-NHC complexes to various polymers to form polymer-complex conjugates, 
or physical encapsulation of the Ag(I)-NHC complexes into polymeric micelles 
will be considered. Furthermore, screening of Ag(I)-NHC complexes and 
imidazolium salts using a unique electrochemical biosensing device, to evaluate 
their effect on a phospholipid monolayer, may help understand their mechanism 
of action, since the phospholipid monolayer mimics biological membranes. 
Determination of limit of detection (LoD) of complexes using this biosensing 
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Chapter 2  
Synthesis and anticancer activity of silver(I)-N-heterocyclic 
carbene complexes derived from the natural xanthine products 
caffeine, theophylline and theobromine 
 
2.1 Introduction 
Natural xanthine derivatives caffeine, theophylline and theobromine are found in 
cocoa beans and tea leaves, are readily available and have low toxicity.1 
Medicinally, xanthines have been used as central nervous system stimulants,2 
diuretics3 and smooth muscle relaxants.4-6 Caffeine has been consumed for 
centuries in different beverages, and its pharmacokinetics such as absorption and 
metabolism, including its demethylation to paraxanthine, theophylline and 
theobromine, are well studied (Figure 2.1).7, 8  
 
 
Figure 2.1: Metabolism of caffeine with its reported percentages of metabolites7 
 
As the aim of this project is to use natural precursors to synthesise Ag(I)-NHC 
complexes with non-toxic metabolites, caffeine theophylline and theobromine 
were used in the synthesis of imidazolium salts, which were subsequently 
deprotonated and coordinated to silver for cancer therapy.  
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2.2 Ligand synthesis 
Caffeine, theophylline and theobromine were used as precursors for the 
synthesis of imidazolium salts. Substitution on the second nitrogen of these 
xanthines was anticipated to be challenging due to the delocalisation (electron 
withdrawing) of electrons into the backbone dioxopyrimidine ring. This negative 
mesomeric effect (-M, Scheme 2.1) renders the unsubstituted nitrogen atom on 





Scheme 2.1: Mesomeric effect of caffeine9 
 
Contrary to caffeine, N-substituted imidazolium salts have a positive mesomeric 
effect (+M effect), where electrons are released from the dioxopyrimidine to the 
imidazolium ring (Scheme 2.2). This effect stabilises a subsequent metal-
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2.2.1 Imidazolium salts prepared from caffeine  
Caffeine was used to synthesise imidazolium salt L1, and according to a literature 
procedure by Youngs et al., heating caffeine at reflux with excess methyl iodide 
in DMF yields the desired 1,3,7,9-tetramethylxanthinium iodide.1 Several 
attempts to prepare the desired methylated imidazolium salt were made using 
Youngs procedure and modified conditions, including changes of solvent, 
temperature, reaction time, and equivalents of methyl iodide (Table 2.1).  
Reaction in acetonitrile yields the imidazolium salt after 48 hours of heating in a 
sealed vessel with 20 equivalents of methyl iodide (Table 2.1, entry 4).  Since 
methyl iodide is volatile and has a boiling point of 40°C, using a sealed system 
prevents its escape and increases pressure.  Changing the solvent to DMF and 
heating to 145°C resulted in an increase in yield slightly, even with less 
equivalents of methyl iodide (entry 5). This could be attributed to the higher 
solubility of caffeine in DMF though is likely due to the higher reaction 
temperature. Doubling the equivalents of methyl iodide in DMF increased the 
yield further to 61% (entry 6). Using a sealed system significantly increased the 
yield to 78% in DMF (entry 7). 
 
                                                   Caffeine                                    L1 
a sealed reaction vessel  b determined using isolated yield 
 
Table 2.1: Methylation of caffeine under different reaction conditions  








MeCN 10 90 24 0 
MeCN 20 90 24 0 
MeCN 20 90 48 0 
MeCN 20 90a 48 46 
DMF 10 145 24 51 
DMF 20 145 24 61 
DMF 20 145 a 24 78 
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The formation of imidazolium iodide L1 can be observed in the 1H NMR spectrum 
by the downfield shift of the carbon atom between the two nitrogen atoms of the 
imidazole / imidazolium ring (C1) (Figure 2.2). The C1 proton in caffeine, which 
appears at 8 ppm is shifted to 9.28 ppm in the imidazolium iodide, along with the 
presence of four singlet peaks between 4.2-3.2 ppm that correspond to the four 
methyl groups. L1 was further characterised using 13C{1H} NMR spectroscopy 
and HRMS. A peak corresponding to [M-I]+ is observed at m/z 209.1038 in the 
mass spectrum (ESI+).  
      
 
Figure 2.2: Overlay of the 1H-NMR spectra (300 MHz, DMSO-d6) of caffeine 
(top) and its methylated imidazolium iodide (bottom). Suppression of the H2O 
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Investigation into the use of other methylating agents in place of methyl iodide 
was carried out. The reaction of caffeine with 1.2 equivalents of dimethyl sulphate 
and methyl tosylate led to similar yields as 20 equivalents of methyl iodide 
(Table 2.2). Imidazolium salts L1.1 and L1.2 were successfully synthesised, 
however the products were sticky and challenging to purify and isolate, even after 
extraction of the product into CH2Cl2 and several re-crystallisations. Conversely, 
excess methyl iodide is easily removed from the solution by heating in vacuo to 
yield a white solid. Methyl iodide was therefore used going forward. 
 
Table 2.2 : Methylation of caffeine using different reagents to form 
imidazolium salts L1, L1.1 and L1.2 
 Methylating 
Agent 
Equivalents Imidazolium salt Yield (%)a 
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2.2.2 Imidazolium salts prepared from theophylline 
To synthesise imidazolium salts with a variety of N-substituents other than 
methyl, it was necessary to use theophylline as the precursor as opposed to 
caffeine. Efforts were made to alkylate caffeine using benzyl bromide and butyl 
iodide, including reactions in a sealed vessel in DMF and microwave reactions 
under pressure. These led to very poor yields of the desired imidazolium salts, 
which is likely due to the relatively low basicity of the nitrogen atom as shown in 
Scheme 2.1.The two nitrogen atoms on the imidazole ring of theophylline are 
unsubstituted, with one bearing an acidic proton. This can be deprotonated to 
render a nucleophilic nitrogen atom for substitution. It was possible to alkylate 
theophylline with both a benzyl and a butyl group, in the presence of a base, 
furnishing white solids P1 and P2 with yields in excess of 70% (Scheme 2.3). 
Following the substitution of the first nitrogen atom, the theophylline based ligand 
precursors P2 and P3 are similar to caffeine as three of the nitrogens of the 
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Methylation of P1 using methyl iodide under microwave conditions (17.5 bar) 
gave imidazolium salt L2 (Table 2.3).  All microwave reactions were prepared 
with 3 mL of DMF in microwave vessels fitted with a rubber seal. This rubber 
fitting allows pressure release in order to maintain the set pressure, and possibly 
results in loss of volatile methyl iodide. Increasing the reaction time from 20 to 30 
minutes at 100°C (Entries 1 and 2, Table 2.3) has minimal effect on the yield of 
L2 while increasing the temperature to 145⁰C does have a positive effect. 
Increasing the equivalents of methyl iodide from 20 to 30 (Entries 3 and 4) at 
145°C increases the yield from 36% to 54%. 30 equivalents of methyl iodide and 
a reaction time of 30 minutes furnishes 77% yield (entry 5). Treating P2 in the 
same manner as caffeine by heating in a sealed vessel in DMF with excess 
methyl iodide gave L2 in a yield of 87% (Scheme 2.4), while reaction with P3 
gave L3 in 20% yield. 
 
Table 2.3: Microwave reactions to synthesise imidazolium iodide L2  
 Temp (°C) Eq. CH3I Time (minutes) Yield (%)a   
1 100 30 20 6 
2 100 30 30 7 
3 145 20 20 36 
4 145 30 20 54 
5 145 30 30 77 
a determined by peak integrations in 1H NMR spectrum. 
 
 
Scheme 2.4: Synthesis of imidazolium salts L2 and L3 
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Alkylation of theophylline using benzyl bromide or butyl iodide, followed by 
methylation to form the imidazolium iodide can be monitored using 1H NMR 
spectroscopy (Figure 2.3). Upon alkylation, the resonances (4.23, 1.74, 1.21 and 
0.88ppm) corresponding to the nbutyl protons in P2 (Figure 2.3, middle) display 
the most substantial shift from theophylline (top). The proton on the C1 carbon 
and the methyl proton peaks only shift by 0.02-0.05 ppm. Significant shifts in the 
1H-NMR spectrum between P2 (middle) and L2 (bottom) can be observed; the 
proton on the C1 carbon shifts downfield from 8.09 ppm to 9.41 ppm in L2. The 
singlet peaks corresponding to the backbone methyl groups also shift downfield 
significantly, while the CH3 (0.88 ppm) and CH2 (4.23, 1.74 and 1.21 ppm) peaks 
of the nbutyl group only shift slightly.  
           
  
Figure 2.3: 1H NMR spectra (300 MHz, DMSO-d6) of theophylline (top), P2 
(middle) and L2 (bottom). Suppression of the H2O peak was performed, 
therefore peaks in the same region are correspondingly suppressed.        
Attempts to synthesise further imidazolium salts through reaction of P1 or P2 
with benzyl bromide or nbutyl iodide were unsuccessful, likely due to the weak 
basicity of the nitrogen atom of the imidazole as discussed previously. 
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Heating P3 at reflux with methyl tosylate results in imidazolium  L3.1 (Figure 2.4) 
in 35% yield. P2 was unreactive under the same reaction conditions, 
demonstrating that methyl iodide as a more effective and general methylating 
agent. Single crystals of L3.1 suitable for X-ray diffraction analysis were grown 
by the vapour diffusion of pentane into a concentrated solution of the ligand in 
CH2Cl2. It was found to crystallise in the triclinic crystal system, with the structural 
solution being performed in the space group P1. Inspection of the extended 
structure reveals the presence of π-π stacking between the benzene ring of the 
tosylate and the xanthine ring of the ligand (Figure 2.4). The xanthine ring and 
the tosylate are coplanar, while the benzyl group is significantly bent out of plane 
due to the neighbouring bulky tosylate counterion. Two molecules of L3.1 are 
present in the asymmetric unit.  
 
 
             
 
Figure 2.4: Molecular structure of L3.1. The molecular structure on the right 
depicts the π-π stacking interactions between the xanthine ring and the 
benzene ring of the tosylate. Ellipsoids are drawn at 50% probability and H 
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Single crystals of imidazolium salts L2 and L3 (Figure 2.5) were grown by vapour 
diffusion of n-pentane into concentration solutions of the ligands in CH2Cl2. While 
L2 was found to crystallise in the monoclinic crystal system with the structural 
solution performed in the space group Cc, L3 crystallised in the orthorhombic 
crystal system and the structural solution was performed in the space group 
Pna21. The trimethyl xanthine ring system in both ligands exhibit a planar 
geometry with both the benzyl in L3 and the butyl in L2 groups oriented out of the 
defined planes (Table 2.4).   
 
 
                           L2                                             L3 
Figure 2.5: Molecular structures of L2 and L3. Ellipsoids are drawn at 50% 
probability level and H atoms are omitted for clarity 
 
Table 2.4: Selected bond lengths and angles for L2, L3 and L3.1 derived 
from theophylline 
Bond lengths (Å) and angles (°) L2 L3 L3.1 
N1-C1-N2 113.4(11) 108.8(8) 110.2(3) 
N1-C6-C7 113.6(13) 108.2(9) 112.0(3) 
C1-N1-C6 129.0(12) 125.5(8) 123.0(3) 
N1-C1 1.344(16)   
 
1.285 (14) 1.313(5) 
N1-C6 1.484(18) 1.513(13) 1.487(5) 
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Although the benzyl group is seemingly slightly more restricted than the butyl 
group in the solid state structure, due to its flexibility it is not considered a bulky 
group hence will not in theory hinder the release rate of silver in solution. An 
aromatic ring that is directly attached to the imidazole would provide more steric 
protection and kinetic stabilisation of the Ag(I)-NHC bond, which may lead to a 
prolonged release of silver in vivo. Therefore, a phenyl derivative was 
synthesised using an Ullmann coupling reaction (Scheme 2.5). The reaction was 
initially performed with DL-proline as the ligand though no product was formed. 
Modification of the reaction by replacing DL-proline with isobutyryl cyclohexanone 




Theophylline                                                                     P4 (34%) 
 
Scheme 2.5: Synthesis of phenyl substituted ligand precursor P4 from 
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Methylation of P4 to form L4 was performed in both a sealed vessel and in a 
microwave (Scheme 2.6). The yield obtained in a sealed vessel was over double 
that obtained in the microwave, demonstrating again the higher efficiency of a 
sealed system. Single crystals of L4 were grown by slow evaporation of MeCN. 
L4 crystallised in the monoclinic crystal system with the structural solution 
performed in the space group P21/n. The imidazolium crystallised with two 
molecules of water though there is no evidence of hydrogen bonding between 
the water and the iodide counterion. The direct attachment of an aromatic phenyl 
ring to the imidazole renders it almost coplanar in the solid state, increasing the 
intermolecular π overlap between the two aromatic systems and significantly 
shortening the N1-C6 bond length to 1.438 Å (5) versus N1-C6 bond length in 
L2, L3 and L3.1 which are between 1.48-1.51 Å.   
 
  
                P4                                             L4               
                                                                                adetermined using isolated yield     
 
Scheme 2.6: Synthesis imidazolium salt L4. 
 
                     L4  
Figure 2.6: Molecular structure imidazolium salt L4. Ellipsoids are drawn at 50% 
probability level. Water molecules and H atoms have been omitted for clarity 
 Reaction  Yield (%)a  







N1-C1 1.335 Å (5) 
N1-C6 1.438 Å (5) 
C(7) 
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2.2.3 Imidazolium salts prepared from theobromine  
To investigate the effect of water solubility on anticancer activity, a hydroxylated 
ligand precursor P5 was synthesised from theobromine following a method 
reported by Youngs et al. (Scheme 2.7).10 The presence of the hydroxyethyl 
group on P5 retains the water solubility of theophylline, as opposed to P2-P4 
which are insoluble in water. L5 was prepared through reaction of P4 with methyl 
iodide at 145⁰C in a sealed vessel. The characteristic imidazolium proton peak 
appears at 9.27 ppm in the 1H NMR spectrum of L5 (Figure 2.7).  
 
 
  Theobromine                                                           P5 (94%)                                     L5 (31%) 
 
Scheme 2.7: Hydroxylation of theobromine to P5 and synthesis of L510 
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2.3 Silver-(I) NHC complexes  
Coordination of silver to xanthine-derived imidazolium salts L1-L5 was initially 
attempted via reaction with Ag2O under different reaction conditions, with varying 
solvents (MeCN, CH2Cl2, MeOH and H2O) and temperatures ranging from room 
temperature to 90°C. Although the characteristic imidazolium proton peak at ≈ 9 
ppm disappears following these reactions, several peaks at ≈ 8 ppm appear. This 
indicates the presence of imidazolium salts with different counter anions (e.g. 
AgX2-), which may be a result of Ag(I)-NHC decomposition. A different route using 
AgOAc in methanol at room temperature reported by Youngs et al. was used 
(Scheme 2.8).1 C1 was prepared at room temperature in 1 hour, and isolated as 
a stable solid in 56% yield. The reaction can be easily monitored by observing 
the disappearance of the imidazolium proton peak in the 1H NMR spectrum 
(Figure 2.8). The complex is very stable and does not decompose when stored 
as a dry solid.  
 
                             L1                                                                        C1 
Scheme 2.8: Synthesis of Ag(I)-NHC complex C1 using AgOAc1 
  
Figure 2.8:1H-NMR spectra (300MHz, DMSO- d6) of Ag(I)-NHC complex C1 
(bottom) and imidazolium salt L1 (top) 
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Single crystals of C1 were grown by slow evaporation of a solution in MeOH. The 
molecular structure obtained (Figure 2.9) shows the bond length between the 
carbenic carbon and silver atom is 2.068(3) Å and the N1-C1-N2 bond angle 
105.7°(3) is within error to the solid state structure reported by Youngs et al.1 The 
Ag(I)-NHC complex is almost linear at the silver centre with an C1-Ag1-O3 angle 
of 168.21°(10). C1 crystallises in the monoclinic crystal system with the structural 
solution being performed in the space group P21/n. The xanthine group is 
perfectly planar and co-crystallises with two water molecules which form H-bonds 




Figure 2.9: Molecular structure of Ag(I)-NHC complex C1. Ellipsoids are shown 
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A library of four further neutral Ag(I)-NHC complexes C2-C5 were synthesised 
using two equivalents of silver acetate in either MeOH or a solvent mixture of 
CH2Cl2 and MeOH to improve the solubility of the ligands (Scheme 2.9). The 
complexes were fully characterised using 1H and 13C{1H} NMR spectroscopy, 
HRMS and elemental analysis, and the molecular structures of the novel 




                                                                C1: R1 = Me, R2 = Me (54%) 
                                                                             C2: R1 = Me, R2 = nBu (55%) 
                                                                             C3: R1 = Me, R2 = Bn (40%) 
                                                                             C4: R1 = Me, R2 = Ph  (69%) 
                                                                             C5: R1 = (CH2)2OH, R2 = Me  (28%) 
 
                                                   
Scheme 2.9: Synthesis of neutral Ag(I)-NHC acetate complexes C1-C5 
Single crystals of complexes C2-C4 were grown by vapour diffusion of pentane 
into concentrated solutions of the complexes in CH2Cl2. All three complexes 
crystallise in the triclinic crystal system and all three were solved in the P-1 space 
group (Figure 2.10 and Figure 2.11). Upon coordination to silver, the C1-N1-C6 
angle decreases for all three complexes from their corresponding imidazoliums, 
which is a common feature of NHC formation. Unlike C3 and C4, C2 crystallises 
as a dimer with a ligand-unsupported argentophilic interaction (Ag---Ag = 3.19 Å, 
Figure 2.10, Table 2.5) which is in agreement with previously reported binuclear 
Ag(I)-NHC complexes.11, 12 C2 also crystallises with one molecule of water which 
forms a hydrogen bond with the acetate group.  
 





Figure 2.10: Molecular structure of C2.  H atoms have been omitted (except for 
water) for clarity and ellipsoids are shown at 50% probability  
  
                C3                                                      C4 
Figure 2.11: Molecular structures of Novel xanthine based neutral Ag(I)-NHC 
acetate complexes C3 and C4 . H atoms have been omitted for clarity and 
ellipsoids are shown at 50% probability              
Table 2.5: Selected bond distances, bond angles and torsion angles for 
Ag(I)-NHC complexes C2-4 
Bond lengths (Å) and angles (°) C2 C3 C4 
Ag1-C1-N1 126.68(11) 127.8(4) 125.3(2) 
N1-C6-C7 111.08(12) 113.4(5) 119.2(3) 
C1-N1-C6 123.66(12) 123.4(5) 122.4(3) 
Ag1-C1 2.078(3)   
 
2.052(7) 2.068(4) 
Ag1-Ag2 3.1931(3) - - 
C1-N1-C6-C7 94.14(18) 85.4 -55.7(5) 
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The stability of the silver complexes in water was investigated to enable 
prediction of how they might behave in a biological system. A 1H NMR 
experiment containing equal equivalents of the silver complex and DMSO 
(internal standard) in D2O was conducted to measure the rate of decomposition. 
C1-C5 were found to be stable for 24 hours with minimal decomposition. Figure 
2.12 shows the 1H NMR spectrum of C5 as an example. Decomposition of the 
complex was monitored by first determining the ratio of the integration of the 
CH3 peak of the complex (red) to the integration of the CH3 peaks of DMSO 
(green) at 0 hours, after which the ratios at different hours is compared to. The  
decrease in ratio is the % decomposition since the integration of  complex peaks 
(e.g. CH3 peak) decrease upon decomposition as new peaks appear. After 48 
hours, 16 % decomposition was observed, and increases to 23 % 
decomposition after 72 hours. The stability of C1-C5 in H2O for at least 24 hours 
indicates the possibility of high bioavailability and long half-life of the intact 
complexes in vivo. 
                                      
Figure 2.12: 1H-NMR spectra (300MHz, D2O) of C5 and DMSO in 1:1 ratio. 
1) 0 hours, 2) 4 hours, 3) 7 hours, 4) 12 hours, 5) 24 hours, 6) 48 hours, 7) 
72 hours 
: C5 
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2.4 Hydrophobicity measurements 
The hydrophobicity of complexes C1-C5 was measured by partitioning these 
complexes between octanol and water, hence predicting how they would partition 
between the blood and lipid bi-layers inside the body. A correlation between Log 
P and cytotoxicity has frequently been made.13 Hickey et al. reported that ‘tuning’ 
the Log P to achieve intermediate hydrophobicity/hydrophilicity gave the optimal 
potency, as a complex that they developed with intermediate lipophilicity (Log P 
= -0.29) was the most active against tumorigenic breast cancer cell lines MDA-
MB-231 and MDA-MB-468 in addition to possessing higher selectivity to these 
cancerous cell lines over the non-cancerous human mammary epithelial cells 
HMEC.14 The importance of determining the lipophilicity of a drug as a predictor 
of its activity is highlighted in Lipinski’s ‘rule of 5’.15 This rule predicts that poor 
absorption (in bloodstream) or permeation (through membranes) of a drug is 
more probable when there are more than 5 H-bond donors, 10 H-bond acceptors, 
the molecular weight is greater than 500 and the calculated Log P is greater than 
5. 15, 16 Although this rule applies to organic compounds, aiming to follow the rule 
for our organometallic complexes may improve their absorption i.e. their oral 
activity. 
Equal volumes of octanol and NaCl-saturated water were stirred at room 
temperature for 24 hours, and separated to give octanol-saturated water and 
water-saturated octanol. The water layer represents the bloodstream while the 
octanol represents the lipid bi-layers. Five standard concentrations (5, 10, 20, 40 
and 60 µM) of the complexes were prepared from the octanol-saturated water. 
Analysis by UV/ vis spectroscopy was used to determine the wavelength at which 
the maximum absorbance of each sample is reached. An example is shown in 
Figure 2.13A where the maximum absorbance for 5 samples with different 
concentrations of complex appear to be reached at the same wavelength of 
274nm. A calibration curve of absorbance vs. concentration at this wavelength 
was calculated (Figure 2.13B), and the formula for the curve was obtained. 
Following calibration, seven samples of concentration 50 µM were made up from 
one stock solution in the octanol-saturated water. 3 mL of octanol-saturated water 
containing the complex was placed in a centrifuge tube and 3 mL of water-
saturated octanol was layered on top. Six samples were shaken for 4 hours using 
a vibrax machine at 500 g/min, and the last one was left unshaken. The 
absorbances of the seven samples were measured using UV/vis spectroscopy 
(Figure 2.14). 
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A.                                                        
B.  
Figure 2.13: UV/vis spectroscopy measurements of samples with concentration 
5, 10, 20, 40 and 60 uM, example graph A. displays the wavelength at which 
the maximum absorption for each concentration is reached and B. is an 
example of a calibration curve of concentration vs. absorbance 
 
 
Figure 2.14: Differences in absorbances of shaken and unshaken samples 
 
The concentration of the six shaken samples and the unshaken sample were 
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274nm using the equation generated from the calibration curve. The average of 
the concentrations of the six shaken samples represents the concentration of the 
complex in the aqueous phase. The concentration of the complex in octanol is 
calculated by subtracting the average concentration of the shaken samples 
(conc. in aqueous phase) from the concentration of the unshaken sample. The 
partition coefficient (Log P) of the complex is calculated as Log P = Log ([conc. 
in octanol]/[conc. in aqueous]). A positive Log P value indicates a hydrophobic 
complex and a negative Log P is an indication that the complex is hydrophilic. 
 
 
Figure 2.15: Log P values for Ag(I)-NHC complexes C1-C5. 
Unsurprisingly, the N-hydroxyethyl substituted complex C5 is the most 
hydrophilic (Log P = -1.96), followed by the N-methyl substituted complex C1 
(Log P = -0.01) while all three N-butyl, N-benzyl and N-phenyl substituted 
complexes C2-C4 are hydrophobic (positive Log P). It is clear that adding the N-
hydroxylethyl group onto the xanthine complexes significantly increases the 
hydrophilicity, though is not as hydrophilic as cisplatin which has frequently been 
reported with a Log P of -2.36.17 However, hydrophobicity measurements using 
the same method as for C1-C5 obtained a Log P value of -1.35 for cisplatin, 
making C5 more hydrophilic than cisplatin when measured under the same 
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2.5 Anticancer testing 
Antiproliferative studies were conducted by Prof. Roger Philips (University of 
Huddersfield) using MTT-based assays. The Ag(I)-NHC complexes were tested 
against eight cancerous cell lines, colorectal carcinoma HCT116 and human 
colorectal adenocarcinoma HT-29 (colon cancer), glioblastoma LN229, 
glioblastoma astrocytoma U-87MG and glioblastoma astrocytoma grade III-IV 
malignant tumor U-251 (brain), human pancreatic carcinoma Panc 1, cervival 
cancer SiHa and malignant melanoma  A375 (skin cancer). Results are shown in 
Figure 2.16 including values obtained for cisplatin against the same cell lines. 
Cisplatin was found to be more cytotoxic than C1-C5 against all cell lines.  
From the five xanthine-derived complexes the most hydrophilic C5 showed 
enhanced cytotoxicity against most cell lines in comparison to C1-C3, except 
against U-87MG and Panc 1 where C2 shows greater cytotoxicty than C5, and 
on U-251 where C3 shows better cytotoxicty than C5. The general increased 
activity of C5 against most of the cell lines may be attributed to its improved water 
solubility due to the presence of the hydroxyethyl group. Although hydrophilicity 
appears to play a role in cytotoxicity, complex C4 showed overall similar potency 
to C5, with higher potency in some of the cell lines including Panc 1, U-251 and 
U-87MG. C4 displays superior anticancer activity compared to C1-C3 on all eight 
cell lines except for U-87MG where C2 shows better potency. C4 can therefore 
be considered the most cytotoxic complex on average out of the Ag(I)-NHC 
complexes C1-C5. This could be attributed to the steric bulk provided by the 
phenyl substituent which stabilises the Ag-NHC bond and results in its slow 
release into solution, and hence slow release in biological media. 
The general superior cytotoxicity of both C4 and C5, which are attributed to steric 
bulk and hydrophilicity respectively, suggests that a combination of both water 
solubility and substituents providing steric bulk may lead to the optimum 
anticancer Ag(I)-NHC complex.18 It is also important to point out the anticancer 
activity of C2 on the glioblastoma astrocytoma U-87MG cell line, which is superior 
to the activities of both C4 and C5. This implies that the anticancer activity of C2 
is tumour specific and may be worthy of further investigation against more 
cancerous cell lines in the future.  
 
 
































Different routes to synthesise imidazolium salts from caffeine were attempted, 
leading to the development of a successful route for the methylation of caffeine 
with good yield. Other alkyl groups could not be added to caffeine due the low 
basicity of the nitrogen atom, therefore theophylline and theobromine were 
used as the starting precursors to alkylate with varying groups before 
methylation and the formation of imidazolium iodides. 
Neutral monodentate Ag(I)-NHC complexes were synthesised by reaction of 
the imidazolium salts with silver acetate, and full characterisation was 
obtained including X-ray diffraction analysis. The stability of all complexes in 
water was examined with minimal decomposition after 24 hours. 
Hydrophobicity/hydrophilicity profiles were determined with the utility of UV/vis 
spectroscopy and Log P values were calculated. The Log P values indicate 
how well these complexes will go through the bloodstream and cross the 
biological membranes. The presence of a hydroxyethyl group on the ligand 
backbone rendered complex C5 hydrophilic as opposed to the complexes with 
nbutyl, benzyl and phenyl N-substituents (C2, C3 and C4), which were 
hydrophobic. 
The cytotoxicity of C1-C5 against 8 different cancerous cell lines was 
measured and compared to cisplatin. All five complexes show promising 
antiproliferative activity as IC50 values were in the micromolar range, however 
not as cytotoxic as cisplatin. It is evident that increased steric effects of the 
ligand enhances cytotoxicity as the most cytotoxic Ag(I)-NHC complex C4 is 
hydrophobic and contains a bulky phenyl group. It is also clear that water 
solubility enhances cytotoxicity, as C5, which contains a hydroxyethyl group 
and is the most hydrophilic complex, shows superior cytotoxicity compared to 
C1.  
A combination of steric bulk and water solubility in a Ag(I)-NHC complex will 
potentially optimise anticancer activity. This combines the benefits of the steric 
effects that lead to slow release of silver into the cells, and the improved 
solubility in water that will improve its transport through the bloodstream, 
increasing its infiltration into tumours through their “leaky” blood vessels19-21. 
This combination can also maintain an “intermediate lipophilicity”, a property 
suggested by Hickey et al. that acquires the optimum anticancer activity.14 
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Chapter 3                                                                                
Copper- and ruthenium-N-heterocyclic carbene complexes 
derived from the natural xanthine precursors caffeine and 
theophylline 
3.1 Introduction 
Metal-NHCs have shown potential as anticancer agents and are a fast growing 
field of research.1 Although Pt-2, 3 and Au-NHCs4-12 have been the main focus 
in this area, Ru-13-17 and Cu-NHCs18, 19 have also been reported for their 
potential use as anticancer agents. These were discussed in detail in section 
1.6.3, and examples of Cu(I)-NHC19 and Ru(II)-NHC20 complexes with reported 
anticancer activities are shown in Figure 3.1 and Figure 3.2. The promising 
anticancer activity of Cu(I)- and Ru(II)-NHC complexes reported in the 
literature,21 inspired us to synthesise and study xanthine-derived Cu(I)-NHC and 
Ru(II)-NHC complexes.  
         
         
 
Figure 3.1: Cu(I)-NHC complexes that exhibit anticancer activities19  
 
Figure 3.2: Ru(II)-NHC complexes that exhibit anticancer activities20 
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3.2 Electrochemical synthesis 
The electrochemical synthesis of metal-NHCs is a well-established technique in 
the Willans group.22-25 Attempts were made to electrochemically synthesise a 
Ag(I)-NHC complex starting from L1, using a silver anode and a copper cathode, 
under anhydrous conditions. The theoretical reaction time was calculated to be 
32 minutes using Faraday’s law (Figure 3.3) with 0.2g (0.6mmol) of L1. 
However, after 2 hours at 30 mA, a mixture of Ag(I)-NHC and L1 were observed 
by 1H NMR spectroscopy (Figure 3.4 (1)).  
 
                     Q= nFN                          Q = total charge [C or A s] 
                                                 n = number of electrons transferred 
       t= Q/I                            F = Faraday’s constant [C mol-1] 
                                                N = moles of starting material [mol] 
                     t = nFN/I                         I = current [A] 
          t = time [s] 
 
E.g.  t = 1 x F x 0.0006 mol = 1914 seconds or 32 minutes 
                                    0.03 A 
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3.2.1 Electrochemical synthesis of Cu(I)-NHC complexes 
For the electrochemical synthesis of xanthine-derived Cu(I)-NHC complexes a 
copper anode was utilised, in addition to the copper cathode. The method was 
successful in furnishing Cu(I)-NHC complexes starting from ligands L1, L2 and 
L3 (Scheme 3.2) to give Cu(I)-NHC complexes C1.Cu, C2.Cu and C3.Cu. The 
Cu(I) complexes are insoluble in MeCN and precipitate out of solution when 
formed. Interestingly, C1.Cu, C2.Cu and C3.Cu are unusually stable in air in the 
solid state, and only begin to oxidise to Cu(II) after six hours in DMSO-d6 
following exposure to air. This observation regarding their stability is unlike 
literature examples of Cu(I)-NHC complexes, which oxidise to Cu(II) upon 
exposure to low levels of oxygen.22, 23, 25 This stability may be due to the electron 
withdrawing effect of the xanthine backbone, leading to a ‘softer’ NHC ligand 
(carbon donor), strengthening the ‘soft-soft’ interaction with Cu(I). The relatively 
‘soft’ iodide anion may also be contributing to the stability of the complex. The 
same synthetic route was applied to L4 and L5 in order to complete a library of 
five Cu(I) complexes, however, these did not form the desired Cu(NHC)I 
complexes  C4.Cu or C5.Cu (Scheme 3.2). Comparison of the 1H NMR spectra 
of the electrochemical product from Scheme 3.1 and the Cu(NHC)I product from 
Scheme 3.2(1.) are shown in Figure 3.4. The 1H NMR spectra display the 
successful facile synthesis of pure C1.Cu unlike its corresponding Ag(I) 
complex.  
 
                                            
     
1. L1: R = Me, R’ = Me                                C1.Cu: R = Me, R’ = Me       √ 
2. L2: R = nBu, R’ = Me                              C2.Cu: R = nBu, R’ = Me      √ 
3. L3: R = Bn, R’ = Me                                C3.Cu: R = Bn, R’ = Me       √ 
 
4. L4: R = Ph, R’ = Me                                C4.Cu: R = Ph, R’ = Me           X 
5. L5: R = Me, R’ = (CH2)2OH                     C5.Cu: R = Me, R’ = (CH2)2OH X 
 
Scheme 3.2: Electrochemical synthesis of Cu(I)-NHC complexes 




Figure 3.4: 1H-NMR (300MHz, DMSO- d6) of (1). the attempted 
electrochemical synthesis of Ag(NHC)I (unsuccessful)  and (2). the successful 
electrochemical synthesis of C1.Cu (Cu(NHC)I) 
Single crystals of complex C1.Cu were grown by vapour diffusion of diethyl ether 
into concentrated solution of the complex in DMSO. C1.Cu crystallises in the 
triclinic crystal system and was solved in the P-1 space group (Figure 3.5). The 
bent geometry around the Cu atom is due to the formation of a halide-bridged 
dimer in the solid state. The bond length between the carbenic carbon and copper 
atom is 1.928(5) Å and the bond angle N1-C1-N2 is 105.3(4)° which are similar 
to those found for the corresponding silver acetate complex C1 (Chapter 2). 
 
Figure 3.5: Molecular structure C1.Cu. H atoms have been omitted for clarity 
and ellipsoids are shown at 50% probability 
(1) 
(2) 
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The unusual stability of these Cu(I)-NHC complexes may be advantageous in 
catalysis, therefore, they were examined in a copper catalysed Ullmann reaction. 
Cu(I)-NHC complexes have been previously reported by the Willans group to 
exhibit reasonable activity in the etherification reaction of 3,5-dimethylphenol.22 
Therefore, complexes C1.Cu, C2.Cu and C3.Cu were investigated as catalysts 
in the same reaction (Scheme 3.3). In situ generated catalysts were examined, 
using 10 mol% of the ligand precursors L1, L2, L3 and L4 and 10 mol% of CuI 
and the results were compared to those obtained using ligand 1,3-bis(2,4,6-
trimethylphenyl)imidazolium chloride (IMes). Electrochemically preformed Cu(I)-
NHC complexes C1.Cu, C2.Cu and C3.Cu were also tested with a 10 mol% 
loading and the results were compared to both mono-substituted Cu(IMes)Cl and  
bis-substituted Cu(IMes)2PF6. The yields of the coupled product, which are 
presented in Table 3.1, show that these Cu(I)-NHC complexes are not effective 
in the Ullmann reaction, with yields less than 20%.  
 
Scheme 3.3: Copper catalysed arylation reaction 
Table 3.1: Reaction conditions: 1.2 mmol 3,5-dimethylphenol, 1.0 mmol 4-
iodoanisole, 2.0 mmol Cs2CO3, 0.1 mmol catalyst, 5 mL MeCN, 90°C, 24h 
Entry Catalyst (10 mol%) GC yield (%)a 
1 CuI  5 
2 CuI + IMes.Cl  28 
3 Cu(IMes)Cl  11 
4 C1.Cu 3 
5 C2.Cu 11 
6 C3.Cu  6 
7 CuI + L1 4 
8 CuI +  L2 5 
9 CuI+ L3 3 
10 CuI+  L4 17 
a Yields were determined by GC using p-cymene as an internal standard 
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3.3 Synthesis of Ru(II)-NHC complexes 
Xanthine-derived Ru(II)-NHC complexes C1.Ru, C2.Ru and C3.Ru were 
synthesised by transmetallation from Ag(I)-NHC complexes formed in situ, 
utilising Ag2O and [Ru (p-cymene)Cl2]2 (Figure 3.6). Visual monitoring of the 
reaction was possible by observing the precipitation of silver salt. Reaction times 
of 2 hours gave the desired complexes, with longer reaction times (˃ 3 hours) 
resulting in the decomposition of the complex, observed by a change in the 
solution colour from red/orange to dark green. C1.Ru, C2.Ru and C3.Ru are 
stable orange/red powders when stored as dry solids for several months. 
Reaction of L4 under similar conditions to L1, L2 and L3 required longer time (3 
hours) to form the desired product, however, C4.Ru decomposes to a green solid 
in a few hours when stored as a dry solid, so was not taken forward to cell-line 
testing. Although reaction with L5 furnishes a red solid, the product analysed was 




1. L1: R = Me, R’ = Me                                C1.Ru: R = Me, R’ = Me            √ 
2. L2: R = nBu, R’ = Me                               C2.Ru: R = nBu, R’ = Me           √ 
3. L3: R = Bn, R’ = Me                                C3.Ru: R = Bn, R’ = Me            √ 
 
4. L4: R = Ph, R’ = Me                                 C4.Ru: R = Ph, R’ = Me            √ 
5. L5: R = Me, R’ = (CH2)2OH                      C5.Ru: R = Me, R’ = (CH2)2OH X 
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A comparison of the 1H NMR spectra of C1.Ru, C2.Ru and C3.Ru (Figure 3.7) 
reveals an interesting shift in the doublet resonance corresponding to two of the 
p-cymene protons which are shifted downfield from ≈ 5.45 ppm (C1.Ru / C2.Ru) 
to 7.03 ppm in C3.Ru. This downfield shift is likely due to a deshielding effect 
caused by the close proximity of the aromatic benzyl substituent to the p-cymene.  
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Single crystals of complexes C2.Ru and C3.Ru were grown by vapour diffusion 
of Et2O into concentrated solutions of the complexes in CHCl3. C2.Ru and 
C3.Ru both crystallise in the orthorhombic crystal system and structural 
solutions are solved in the P212121 space group. The molecular structures of 
are displayed in Figure 3.8. C3.Ru shows a hydrogen bond between a 
methylene proton of the benzyl substituent and a chloride. The packing diagram 
of C2.Ru displays intermolecular T-stacking interactions between the aromatic 
xanthine rings, holding planes of molecules together, which is not observed in 
the packing of C3.Ru.  
 
 
A.                    C2.Ru                                      B.                        C3.Ru 
C.  
Figure 3.8: Molecular structures of A. C2.Ru and B. C3.Ru and C. packing 
diagram of C2.Ru along the b axis. Ellipsoids are shown at 50% probability level 
and H-atoms (except those on C(6) in C3.Ru) are omitted for clarity 
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3.4 Anticancer Testing 
Xanthine-derived Cu(I)-NHC complexes C1.Cu, C2.Cu and C3.Cu and Ru(II)-
NHC complexes C1.Ru, C2.Ru and C3.Ru  were evaluated for their anticancer 
activity. Cytotoxicity studies (MTT-based assays conducted at the University of 
Huddersield) against pancreatic adenocarcinoma cell line Panc 10.05 revealed 
poor or negligible cytotoxicity of all six complexes (Table 3.2). Further studies 
using SRB assays were conducted at the University of Heidelberg against nine 
cell lines including colorectal carcinoma cell lines HT116 wt and HT116 p53-/-, 
human colorectal adenocarcinoma HT29, prostate adenocarcinoma LNCaP, 
prostate carcinoma DU145, grade IV prostate adenocarcinoma PC3,  mammary 
gland adenocarcinoma MDA-MB-231 and pancreatic adenocarcinoma cell lines 
MiaPaca and Panc1. Surprisingly, all six complexes showed no or poor 
anticancer activity against the nine cell lines, despite their corresponding Ag(I)-
acetate complexes C1.Ag, C2.Ag and C3.Ag having shown good anticancer 
activity against various cancerous cell lines (Chapter 2).26 Comparison of the 
anticancer activity of nine Ag(I), Cu(I) and Ru(II)-NHC complexes against three 
cell lines, HT29, HTC116 and Panc 1 (Figure 3.10), illustrates the superior 




Table 3.2: IC50 values of Cu(I)-NHC complexes and Ru(II)-NHC complexes 




C1.Cu C2.Cu C3.Cu C1.Ru C2.Ru C3.Ru 
a Panc 10.05 >100 >100 51±25 94 ±5 >100 >100 
bHT116  >100 >100 >100 >100 >100 >100 
bHT116 p53-/- >100 >100 >100 >100 >100 >100 
bHT29 >100 >100 >100 >100 >100 >100 
bLNCaP >100 >100 >100 >100 >100 >100 
bDU145 >100 >100 >100 >100 >100 >100 
bMiaPaca >100 >100 >100 >100 >100 >100 
bMDA-MB-231 >100 >100 >100 >100 >100 >100 
bPanc1 >100 >100 >100 >100 >100 >100 
bPC3 >100 >100 >100 >100 >100 >100 




Figure 3.9: IC50 (µM) values of Ag(I)-NHC complexes C1.Ag, C2.Ag and 
C3.Ag 26 and their analogous Cu(I)-NHC C1.Cu, C2.Cu and C3.Cu and Ru(II)-
NHC C1.Ru, C2.Ru and C3.Ru complexes against three cancerous cell lines 
 
3.5 Conclusions 
Xanthine-derived imidazolium iodides L1, L2 and L3 were used in the 
electrochemical synthesis of three Cu(I)-NHC complexes, C1.Cu, C2.Cu and 
C3.Cu, and the synthesis of three Ru(II)-NHC complexes C1.Ru, C2.Ru and 
C3.Ru  via transmetallation using Ag2O and Ru p-cymene dimer. Synthesis of 
xanthine-derived Pt(II)-NHC complexes proved challenging as mixtures of 
products appear to form. The antiproliferative activity of the six Cu(I)-NHC and 
Ru(II)-NHC complexes was evaluated against ten cancerous cell lines, 
showing little or no cytotoxicity.27 Comparison of the antiproliferative activity 
with those of three previously reported Ag(I) complexes, C1.Ag, C2.Ag and 
C3.Ag,26  displays the superior activity of the Ag(I)-NHC complexes. This may 
be due to a stronger Cu-carbene and a Ru-carbene bond that hinders the 
release of the metal ions required for the anticancer activity, while the Ag-
carbene is a weaker bond. Another possible reason is that the redox potential 
of these complexes required to form the active species is not in the redox 
potential window of their biological target, e.g. mitochondrial redox potential 
window.19 These interesting findings suggest that Ag(I)-NHC complexes have 
greater potential as anticancer agents over either Cu(I)-NHC or Ru(II)-NHC 
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Chapter 4  
Synthesis and anticancer activity of silver(I)-N-heterocyclic 
carbene complexes derived from clotrimazole 
 
4.1 Introduction 
Clotrimazole (Figure 4.1) is an imidazole containing compound that is 
predominantly used topically as an antifungal agent. It is widely used and highly 
effective in the treatment of fungal diseases in plants, humans and animals.1 
Clotrimazole is known to be of low toxicity, with its metabolism being well studied 
and understood.1 Regarding its biosafety, it was found to be non-toxic towards 
mammalian cells when tested on cell line HepG2, with reported cell viability in 
excess of 80%.2 Recently, a clotrimazole-coordinated silver complex (Figure 4.2) 
was reported by Govender et al. to be effective against Staphylococcus aureus 
and MRSA.2   
 
                              
                       
Figure 4.1: Molecular structure of clotrimazole, and its metabolites, 2-




Figure 4.2: Clotrimazole-coordinated silver complex with potent antibacterial 
properties 




Antitumor activity in lung metastases has also been reported for clotrimazole, 
including inhibition of cell proliferation both in vitro and in vivo.3 Its in vitro activity 
is attributed to its cellular effect of depleting intracellular Ca2+ stores, interfering 
with the cellular homeostasis and contributing to the inhibition of cell proliferation 
in a dose-dependent manner. In addition, in vivo studies show the inhibitory effect 
of clotrimazole on lung metastases produced in mice, demonstrating its potential 
as an antiproliferative agent. Halperin et al. further investigated the intracellular 
role of clotrimazole resulting from Ca2+ depletion, and concluded that it has an 
effect on the activation of protein kinase R  (PKR) followed by phosphorylation of 
translation initiation factor eIF2α, thereby inhibiting protein synthesis at the 
translation initiation level leading to blockage of the cell cycle in G1.4 
Cu2+, Co2+, Zn2+ and Ni2+ coordination complexes of clotrimazole have recently 
been synthesised by Barba-Behrens et al., with reported oxidative DNA damage 
(Figure 4.3).5  The reduction of Cu2+ to Cu+, which was studied electrochemically 
in one complex, appears to be the source of oxidative DNA damage properties. 
Mn(I) complexes of clotrimazole and related antifungals such as ketoconazole 
have been synthesised and tested against different strains of bacteria, showing 
good antiparasitic activity.6 
 
 
Figure 4.3: Cu2+, Co2+, Zn2+ and Ni2+ clotrimazole-coordination complexes that 
exhibit anticancer properties5 and Mn+ complex with antibacterial activity6 
As clotrimazole has low toxicity and has exhibited anticancer activities, it was 
used in the synthesis of imidazolium salts, followed by coordination to silver to 
give novel Ag(I)-NHC complexes. These were examined against a range of 








4.2 Ligand synthesis 
4.2.1 Clotrimazole-derived imidazolium salts 
Only a small number of imidazolium salts prepared from clotrimazole have been 
reported to date.7, 8 In this study, clotrimazole was initially used for the synthesis 
of imidazolium iodide salts through reaction with alkyl halides such as methyl 
iodide. Reaction at RT gave 45% yield after 24 hours (Table 4.1, entry 1), 
therefore the reaction was heated at reflux in CH2Cl2 (entry 2). A higher yield of 
67% was obtained, which could be increased further to 74% after only 15 minutes 
by using microwave conditions (entry 3).  
 









Reactions were also performed with nbutyl iodide under microwave conditions 
and with 2-iodoethanol under reflux to synthesise imidazolium iodides L7 and L8 
(Scheme 4.1). Ligands L6-L8 were fully characterised using 1H and 13C{1H} NMR 
spectroscopy, HRMS and elemental analysis.  
 
 
Scheme 4.1: Synthesis of imidazolium iodide salts L6-L8 from clotrimazole 
Table 4.1: Reaction conditions tested for the synthesis of methyl 
substituted imidazolium salt L6 
 Temperature Time (hours) Yield % 
1 Room temperature 24 45 
2 Reflux 24 67 
3 Microwave conditions 
(45⁰C, 17.5 bar) 
0.25 74 




Single crystals of L6-L8 suitable for X-ray diffraction analysis were grown by the 
vapour diffuson of Et2O into concentrated solutions of the ligands in CH2Cl2. The 
solid state structures (Figure 4.4) show the expected imidazolium salts with no 
evidence of hydrogen bonding between the iodide anions and the electron 
deficient imidazolium N-C-N rings. A C-H…I hydrogen bond might be expected to 
occur from a combination of electrostatic, charge transfer, polarization and 
dispersion between N-CH-N (proton donor) and the iodide (acceptor).9 L6 
crystallised in the orthorhombic crystal system and was solved in the space group 
Pbca, while L7 and L8 both crystallised in the triclinic crystal system and their 
structural solutions were performed in the space group P-1. The tetrahedral 
geometry at C4 of the triphenyl group is consistent in all three ligands in which all 
four angles around C4 are ≈ 109° (Table 4.2). Although there is no evidence of 
anion-π interactions between the iodide anion and the imidazolium ring in any of 
the ligands,  anion-π interactions appear to be present in both L7 and L8 between 
the aryl chloride and the imidazolium ring centroid, indicated by the short aryl 
chloride….imidazolium  centroid  distances of 3.278 Å and 3.331 Å respectively, 
which fall below the sum of the Van der Waals radii (Figure 4.5).  
                             
                                      
Figure 4.4: Molecular structures of imidazolium salts L6-L8. Ellipsoids are 








An interesting finding in the solid state structure of L8 is the substitutional disorder 
between the chloride of the trityl group and the iodide counterion, most likely due 
to an exchange between the two. This results in a mixture of 97% Cl(1) and 3% 
I(2) on the phenyl, and a mixture of 29% Cl(2) and 71% I(1) as the counterion.  
 
       
                                         L7                                              L8 
Figure 4.5: Anion-π interactions observed in L7 and L8 
 




Bond Lengths (Å) and angles (°)        L6       L7      L8 
N1-C1-N2 108.9(2) 109.2(2) 109.0(4) 
N1-C4-C5 107.1(3) 106.31(19) 106.0(3) 
N1-C4-C17 108.3(3) 110.4(2) 108.0(3) 
N1-C4-C11 104.4(3) 107.8(2) 110.6(3) 
C5-C4-C11 112.8(3) 113.2(2) 111.9(3) 
C17-C4-C11 114.0(3) 109.6(2) 109.1(3) 
C17-C4-C5 109.8(3) 113.2(2) 111.1(3) 
C6-Cl1 1.741(4) 1.745(3) 1.747(5) 
N1-C4 1.508(4) 1.513(3) 1.519(5) 
N2-C23 1.465(4) 1.478(3) 1.469(5) 
Cl1……C1 5.511 3.188 3.201 
I1……..C1 3.729 3.815 3.630 
Cl1……I1 6.864 4.771 4.443 




4.2.2 Imidazolium salts synthesised from 2-chlorotrityl chloride 
In order to prevent mixed halides between the phenyl group and the counterion, 
a second route was developed for the synthesis of the desired imidazolium salts. 
Substituted imidazoles were reacted with 2-chlorotrityl chloride in either CH2Cl2 
or MeCN at reflux to give imidazolium chloride salts L9-L13 (Scheme 4.2), which 





Scheme 4.2: Synthesis of imidazolium chloride salts L9-L13 from 2-chlorotrityl 
chloride 
Single crystals of L9, L10, L12 and L13 suitable for X-ray diffraction analysis were 
grown by vapour diffusion of Et2O into concentrated solutions of the ligands in 
either CH2Cl2 (L9, L10 and L12) or MeOH (L13). L9 and L12 crystallised in the 
monoclinic crystal system with the structural solution of L9 solved in the space 
group P21 and L12 solved in the space group P21/c. L10 crystallised in the 
orthorhombic crystal system and the structural solution solved in the space group 
Pbca, while L13 crystallised in the triclinic crystal system and its structural 
solution solved in the space group P-1. Both L10 and L12 crystallised with a 
molecule of H2O which forms hydrogen bonds with the chloride counterion 
(Figure 4.6). Hydrogen bonding of the chloride counterion with the imidazolium 
N-CH-N is only observed in the molecular structure of L9. 
 




           
                     L9                                                           L10 
 
                      L12                                                           L13 
Figure 4.6: Molecular structure of imidazolium chloride salts L9, L10, L12 and 
L13. Ellipsoids are drawn at the 50% probability level and H atoms (except those 
on H2O) have been omitted for clarity 
Table 4.3: Selected bond lengths and angles for L9, L10, L12 and L13. 
Bond Lengths (Å)  
and angles (°) 
     L9       L10       L12       L13 
N(1)-C(1)-N(2) 108.1 (3) 108.53 (17) 108.21 (16) 108.99 (14) 
N(1)-C(4) 1.514 (4) 1.503 (2) 1.516 (2) 1.509 (2) 
N(2)-C(23) 1.478 (4) 1.467 (2) 1.485 (2) 1.470 (2) 
Cl(1)-C(6) 1.755 (3) 1.745 (2) 1.752 (2) 1.7471 (17) 
Cl(1)∙∙∙∙∙C(1) 3.271 3.255 3.256 3.230 
Cl(2)∙∙∙∙∙C(1) 3.323 3.432 3.782 3.371 
Cl(1)∙∙∙∙∙Cl(2) 5.661 5.415 7.026 4.247 




Similarly to L7 and L8, anion-π interactions between the chloride on the trityl 
group (labelled Cl(1) in the molecular structures) and the N-C-N carbon atom 
(labelled C(1)) are present in L10, L12 and L13, indicated by the short distances 
between them (Table 4.3). Intermolecular hydrogen bonds between the protons 
in the H2O molecules and the chloride counterion are observed in the packing of 
L10 and L13 (Figure 4.7). The packing diagrams of L10 and L13 show that the 
molecules pack head-tail-tail-head on all axes, with intermolecular hydrogen 
bonds between the OH of one molecule and chloride counterion of another in the 
centre of the planes. 
 
A.          
                 L9                       L10                      L12                      L13 
 
             B.            L10  L13       
 
Figure 4.7: A. anion-π interactions observed in L9, L10, L12 and L13, and B. 









4.2.3 Imidazolium salts synthesised from trityl chloride 
Imidazolium salts L17-L21 were prepared from trityl chloride in order to examine the 
effect of removing the chloride from the trityl group (Scheme 4.3) on anticancer 
activity. Slight shifts in the 1H NMR spectra are observed between the chloride-
containing ligands L9-L13 and their non-chloride analogous L14-L18. Bigger shifts 
are observed in the 13C{1H} spectra where the loss of Cl generates a symmetrical 
trityl group as shown in Figure 4.8. 
 
Scheme 4.3: Synthesis of imidazolium chloride salts L14-L18 from trityl chloride 
  









Single crystals of L18 suitable for X-ray diffraction analysis were grown by vapour 
diffusion of Et2O into a concentrated solution in MeOH. L18 crystallises in the 
monoclinic crystal system and the structural solution was performed in the P21/c 
space group. A hydrogen bond between the chloride counterion and the terminal 
OH group can be seen in the solid state structure (Figure 4.9), which is not 
observed in other OH containing imidazolium salts L8 and L13. 
 
Figure 4.9: Molecular structure of L18. Ellipsoids are shown at 50% probability 
level and H atoms (except OH) are omitted for clarity 
Thirteen clotrimazole-derived ligand precursors L6-L18 have been synthesised 
and are categorised into three groups: 1) those containing an iodide counterion 
and 2-chlorotrityl group (L6-L8), 2) those containing a chloride counterion and 2 
chlorotrityl group (L9-L13), and 3) those containing a chloride counterion and trityl 
group (L14-L18) (Figure 4.10).   
 
 
            




Figure 4.10: Clotrimazole-derived imidazolium salts synthesised in this work 
N(1)-C(1)-N(2)     108.62 (13)° 
N(1)-C(4)     1.5086 (18) Å 
N(2)-C(23)     1.4723 (19) Å 
Cl(1)∙∙∙∙∙C(1)     3.608 Å 
Group X    Me    allyl    nBu     Bn (CH2)2OH Y 
1      I    L6       -    L7       -      L8     Cl 
2    Cl    L9     L10    L11    L12      L13     Cl 
3    Cl    L14     L15    L16    L17      L18     H 
Y = Cl, H  
X = I, Cl  
 
R = Me, allyl, nBu, Bn, (CH2)2OH 
 




4.3 Silver(I)-NHC complexes 
Silver(I)-NHC complexes were synthesised by reaction of the thirteen ligand 
precursors with Ag2O in CH2Cl2 at reflux (Scheme 4.4). The thirteen complexes 
C6-C18 were fully characterised using 1H and 13C{1H} NMR spectroscopy, HRMS 
and elemental analysis. Both mono(NHC) and bis(NHC) complexes are observed 
in the HRMS data, which is not uncommon for Ag(I)-NHC complexes (Figure 
4.11).10-12 The elemental analysis reveals the formation of mono(NHC) in each 
case except C8, C11 and C17 which revealed a mixture of mono(NHCs) and 
bis(NHCs) (see experimental). In the case of C13 and C18, increasing the 
amount of Ag2O in the reactions gave only mono(NHC) complexes. Therefore 
the complexes are numbered C13A and C18A (purely mono(NHCs)), and C13B 




Scheme 4.4: Synthesis of silver(I)-NHC complexes C6-C18.*Elemental 
analysis reveals a mixture of Ag(NHC)X and [Ag(NHC)2]X, where X = I or Cl 
 
 




Single crystals suitable for X-ray diffraction analysis of C7, C13B, C14, C15 and 
C17 were obtained by vapour diffusion of Et2O (C13, C14, C15 and C17) or C5H12 
(C7) into concentrated solutions of the complexes in either CH2Cl2 (C7, C14, C15 
and C17) or MeOH (C13B). All five complexes crystallise in the monoclinic crystal 
system, with their structural solutions performed in different space groups; C7, 
C14 and C17 were solved in P21/n, C13B in C2/c and C15 in P21 space groups. 
While complexes C14 and C15 crystallise as mono(NHC) complexes, C7, C13B 
and C17 crystallise as the bis(NHC) complex (Figure 4.12). Interestingly, two 
bis(NHC) molecules of C7 are present in one unit cell, and co-crystallise with a 
molecule of n-pentane and [AgCl]2  as shown in Figure 4.12, in addition halide 
exchange can be observed between the Clˉ on the triphenyl and the Iˉ counterion. 
C17 Co-crystallises with a molecule of H2O and two molecules of CH2Cl2, one of 
which it forms hydrogen bonds with an aromatic hydrogen. The silver centres in 
each solid-state structure deviate slightly from linearity (Table 4.4). Similar to the 
packing of its ligand precursor L13, the molecules in C13B pack head-tail-tail-












    
                                C7                                                    C13B 
        
                               C14                                                      C15 
 
                                                                     C17 
Figure 4.12: Molecular structures of C7, C13B, C14, C15 and C17. Ellipsoids 
are shown at 50% probability for C14 and C15, 40 % for C17 and 35% for C7 
and C13B. H atoms are omitted for clarity 






Figure 4.13: Packing diagram of C13B along the c axis. Ellipsoids are shown at 
35% probability and H atoms are omitted for clarity 
  
Table 4.4: Selected bond lengths and angles for C7, C13B, C14, C15 and C17 
Selected bond 
lengths (Å)    
and angles (°) 
    C7    C13B    C14    C15    C17 
     Ag1-C1   2.08 (2) 2.109 (10)  2.091 (5) 2.102 (4) 2.121 (3) 
     Ag1-Cl1       -       - 2.3216 (14) 2.3633 (12)        - 
    N1-C1-N2 104.9 (17)  106.0 (9)  105.9 (5) 103.9 (3) 104.1 (3) 
   Ag1-C1-N1 130.4 (15)  131.8 (7)  127.3 (4) 132.9 (3) 127.8 (3) 
   C1-Ag1-C1  171.2 (7)  171.3 (5)        -         - 173.66 (12) 








4.4 Hydrophobicity measurements 
The hydrophobicity of complexes C6-C18 was measured in a similar fashion as 
previously reported for xanthine-derived complexes (section 2.4). Unlike 
xanthine-derived complexes C1-C5 which were more soluble in the aqueous 
layer, clotrimazole derived complexes were found to be more soluble in the 
octanol layer, and hence measurements for C6-C18 were conducted in the 
octanol layer. As discussed in chapter 2, a negative Log P value indicates a 
hydrophilic complex, and a positive Log P indicates a lipophilic complex which is 
more likely to cross biological membranes through passive diffusion. 
Due to the triphenyl group, all thirteen complexes C6-C18 showed positive Log 
P values indicating that they are all hydrophobic (Table 4.5). In general, 
hydrophobicity increases where R = hydroxyethyl ˂ methyl ˂ allyl ˂ butyl ˂ 
benzyl, across the three groups of complexes. The 2-chlorotrityl complexes C9-
C13 are slightly more hydrophobic than their trityl derivatives C14-18. 
Exchanging the counterion from Iˉ to Clˉ decreases the hydrophobicity i.e. C6-C8 
are more hydrophobic than C9, C11 and C13. The Log P of cisplatin was 
measured using the same method. Cisplatin was more soluble in the aqueous 
layer and a value of -1.35 was obtained, which is less negative than the literature 
















Table 4.5: Log P values of C6-C18 and cisplatin 
Complex Log P ±SD 
Cisplatin -1.35 0.26 
C6 0.41 0.09 
C7 0.59 0.07 
C8 0.36 0.06 
C9 0.37 0.05 
C10 0.45 0.07 
C11 0.55 0.02 
C12 0.58 0.08 
C13A 0.28 0.11 
C13B 0.30 0.06 
C14 0.34 0.07 
C15 0.42 0.07 
C16 0.52 0.03 
C17 0.55 0.05 
C18A 0.25 0.14 






















4.5 Anticancer testing 
The in vitro cytotoxicity of complexes C6-C18 was measured using MTT-based 
assays against cancerous cell line Panc 10.05, a pancreatic adenocarcinoma cell 
line, in addition to non-cancerous ARPE-19, a retinal epithelial cell line. 
Complexes that exhibited promising cytotoxicity and/or selectivity were further 
tested against the cancerous cell lines Mia-PA-CA-2 (pancreatic carcinoma) and 
BE (colorectal carcinoma). The results are summarised in Table 4.6 and Figure 
4.16. It is evident that the 2-chlorotrityl complexes (C9-C13) are consistently 
more cytotoxic than their trityl analogues (C14-C18) against Panc 10.05. This 
indicates a positive effect of having a 2-chloro substituent on the trityl which may 
be attributed to increased hydrophobicity, improving the complexes ability to 
cross cellular membranes.13  
Interestingly, the N-hydroxyethyl substituted complexes C13 and C18 (including 
mono-NHCs (C13A and C18A) and mixed mono/bis(NHCs) (C13B and C18B)) 
are the most cytotoxic in their groupings (highlighted in red, Table 4.6). These 
are followed by the N-benzyl containing complexes C12 and C17 (highlighted in 
green), possibly attributed to their lipophilicity which allows them to cross cell 
membranes. Improved water solubility allows a drug to flow more freely through 
the bloodstream and reach its site of action, which is beneficial in vivo.14, 15 In 
addition, improved water solubility (increased relative hydrophilicity and lower 
Log P) leads to a drug with a more “intermediate lipophilicity”, which is reportedly 
optimum for anticancer activity.16  
N-hydroxyethyl substituted complexes C13B and C18B are significantly more 
selective towards Panc 10.05 over ARPE-19 than other complexes in their 
groups. C13B has similar cytotoxicity to cisplatin, with an IC50 value of 1.3 (± 0.5), 
compared to cisplatin’s 1.7 (± 0.4) against Panc 10.05. Furthermore, C13B 
displays much improved selectivity over cisplatin, with an ARPE-19 / Panc 10.05 
selectivity ratio of 17.5 (cisplatin = 3.8) an ARPE-19 / Mia-PA-CA2 selectivity ratio 
of 6.62 (cisplatin = 2.3). The selectivity ratios represent the selectivity of the drug 
towards cancerous over non-cancerous cell lines, and is presented as a value of 
IC50 non-cancerous / IC50 cancerous e.g. IC50 ARPE-19 / IC50 Panc10.05, where 
a higher value indicates higher selectivity towards cancerous cell line. It is worthy 
to note that C18A, C13A, and C9 display no toxicity towards the non-cancerous 
cell line at the highest concentration (50µM) indicating that these complexes may 
be selective towards cancer cell lines. 
 




Iodide-containing complexes C6-C8 were evaluated against the 3 cancerous cell 
lines Panc 10.05, Mia-PA-CA2 and BE and the non-cancerous ARPE-19. The 
results on the colorectal carcinoma BE indicate that the same trends observed 
above for C9-C18 also apply to C6-C8 on this specific cell line, with hydroxyethyl 
substituted complex C8 showing the lowest IC50 value (2.0 ± 0.3). In particular, 
C8 appears selective towards BE over the other cell lines, and has significantly 
improved cytotoxicity compared to the analogous complexes with chloride 
counterions.  This indicates that the presence of the iodide counter anion 



















Table 4.6: Responses of Panc 10.05, Mia-PA-CA-2 and BE cancerous cell lines and ARPE-19 non-cancerous cell line to silver(I)-
NHC complexes C6-C18. Values presented are IC50 (µM) ±SD for three independent experiments. *minimum value if IC50 for ARPE-
19 is 50 µM. 
Cell Line 
Panc 10.05         Selectivity ratio 
                    (ARPE-19/Panc10.05) 
Mia-PA-CA2          Selectivity ratio 
                    (ARPE-19/MIA-PA-CA2) 
BE              Selectivity ratio 
                  (ARPE-19/BE) 
ARPE-19 
Cisplatin 1.7  ± 0.4 3.8 2.8 ± 2.1 2.3 0.7 ± 0.3 9.7 6.4  ± 1.0 
C6 10.0 ± 7.0 2.4 5.7 ± 2.3 4.2 3.3 ± 1.2 7.3 24.2  ± 2.6 
C7 3.9 ± 2.0 2.3 4.6 ± 3.9 1.9 3.6 ± 0.9 2.4 8.7  ± 1.5 
C8   13.3 ± 8.0 1.2   6.9 ± 2.1 2.3 2.0  ± 0.3 8.5 26.0 ± 1.7 
C9 7.1 ± 3.7 7.0*   11.7 ± 1.6 4.3*  18.0 ± 4.4 2.8* > 50 
C10 9.4 ± 5.6 1.2 6.3 ± 4.8 1.8 6.7 ± 1.1 1.7 11.5 ± 3.0 
C11 10.1  ± 4.6 1.6 - - - - 16.3  ± 3.2 
C12 5.8 ± 1.4 1.8 7.0 ± 1.6 1.5 8.4 ± 1.3 1.2 10.3  ± 0.8 
C13A - - 3.3 ± 0.9 15.2* - - ˃ 50 
C13B 1.3 ± 0.5 17.5 3.3 ± 1.2 6.6 5.8 ± 4.6 3.8 21.9 ± 4.4 
C14 16.1 ± 0.9 1.7 - - - - 26.7  ± 7.8 
C15 16.1  ± 2.0 1.7 - - - - 27.5  ± 7.5 
C16 16.8  ± 1.9 0.8 - - - - 13.8 ± 6.5 
C17 9.6  ± 1.2 3.4 - - - - 32.1  ± 3.3 
C18A - - 2.7 ± 0.3 18.3*   ˃ 50 
C18B 5.3 ± 1.7  5.3 5.9 ± 1.3 4.8 6.1 ± 3.0 4.6 28.0  ± 4.2 




























Figure 4.16: Bar chart to show IC50 values for complexes C6-C18 in comparison to cisplatin against Panc 10.05, Mia-PA-CA-2 
and BE cancerous cell lines and ARPE-19 non-cancerous cell line 
Panc 10.05 Mia-PA-CA2 BE ARPE-19 





Thirteen imidazolium salts derived from clotrimazole (Group 1), 2-chlorotrityl 
(Group 2) and trityl (Group 3) were synthesised with varying counterions, N- 
substituents and triphenyl susbstituents. All thirteen imidazolium salts were 
used as ligand precursors for the synthesis of thirteen silver(I)-NHC 
complexes C6-C18. The ligand precursors L6-L18 and silver(I)-NHC 
complexes C6-C18 were fully characterised using 1H and 13C{1H} NMR 
spectroscopy, HRMS and elemental analysis; molecular structures for most of 
the ligands were obtained using X-ray diffraction analysis. Solid-state 
structures of five complexes were obtained indicating the presence of both 
mono and bis(NHC) complexes. Hydrophobicity measurements conducted in 
octanol provided positive Log P values for all complexes, pointing to their 
lipophilic nature attributed to the bulky triphenyl substituent. Cisplatin, which 
is hydrophilic, had a measured Log P value of -1.35. 
Cytotoxicity studies were conducted using C6-C18 against the cancerous cell 
line Panc 10.05 and the non-cancerous cell line ARPE-19, and selectivity 
ratios were calculated. Complexes with promising cytotoxicity or selectivity 
values were further tested against cancerous cell lines Mia-PA-CA2 and BE. 
The antiproliferative results show that a hydroxyethyl substituent has a 
positive effect on cytotoxicity, with C13 having a similar IC50 value to cisplatin 
against Panc 10.05, and significantly higher selectivity for the cancerous cell 
line over the non-cancerous cell line ARPE-19 (selectivity ratio for C13B = 
17.5 and cisplatin = 3.8). C13 and C18 have the lowest Log P values of this 
class and are therefore of “intermediate lipophilicity”, which has previously 
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Chapter 5                                                                                   
Synthesis and anticancer activity of water soluble 
hydroxyethyl-substituted and carboxylic acid-substituted 
silver(I)-N-heterocyclic carbene complexes 
 
5.1 Introduction 
The synthesis of water-soluble Ag(I)-NHC complexes has been previously 
reported in the literature.1-3 The improved water solubility was achieved by the 
addition of alcohol or ether groups to the NHC ligands, resulting in improved 
biological availability of these complexes.1, 2 Youngs et al. reported the synthesis 
of Ag(I)-bis(NHC) complexes with alcohol N-substituents of different chain 
lengths (Figure 5.1A).4 Braunstein et al. reported simple alcohol and ether N-
substituted Ag(I)-bis(NHC) complexes (Figure 5.1B and C), and Napoli et al. also 
report Ag(I)-bis(NHC) complexes with varying alcohol N-substituents (Figure 
5.1D). These complexes have shown promising antibacterial properties when 
tested against bacterial strains of Escherichia coli and Bacillus subtilis. Therefore, 
with the aim of improving the bioavailability of Ag(I)-NHCs for cancer therapeutics 
through the formation of water soluble complexes, alcohol, carboxylic acid and 
ester N-substituted NHCs were synthesised. 
 
A. B.    C.    
 
D.   
 
Figure 5.1: Water soluble Ag(I)-NHC complexes reported in the literature1, 2, 4 
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5.2 Ligand synthesis 
5.2.1 N-Hydroxyethyl-substituted imidazolium salts 
Nine imidazolium salts L19-L27 were synthesised using modified methods 
reported by Braunstein et al., starting with an N-substituted imidazole which is 
reacted with 2-chloroethanol (Scheme 5.1).3 The reagents were heated in MeCN 
in a sealed vessel at 90°C for 24-72 hours. Commercially available substituted 
imidazoles were used for the synthesis of L19-L23, while for L24-L27 the starting 
imidazoles were synthesised following methods reported in the literature.5, 6  L19-
L27 were fully characterised using 1H and 13C{1H} NMR spectroscopy, HRMS 
and elemental analysis. Facile purification of L20-L27 through recrystallisation 
from MeOH and Et2O furnished the products with yields shown in Scheme 5.1. 
On the other hand, purification of  L19 was more challenging as both the starting 
1-(2-hydroxyethyl) imidazole and the resulting imidazolium salt have similar 
solubility’s in a number of solvents including MeOH, (CH3)2CO, H2O, MeCN, 
CH2Cl2 and CHCl3. Therefore optimum conversion was essential in this reaction, 
which required heating the reagents in MeCN in a sealed vessel at 90°C for 6 




Scheme 5.1: Synthesis of imidazolium salts L19-L27 
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5.2.2 L-Alanine derived imidazolium salt 
Following methods reported by  Meyer et al.,7 L-alanine was reacted with glyoxal 
and formaldehyde, resulting in its cyclisation to form the imidazole P28A. Addition 
of thionyl chloride to the imidazole in MeOH forms methyl ester P28B (Scheme 
5.2). Reaction with excess methyl iodide in a sealed vessel was performed to 
give L28. The 1H NMR spectrum performed in MeOD is shown in Figure 5.2.  
 
Scheme 5.2: Synthesis of imidazolium salt L28 from L-alanine 
  
 
Figure 5.2: 1H NMR spectrum (300 MHz, MeOD) of L28  
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5.2.3 Bis-imidazolium salts 
The initial aim was to synthesise a bis-imidazolium salt from L-alanine following 
methods reported by Meyer et al.,7 through reaction of P28B with diiodomethane 
(Scheme 5.3). However, the desired product was not synthesised, possibly due 
to polymerisation of diiodomethane. Instead, carboxylic acid N-substituted bis-
imidazolium salts were prepared. Reaction of imidazole with dibromomethane in 
a minimum amount of H2O, in the presence of KOH and a phase transfer agent 
(tetrabutylammonium bromide), yields bis-imidazole (Scheme 5.4). Further 
reaction with two equivalents of a chloroacetate (methyl, tert-butyl and benzyl 
chloroacetate) rendered bis-imidazolium salts L29-L31. Figure 5.3 illustrates the 
amino acid glycine as an integrated portion of L29-L31, which can arguably 
categorise them as ‘biologically relevant’.  
 
Scheme 5.3: Attempted synthesis of bis-imidazolium salt from L-alanine7 
  




                                                                                                                
Figure 5.3: Illustration of glycine amino acid incorporated in L29-L31 
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The exact nature of L30 was challenging to identify, as the cleavage of the tert-
butyl to form carboxylic acid may have occurred. This is likely due to the stability 
of the tert-butyl carbocation, which can be cleaved under the reaction conditions. 
The 1H-NMR spectrum of L30 shows the tert-butyl group or carbocation as a 
singlet at 1.47 ppm (Figure 5.4), while HRMS (Figure 5.5), X-ray diffraction 
analysis (Figure 5.6), and elemental analysis indicate presence of terminal 
carboxylic acid groups.  
  
 
Figure 5.4: 1H-NMR spectrum (300MHz, acetonitrile-d3) of L30  
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Single crystals of L30 suitable for X-ray diffraction analysis were grown by vapour 
diffusion of Et2O into a concentrated solution of the ligand in MeOH. L30 
crystallises in the monoclinic crystal system and the structural solution solved in 
the space group I2/a. L30 co-crystallises with a molecule of H2O as shown in 
Figure 5.6, with no evidence of hydrogen bonding between the water molecule 
and the carboxylic acid terminals. The packing structure of L30 along the b axis 
is shown in Figure 5.7. The imidazolium counterion was found to be 50% Cl and 
50% OH. 
 
Figure 5.6: Molecular structure of L30. Ellipsoids are shown at 50% probability 
and H atoms are omitted for clarity 
 
                        




CHAPTER 5                                                                  UNIVERSITY OF LEEDS 
98 
 
5.2.4 Carboxylic acid N-substituted imidazolium salts 
Following results obtained in the synthesis of L30 to give carboxylic acid N-
substituted imidazolium salts, the synthesis of additional N-carboxylic acid 
substituted ligand precursors for coordination to silver was pursued. An 
imidazolium salt with carboxylic acid groups on both nitrogen atoms (L32) was 
synthesised through reaction of imidazole with either chloroacetic acid or with 
tert-butyl chloroacetate (Scheme 5.5). The synthesis of an imidazolium salt with 
a carboxylic acid N-substituent and an anthracene N-substituent (L33) is shown 
in Scheme 5.6. As with L32, reaction of P33 with either chloroacetic acid or with 
tert-butyl chloroacetate renders the desired product L33. The 1H NMR spectrum 
shows the imidazolium proton downfield shift to 11.30 ppm, which is particularly 
deshielded due to the anthracene electron withdrawing effect (Figure 5.8). 
                               
Scheme 5.5: Synthesis of dicarboxylic acid imidazolium salt L32 
                                                                    
Scheme 5.6: Synthesis of L33 
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5.3 Silver(I)-NHC complexes 
5.3.1 Silver(I)-NHC complexes with N-hydroxyethyl substituents 
Reaction of L19-L27 with Ag2O in MeOH gives Ag(I)-bis(NHC) complexes C19-
C27 of the type [Ag(NHC)2]+Clˉ (Scheme 5.7). The formation of the Ag(I)-NHC 
complexes can be monitored using 1H NMR spectroscopy, with disappearance of 
the imidazolium proton peak at ≈ 9 ppm (Figure 5.9). The formation of the Ag(I)-
bis(NHC) cation is also observed through the HRMS data. Purification of C19-
C27 was performed by filtration through celite followed by recrystallisation from 
MeOH and Et2O. Complexes C19-C27 were fully characterised using 1H and 
13C{1H} NMR spectroscopy, HRMS and elemental analysis. The complexes are 
stable as solids and can be stored for several months when kept away from 
atmospheric moisture. However, C21 appears to be an exception, as it 
decomposes during recrystallisation, which is detected by the colour change of 
the complex to a dark grey colour. Although successful synthesis and analysis 




Scheme 5.7: Synthesis of water soluble Ag(I)-NHC complexes C19-C27  
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5.3.2 Two-dimensional polymeric silver(I)-NHC complex  
L-Alanine-derived imidazolium salt L28 was reacted with Ag2O in MeOH 
(Scheme 5.8). However, the basicity of Ag2O was found to hydrolyse the ester, 
allowing the silver to coordinate to the two oxygen atoms, in addition to its 
coordination to the carbene centre. Full analysis of the product, including HRMS, 
NMR spectroscopy, elemental analysis and X-ray diffraction analysis, validates 
the formation of the Ag(I)-NHC complex C28, which is a 2-dimensional polymer 
in the solid state (Figure 5.10). Single crystals of C28 suitable for X-ray diffraction 
analysis were grown by vapour diffusion of Et2O into a concentrated solution of 
the complex in MeOH. C28 crystallises in the monoclinic crystal system and the 
structural solution was solved in the space group P21/n (Figure 5.10). The silver 
atoms display argentophilic interactions, with each coordinating another silver 
atom, two oxygen molecules of the formal ester and the carbenic carbon. This 
coordination has previously been reported in the literature as a dimeric dianion.8 
The Ag-Ag bond length is 3.1039(17) Å, while the  Ag-O bond lengths are 
2.335(8) Å and 2.499(11) Å, and the Ag-C bond length is 2.057(9) Å, all of which 
are in close agreement with the literature.8 
 
 
Scheme 5.8: Synthesis of 2-dimensional Ag(I)-NHC polymer C28 









Figure 5.10: Molecular structure of C28. Ellipsoids are shown at 50% 
probability and H atoms are omitted for clarity 
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5.3.3 Silver(I)-NHC complexes from bis-imidazoliums 
Reaction of imidazolium salts L29-L31 with Ag2O in a solvent mixture of MeOH 
and MeCN under anhydrous conditions, furnished Ag(I)-bis(NHC) complexes 
with two OH counterions (Scheme 5.9). Complexes C29-C31 are isolated as 
white solids, which are stable and very soluble in water. Full characterisation of 
the complexes including HRMS, NMR spectroscopy, and elemental analysis 
suggest that complex C30 has 4 terminal carboxylic acid groups (Figure 5.11) 
and both C29 and C31 have a mixture of carboxylic acids and esters in a 1:1 
ratio. 
 
Scheme 5.9: Synthesis of Ag(I)-NHC complexes C29-C31 
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5.3.4 N-Carboxylic acid substituted silver(I)-NHCs 
Reaction of L35 and L36 with Ag2O in a solvent mixture of MeOH and CH2Cl2 
under anhydrous conditions furnished Ag(I)-bis(NHC) complexes C32 and C33 
(Scheme 5.10). Complexes were characterised using NMR spectroscopy, 
elemental analysis and HRMS (Figure 5.12). 
 
 
Scheme 5.10: Synthesis of carboxylic acid N-substituted Ag(I)-NHC 
complexes C32 and C33 
  
                    
Figure 5.12: HRMS of C33 
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5.4 Hydrophobicity measurements 
Hydrophobicity measurements were conducted using UV/vis spectroscopy on 
C19, C20 and C22-C33 and Log P values obtained (Table 5.1, Figure 5.13).  All 
complexes are water-soluble and therefore the hydrophobicity measurements 
were conducted in the aqueous layer. The Log P values of the fourteen 
complexes vary from -0.35 to 0.496. N-Hydroxyethyl substituted complexes C19, 
C20, C22, the two dimensional Ag(I)-NHC polymer C28, the N-carboxylic acid 
substituted silver dimer  C30 and monomer C33 are hydrophilic with negative Log 
P values. N-Anthracene substituted complexes C27 and C33 and N-benzyl 
substituted silver dimer C31 have a more “intermediate lipophilicity” with Log P 
values ≈ 0.3-0.5.  
 
Table 5.1: Log P values of C19, C20 and C22-C33, and cisplatin 
Complex Log P SD(±) 
Cisplatin -1.35 0.26 
C19 -0.35 0.20 
C20 -0.14 0.16 
C22 -0.07 0.13 
C23 0.02 0.07 
C24 0.11 0.13 
C25 0.005 0.08 
C26 0.08 0.16 
C27 0.29 0.01 
C28 -0.17 0.02 
C29 0.086 0.13 
C30 -0.05 0.07 
C31 0.496 0.21 
C32 -0.21 0.15 
C33 0.33 0.11 
 





Figure 5.13: Log P values of complexes C19, C20 and C22-C33: N-
hydroxyethyl substituted (blue), 2D-polymer (green), N-carboxylic acid / 
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5.5 Anticancer Testing 
The cytotoxicity of C19, C20 and C22-C33 were evaluated against pancreatic 
adenocarcinoma cancerous cell line Panc 10.05 (Table 5.2, Figure 5.14). 
Complexes that displayed promising anticancer activity (i.e. IC50 values below 10 
(C23, C27 and C28)), were further tested against pancreatic carcinoma Mia-PA-
CA-2 and colorectal carcinoma BE cancerous cell lines. The selectivity of C23, 
C27 and C28 towards cancerous cell lines was evaluated by comparison of their 
cytotoxicity with toxicity on non-cancerous retinal epithelial ARPE-19 (Figure 
5.15) 
Alcohol substituted complexes appear more cytotoxic than the corresponding 
carboxylic acid substitued complexes. For example, C19 with two N-hydroxyethyl 
substituents has a significantly lower IC50 value (14.7 ± 3.4) against Panc 10.05 
than C32 with two N-carboxylic acid substituents (IC50 > 100µM). Other examples 
include the N-hydroxyethyl and N-anthracene substituted complex C27, which is 
more cytotoxic than the corresponding N-carboxylic acid and N-anthracene 
substituted C33, and the N-hydroxyethyl and N-benzyl substituted complex C23, 
which is more cytotoxic than N-hydroxyethyl and N-benzyl substituted bis-
imidazole complex C31. Within the bis-imidazole complexes, the N-carboxylic 
acid substituted C30 and C31 are more cytototoxic than C29.  
C23 exhibits the lowest IC50 value (3.0µM ± 0.5) close to that displayed by 
cisplatin (1.7µM ± 0.4) while also having superior selectivity towards cancerous 
cells (selectivity ratio of 7.3 compared to 3.8 for cisplatin, Table 5.2). The 
“intermediate lipophilicity” of C23 and C27 may contribute to their superior 
cytotoxicity, as they contain both hydrophilic (hydroxyethyl) and hydrophobic 
(benzyl or anthracene) N-substituents. Complexes bearing both hydrophilic and 
hydrophobic N-substituents appear to be more cytotoxic than their corresponding 
complexes with only hydrophilic N-substituents. For example, the N-benzyl and 
N-carboxylic acid substituted complex C31 is more cytotoxic than N-carboxylic 
acid substituted complex C30, and N-hydroxyethyl and N-benzyl substituted 
complex C23 is more cytotoxic than N-hydroxyethyl substituted complex C19. 
However, lipophilicity does not appear to be the only factor in determining the 
anticancer activity of water-soluble Ag(I)-NHC complexes, as there are other 
examples of complexes with “intermediate lipophilicity” e.g. C24-C26, which do 
not display good cytotoxicity. 
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The promising cytotoxicity of C28 (7.5µM ± 0.3) may be due to its polymeric 
nature that leads to a prolonged exposure9 of the cancerous cells to the 
cytotoxic portion of the complex. C28 displays superior cytotoxicity against 
cancerous cell lines Mia-PA-CA-2 and BE over both C23 and C27, with the 
















Table 5.2: IC50 values for complexes C19, C20, C22-C33 and 
cisplatin on Panc 10.05 
Complex IC50 (µM) ±SD 
Cisplatin 1.7  ± 0.4 
C19 14.7 ± 3.4 
C20 30.6 ± 3.4 
C22 17.0 ± 4.1 
C23 3.0 ± 0.5 
C24 24.0 ± 3.4 
C25 15.8  ± 1.0 
C26 33.2 ± 3.5 
C27 8.3 ± 2.1 
C28 7.5 ± 0.3 
C29 17.1  ± 6.7 
C30 12.27  ± 3.20 
C31 10.44  ± 1.86 
C32 > 100 
C33 26.3 ± 11.5 





Figure 5.14: IC50 values of complexes C19, C20, and C22-C33 and cisplatin 














































Table 5.3: Responses of Panc 10.05, Mia-PA-CA-2 and BE cancerous cell lines and ARPE-19 non-cancerous cell line to Ag(I)-NHC 
complexes C23, C27, C28 and C33. Values presented are IC50 (µM) ±SD for three independent experiments 
Cell Line 
Panc 10.05      Selectivity ratio 
               (ARPE-19 /Panc10.05) 
MIA-PA-CA2     Selectivity ratio 
              (ARPE-19 /MIA-PA-CA2) 
        BE          Selectivity ratio 
                       (ARPE-19 /BE) 
ARPE-19 
Cisplatin 1.7  ± 0.4 3.8 2.8 ± 2.1 2.3 0.7 ± 0.3 9.7 6.4  ± 1.0 
C23 3.0 ± 0.5 7.3 5.7 ± 1.8 3.8 7.0 ± 2.6 3.1 21.4 ± 2.9 
C27 8.3 ± 2.1 1.7 6.2 ± 3.6 2.2 12.0 ± 3.6 1.1 13.7  ± 2.9 
C28 7.5 ± 0.3 2.5 4.9 ± 2.6 3.9 5.4 ± 3.6 3.5 19.0  ± 5.1 
C33 26.3 ± 11.5 2.6 - - - - 68.7 ± 7.2 
Panc 10.05 Mia-PA-CA2 BE ARPE-19 




Fifteen water-soluble imidazolium salts L19-L33 have been synthesised from 
which Ag(I)-NHC complexes C19-C33 were prepared. N-Hydroxyethyl-
substituted ligands formed Ag(I)-bis(NHC) complexes C19-C27; L-alanine-
derived ligand precursor formed a two-dimensional Ag(I)-NHC complex C28; 
Bis-imidazolium salts formed N-carboxylic acid-substituted Ag(I)-bis(NHC) 
dimers C29-C31;  and the N-carboxylic acid-substituted imidazoliums formed 
Ag(I)-bis(NHC) monomers C32 and C33. All ligand precursors and complexes 
have been fully characterised using 1H and 13C{1H} NMR spectroscopy, HRMS 
and elemental analysis. 
Hydrophobicity measurements were conducted and, as expected, the Log P 
values were small (< 0.5) due to the presence of the hydrophilic side chains, 
with six complexes (C19, C20, C22, C28, C30 and C32) showing negative Log 
P values. Cytotoxicity studies were performed against pancreatic 
adenocarcinoma cell line Panc 10.05 using all the complexes (except C21) 
reported in this chapter. Complexes bearing both N-hydrophilic and N-
hydrophobic substituents (e.g. C23 and C27) tended to be more cytotoxic than 
complexes with solely N-hydrophilic substituents (e.g. C19 and C32). This 
finding supports previous conclusions drawn in Chapters 2 and 4, where 
“intermediate lipophilicity” appears to be a contributing factor for superior 
antiproliferative activity. Lipophilicity of a complex however does not appear to 
be the only factor affecting the cytotoxicity of these complexes, as some that 
also bear both N-hydrophilic and N-hydrophobic substituents do not exhibit high 
antiproliferative activity (e.g. C24-C26).  
C28 exhibited good antiproliferative activity, possibly due to its polymeric 
structure, which suggest the use polymers with Ag(I)-NHC complexes in cancer 
therapy may improve anticancer activity (see Chapter 6). The three complexes 
C23, C27 and C28 with superior cytotoxicity values were further tested against 
pancreatic carcinoma Mia-PA-CA-2 and colorectal carcinoma BE cancerous cell 
lines. Their selectivities were evaluated through testing against non-cancerous 
retinal epithelial ARPE-19 and compared to cisplatin, revealing a higher 
selectivity of C23 over cisplatin on both Panc 10.05 and Mia-PA-CA-2. C23 is 
therefore a promising complex with antiproliferative activity close to cisplatin, 
while showing superior selectivity towards cancerous cell lines Panc 10.05 and 
Mia-PA-CA-2. 
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Chapter 6  
Development of polymer-silver-NHC conjugates and micelles 
for drug delivery 
 
6.1 Introduction 
Polymer-drug conjugates (PDCs) have been investigated as drug delivery 
systems,1-8  and are reported to improve the therapeutic index of low molecular 
weight drugs in different therapeutic areas, including cancer, and infectious and 
inflammatory diseases. Small-molecule drugs have a small therapeutic index i.e. a 
small concentration window where they are effective and non-toxic, due to a high 
clearance rate, and to non-selectivity to their site of action, leading to toxicity and 
a small ‘effective dose’. Since the establishment of Ringsdorf’s model9, 10 (Figure 
6.1A) of a general drug delivery system over three decades ago, variations from 
the original mononuclear model were developed, including polynuclear, starlike 
and dendritic systems (Figure 6.1B-D). Several polymer-drug systems have been 
approved and released to the market that including treatments for hepatitis C and 
leukemia,7 while others have gone through clinical trials including a system that 
involves cisplatin.8 Encapsulation of a drug inside a polymer in the form of a 
polymer-drug micelle (PDM) is a more recent development for drug-delivery.11 
PDMs are referred to in the literature as micelles, polymeric micelles or polymeric 
nanoparticles (NP), when their diameters are in the nanomolar range. 
Encapsulation of drugs has many advantages, including protection from enzymatic 
degradation and hepatic inactivation in vivo, and the possibility of controlled drug 
release. An example of drug encapsulation into micelles is shown in Figure 6.1E, 
with the anticancer drug camptothecin (Cpt), via co-precipitation with polymers.12 
        
Figure 6.1: Structural models of polymer-drug conjugate systems (A-D)2 and 
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Polyethylene-glycol (PEG) is one of the most used polymers in drug delivery 
systems because it is non-toxic, and is FDA approved.4, 5 The non-ionic, hydrophilic 
nature of PEG prevents opsonisation (interaction with blood components), and 
improves water solubility. This prevents aggregation, leading to formulations with 
enhanced stability, in addition to preventing enzymatic cleavage (Figure 6.2). 
Targeting of the PDCs or PDMs in cancer therapeutics can be achieved passively 
due to the enhanced permeability and retention of the cancerous tissues known as 
the EPR effect.13, 14 The use of macromolecules for targeting antitumor drugs 
without cell-specific targeting, and solely based on the biochemical and 
physiological differences of healthy and malignant tissues (Figure 6.3), has been 
introduced by Maeda et al.13, 15 and Jain et al.16, 17 Their work opened a new area 
of polymer-based drug formulations without the use of receptor-recognisable 
groups such as antibodies, oligosaccharides and proteins on the surface of the 
micelle.18, 19 This chapter describes the use of polymers for Ag(I)-NHC conjugation 
or encapsulation, with the aim of utilising the EPR effect to target cancerous cells, 
reduce their renal clearance rates and to increase shelf-life. 
 
Figure 6.2: Illustration of using PEG for drug conjugation4 
 
Figure 6.3: Illustration of EPR effect2 
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6.2 Conjugation of silver-NHCs to polymers 
The synthesis of polymer-Ag(I)-NHC conjugates was attempted using block 
copolymers PM1 and PM2 bearing imidazolium salts. Reaction of PM1 and PM2 
with silver oxide in MeOH under anhydrous conditions successfully forms the 
polymer-silver conjugates PDC1 and PDC2 (Scheme 6.1). Coordination of silver 
is observed in the 1H NMR spectra through the loss of the imidazolium proton peak 
that usually appears at ≈ 9.30 ppm (Figure 6.4). 
 
 
           
Scheme 6.1: Synthesis of polymer-Ag(I)-NHC conjugates PDC1 and PDC2 
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Solid state 13C NMR spectroscopy is consistent with of silver coordination to the 
polymers (Figure 6.5). This is presented by the appearance of the Ag-C shift at 
≈ 180 ppm and 168 ppm for both conjugates PDC1 and PDC2 which is not 
present in the solid state 13C NMR spectra of PM1 and PM2. Following 
Ringsdorf’s model,9, 10 the drug in this PDC is the Ag(I)-NHC, the linker is the 
methylene bridge and the polymer is the block copolymer (Figure 6.6). 
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With the aim to use naturally-derived polymers, poly (L)-glutamic acid (PM3) was 
reacted with imidazolium salt L20 to form an ester linking PM3 and L20 (Scheme 
6.2). The Fischer esterification was conducted in DMF to solubilise PM3, and 
under anhydrous conditions with molecular sieves to remove any water generated 
from the reaction that may possibly hydrolyse the resulting ester bond. 1H NMR 
spectra suggest successful esterification with the appearance of the imidazolium 
proton peak at ≈ 9 ppm and a broad peak ≈ 5 ppm corresponding to CH2 groups 
(Figure 6.7). The PM3-L20 conjugate 1H NMR spectrum is broader than that of 
PM3, due to more signal overlap, and a slower relaxation time as the molecular 
mass increases.  
Reaction with silver oxide in a solvent mixture of DMSO and MeOH did not yield 
the desired product PDC3. The imidazolium proton peak was still present in the 
1H NMR spectrum after 24 hours of slowly increasing the temperature from 40 to 
120°C (Figure 6.8). However, there is a shift in the proton peaks attributable to 
the CH2 groups of PM3-L20, from 3.5-5.5 ppm to 2.0-3.5 ppm. This indicates that 
hydrolysis of the ester may have occurred, which was confirmed through a single 
crystal suitable for X-ray diffraction analysis obtained from vapour diffusion of 
Et2O into the reaction solution. The molecular structure shows that PM3-L20 has 
reacted with DMSO to form an ether link. PM3-L20 crystallised in the 
orthorhombic crystal system and  structural solution was solved in the Pbca space 
group.  
  





Scheme 6.2: Fischer esterification of PM3 and L20 to form PM3-L20 and 
reaction with Ag2O  




Figure 6.7: 1H NMR spectra (300MHz, DMSO-d6) of the Fischer esterification 
reaction to give PM3-L20. 
 
 
Figure 6.8: 1H NMR spectra (300MHz, DMSO-d6) of the reaction of PM3-L20 
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An alternative route was explored which involved reaction of the preformed silver 
complex C20 with PM3 via a Steglich esterification reaction (Scheme 6.3), 
avoiding the use of Ag2O and MeOH. The reaction uses 4-dimethylaminopyridine 
(DMAP) as a catalyst and dicyclohexylcardodiimide (DCC) as a coupling reagent. 
HRMS, IR spectroscopy, NMR spectroscopy (Figure 6.9) and elemental analysis 
suggest successful esterification and formation of PDC3.  
            
                L-glutamic acid (PM3)                      C20                                                              PDC3 
 
Scheme 6.3: Synthesis of PDC3 through a Steglich esterification reaction 
 
 
Figure 6.9: 1H NMR spectra (300MHz, DMSO-d6) of PM3 (top), C20 (middle) 
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The anticancer activity of the polymer-Ag(I)-NHC conjugates PDC1-PDC3 were 
evaluated against pancreatic adenocarcinoma cell line Panc 10.05. The results 
were compared to the corresponding Ag(I)-NHC complex on its own (Figure 
6.10).  The molecular weights of PDCs used for the MTT-assays were 
calculated as a single unit with one Ag atom as shown in Figure 6.10. The ester 
linked drug-polymer conjugate PDC3 showed superior anticancer activity to its 
corresponding drug C20, and the methylene linked drug-polymer conjugate 
PDC2 is also more cytotoxic that it’s corresponding drug C34 previously 
reported by Willans et al.20 These results display the potential of Ag(I)-NHC-
polymer conjugates as a strategy for enhancing the anticancer activity, possibly 
through the slow release of the silver from the polymer.  Further possibility of 
protecting the drug in vivo, ability to tune the polymer for targeting.                                                                 
 
 
Figure 6.10: IC50 values of drug-polymer conjugates PDC1-PDC3 and the 
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6.3 Encapsulation of silver(I)-NHCs into polymers 
Although PDC1-PDC3 may improve targeting of the silver-based drugs through 
the EPR effect, the linearity of the conjugates exposes the Ag(I)-NHCs to 
enzymes. Encapsulation of the Ag(I)-NHCs by polymers which can self-assemble 
under specific conditions to form polymer-drug micelles (PDMs), may protect the 
complexes from enzyme interactions before reaching their target.  
Methoxy-poly(ethylene glycol)-poly(phenyl-alanine) (mPEG5000P(Phe)) PM4 was 
considered for the encapsulation of the complexes due to  the non-toxic 
properties of PEG.21 Initially, the ability of mPEG5000P(Phe) to self-assemble in 
aqueous medium to form micelles was investigated. Dynamic light scattering 
(DLS) revealed self-aggregation of PM4 to particles with an average particle size 
of 121.4 nm. This was also in agreement with the scanning electron microscopy 
(SEM) images (Figure 6.11). The polydispersity index (PDI) of the formed 
particles had a value of 0.26, suggesting successful self-assembly into relatively 
uniformly sized particles. Although a typical nanoparticle delivery system size 
ranges from 10-100 nm, while some groups report larger sized nanoparticles.22 





Figure 6.11: SEM image of particles formed from self-assembly of 
mPEG5000P(Phe) PM4 in water (10µg/mL) 
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The particles formed constitute an inner lining with the hydrophobic block 
(P(Phe)) surrounded by the outer hydrophilic block (mPEG). Encapsulation was 
investigated using a water-soluble Ag(I)-NHC (C20), with varying ratios of 
C20:PM4. DLS analysis revealed the formation of PDM4a with an average 
particle size of 151.7 nm and PDI of 0.307, when using 1:1 ratio of Ag(I)-NHC 
complex to polymer (Figure 6.12). The driving force for the particle formation is 
mainly the interaction of the polar hydrophilic mPEG with the H2O through 
hydrogen bonds, and the non-polar hydrophobic P(Phe) migration to the organic 
solvent (DMF), causing a microphase separation. This is due to the disruption of 
the cohesive energy at the interface of the amphiphile and water, leading to 
formation of micelle-like aggregates. The Ag(I)-NHC may be embedded inside 
the micelle possibly through interactions (van der Waals’ forces) with the 
hydrophobic block P(Phe). 
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SEM analysis of PDM4a revealed the formation of discrete particles (Figure 
6.13A and B). Energy-dispersive X-ray spectroscopy (EDX) was performed on 
the sample to map the location of silver ions (Figure 6.13C). SEM-EDX reveals 
that the silver ions are located within the particle region, shown when images B 
and C in Figure 6.13 are superimposed, suggesting the successful 
encapsulation of Ag(I)-NHC complex C20. The EDX spectrum shows peaks 
corresponding to silver and chloride ions found in the sample, supporting the 
presence of the complex within the particle region (Figure 6.14). 
 
                                 A.                                                                                                
 
B.                                                           C. 
  
 
Figure 6.13: SEM images of PDM4a A. individual particles, B. magnification 
of on a single particle, C. silver ion mapping of image B. 




Figure 6.14: SEM-EDX spectrum showing peaks corresponding to silver and 
chloride ions 
To further understand the role of the NHC in the encapsulation process, 
encapsulation of a silver salt was attempted by employing the same procedure 
with AgOAc. Equivalent amounts of AgOAc and polymer were utilised, with DLS 
results showing PDI values above 0.7, indicating a polydisperse sample. SEM 
images reveal crystallisation of silver salt with no indication of encapsulation or 
micelle formation (Figure 6.15). This result suggests that the NHC ligand plays 
an important role in the encapsulation process.  
 
     
Figure 6.15: SEM image of a 1:1 AgOAc:PM4 mixture in aqueous solution, 
showing crystallisation of AgOAc  
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6.3.1 Confocal fluorescence microscopy 
Fluorescence microscopy may be used to detect the encapsulation of 
compounds bearing a fluorescent moiety. Therefore, various complexes, that 
contain a fluorescent anthracene N-substituent were designed and synthesised 
(C27, C35-C37, Figure 6.16). C37 was found to be insoluble in water and was 
therefore not considered further, while the solubility in water of C27, C35 and 
C39 were estimated. C27 was found to be significantly more soluble than C35 
and C36 (C27 >> C35 > C36). Encapsulation of C27, C35 and C36 were 
performed in a similar manner as PDM4a. C35 and C36 yielded particles with 
PDI values above 0.7, therefore were not further investigated using fluorescent 
imaging. Encapsulation of C27 resulted in particles PDM4b with an average 
particle size of 134.3 nm and a PDI value of 0.668. 
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Encapsulation of C27 into PM4 was performed by adding equal volumes of 
equal concentrations of C27 and PM4 solutions together in CH2Cl2. An equal 
volume of water was subsequently added to the sample with constant agitation. 
CH2Cl2 was removed in vacuo leaving the aqueous medium that contained the 
particles. Confocal microscopy was used to image particles PDM4b, by 
employing an excitation at 405 nm and detection at 370-500 nm. The images 
taken under visible light (Figure 6.17A) and under fluorescence (B), were 
superimposed (C). These images show the fluorescence in the sample, i.e. the 
Ag(I)-NHC complex located in the same region as the particles. Since C27 emits 
fluorescence in the range 370-500 nm (Figure 6.18), the results indicate either 
encapsulation of silver inside micelles, or conjugation to micellar surface.  
A.                                    B.                                     C. 
 
 
Figure 6.17 : Images of PDM4b under A. visible light B. fluorescence C. 
superimposition of images A. and B. 
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6.4 Electrostatic attraction between silver(I)-NHCs and polymers 
Electrostatic attraction as a method of drug-polymer conjugation and subsequent 
micelle formation was investigated. This method is frequently performed with 
poly(lysine) as the cationic polymer for drug-conjugation and delivery.23-27 
Therefore, in this work, mPEG5000poly(lysine) PM5 was used as the cationic 
polymer, while carboxylic acid N-substituted complexes C30, C32 and C33, and 
the corresponding imidazolium salts L30, L32 and L33 were used as anionic 
drugs (Figure 6.19). This technique ensures that micelles are only formed when 
contact between the drug and the polymer occurs, thereby eliminating the 
possibility of conjugation of the drug to the surface of pre-formed polymeric 
micelles (Figure 6.20).  
                                                                                                                                                  
Figure 6.19: Ag(I)-NHC complexes, imidazolium salts and mPEG-polylysine 
PM5 used in micelle formation through electrostatic attraction 
 






                  
                                         
 
 
Figure 6.20: Illustration of polymer-drug micelle formation through electrostatic attraction of oppositely charged ions  
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6.4.1 Synthesis of mPEG-poly(lysine) PM5 
Methoxy-poly(ethylene glycol)-poly(lysine) (mPEG5000poly(lysine)), PM5, was 
synthesised with three different lengths of the poly(lysine), to furnish three 
polymers of varying mPEG to poly(lysine) ratios. The aim was to examine the 
effect of polymer chain length on the size of the micelle formed. The three step 
synthesis of PM5 involves synthesis of L-Lysine carbobenzyloxy N-
carboxyanhydride (L-lysine CBZ-NCA) from L-lysine carbobenzyloxy (L-lysine 
CBZ), via the reaction of L-lysine CBZ with triphosgene in ethyl acetate, in the 
presence of a proton scavenger α-pinene (Figure 6.21). The synthesis of L-
lysine CBZ-NCA was followed by ring opening polymerisation from an 
mPEG5000 amine. Various ratios of NCA to amine (20, 40 and 75) were reacted 
in DMF, furnishing mPEG5000poly(lysine CBZ). Deprotection of poly(lysine CBZ) 
occurs through hydrolysis of CBZ  groups in hydroboromic acid (33%), in acetic 
acid  solution. 
 
 
Figure 6.21: Three step synthesis of mPEG5000poly(lysine) PM5 
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1H NMR spectroscopy was used to monitor the reaction steps, showing the 
formation of CBZ-NCA with the resonance corresponding to the amine proton in 
NCA at 9.06 ppm (labelled 1 in Figure 6.22A). This peak shifts upfield to 8.30 
ppm upon ring opening polymerisation (labelled 8 in B). The aromatic protons 
from the mPEG5000poly(lysine CBZ) (labelled 1 in B) disappear upon deprotection 





Figure 6.22: 1H NMR spectra (300MHz) of A. CBZ-NCA (DMSO-d6), B. 
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Solutions of the three polymers PM5.A-C with varying polylysine to mPEG ratios 
(Table 6.1), and solutions of L30, C30, L32, C32, L33 and C33, at a 
concentration of 1 mg/mL were prepared in HPLC grade water. All solutions 
were filtered through a 0.45 µm followed by a 0.2µm PTFE syringe filter, with 
DLS analysis indicating no particles present after filtration of the solutions. 
Filtered solutions of 1:1 molar ratios of polymer to ligand/complex were 
subsequently prepared and analysed using DLS at 37°C to mimic the body 
temperature. It was found that particles generally increase in diameter with an 
increase in polymer length. However, PDM5.B.C33 had a larger average 
particle diameter than expected of 452.7nm, suggesting vesicle formation. 
Unlike PM5.A, particles formed using PM5.B and PM5.C possessed PDI values 
below 0.7 upon interaction with all six complexes and ligands. Imidazolium salts 
and the corresponding Ag(I)-NHC complexes seem to behave in a similar 
manner to eachother with regards electrostatic interaction, suggesting that the 
presence of Ag(I) neither hinders nor promotes encapsulation.  
 
Table 6.1: Micelle formation via electrostatic attraction (reactions referred to 





n = 39m 
B 
n = 50m 
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SEM images of the particles were obtained and all the results appear to be in 
agreement with the DLS results. PDC PDM5.B.C33 particles appear to be 
vesicles having an ‘outer shell’ (Figure 6.23),  possibly the polymer outer lining 
or the mPEG portion, while the Ag(I)-NHC is likely to be encapsulated inside 
this shell, surrounded by the poly(lysine) portion, and stabilised by electrostatic 
attraction. Figure 6.24 illustrates the behaviour of PM5, and the Ag(I)-NHC 
complex C30 where no particles are observed (A). Upon mixing of the solutions, 
electrostatic attraction between the opposite charges begin to form micelles and 












Figure 6.23: SEM images of PDM5.B.C33  
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Figure 6.24: Illustration of A. a solution of PM5 and Ag(I)-NHC complex C30, 
and B.  micelles formed upon mixing the solutions, and their corresponding 
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6.5 Anticancer activity of drug-polymer micelles 
The anticancer activity of the particles PDM4a, PDM5.B.C30 and PDM5.B.C33 
were evaluated against the pancreatic adenocarcinoma cell line Panc 10.05 
(Table 6.2 and Figure 6.25). The results were compared to those previously 
obtained for the non-conjugated Ag(I)-NHC complexes C20, C30 and C33. The 
particles consistently displayed higher potency against the cancerous cell line 
when compared to the Ag(I)-NHC. This indicates that the polymer coating 
whether mPEG5000P(Phe) (e.g. in PDM4a) or mPEG5000poly(lysine) (e.g. in 
PDM5.B.C30 and PDM5.B.C33)  either exhibits toxicity against the cells, adding 
to the existing cytotoxicity of the drug or leads to slow release of Ag ions by 
protecting the Ag(I)-NHC. The selectivity of the particles towards cancerous 
cells was evaluated by determining cytotoxicity values against the non-
cancerous cell line ARPE-19. In general, the non-encapsulated Ag(I)-NHC 
complexes appear to be more selective towards Panc 10.05 than the PDMs. 
However, in vivo studies are required to determine the benefits of EPR effect 
on the polymeric nanoparticles in comparison to the Ag(I)-NHC complexes. 
Table 6.2: Cytotoxicty data on PDMs versus complexes 
Compound Panc 10.05 ARPE-19 
Selectivity 
ratio 
C20 30.6 ± 13.2 >100 3.3 
PDM4a 25.8 ± 4.3 83.4  ± 17.1 3.2 
C30 12.3 ± 3.2 >100 8.2 
PDM5.B.C30 8.2 ± 1.8 23.6  ± 6.9 2.9 
C33 26.3 ± 11.5 68.7 ± 7.2 2.6 
PDM5.B.C33 16.0 ± 5.5 22.7  ± 2.7 1.4 
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6.6 Conclusions  
The examination of possible delivery vehicles for Ag(I)-NHC complexes as drug 
molecules by the use of polymers, either through forming linear polymer-Ag(I)-
NHC conjugates (PDCs), or through encapsulating the Ag(I)-NHC within 
polymeric micelles (PDMs) has been reported. Encapsulation and/or 
conjugation to polymers increases the size and molecular weight of the 
compound, which is more likely to selectively pass through the cancerous 
tissues due to enhanced permeability and retention (EPR).  This EPR effect 
may also result in longer retention of the drug in cancerous tissues, thereby 
enhancing the anticancer effect. Linear polymer-drug conjugates were 
synthesised using imidazolium salt containing block copolymers PM1 and PM2, 
with silver being coordinated to form PDC1 and PDC2. Ag(I)-NHCs were 
chemically coordinated to poly-(L-glutamic acid) PM3, through formation of an 
ester bond to form PDC3. The anticancer activities of PDC1-PDC3 were 
determined against the cancerous cell line Panc 10.05. The results revealed 
higher potency than the corresponding non-polymer-containing Ag(I)-NHC 
complexes C20 and C34. This indicates improved activity due to polymer 
conjugation which, combined with the in vivo EPR effect, provides significant 
potential for these complexes in the treatment of cancer. 
Encapsulation of Ag(I)-NHCs into self-assembled polymeric micelles was also 
investigated as an alternative approach to delivering the complexes to the site 
of action. mPEG5000-poly-(phenylalanine) PM4 was used to encapsulate C20 in 
water to form PDM4a. DLS studies revealed an average particle size and 
particle size distribution that were in agreement with SEM findings. SEM-EDX 
revealed that C20 was more concentrated within the regions of the particles, 
suggesting successful encapsulation. The encapsulation of fluorescent Ag(I)-
NHC C27 into mPEG5000P(Phe) PM4 to form PDM4b was performed. Confocal 
fluorescent miscroscopy showed fluorescence in the area within the particle, 
also suggesting the success of the encapsulation process.   
Encapsulation was also explored using electrostatic interaction between the 
Ag(I)-NHC drug and the polymer mPEG5000poly(lysine) PM5. In water, the 
terminal secondary amine groups are protonated to bear a positive charge, and 
the carboxylic acid substituents of the NHC ligand are deprotonated to give a 
negative charge. Addition of polymer solutions and Ag(I)-NHCs solutions in 
water resulted in the formation of particles, which is likely due to electrostatic 
attraction. This is supported by the fact that no particles were observed in 
solutions of either the complex or the polymer prior to adding them together. 
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The anticancer activity of the particles PDM4a, PDM5.B.C30 and PDM5.B.C33 
were determined against Panc 10.05. Results show superior activity  (1.1-1.6 
fold increase in anticancer activity) of the PDMs compared to the corresponding 
non-encapsulated Ag(I)-NHC complexes C20, C30 and C33, again showing the 
potential benefits of encapsulation on improving the anticancer activity of Ag(I)-
NHCs.  The improved cytotoxicity may be due to the slow release of Ag+ ions 
from the polymeric particles, leading to a prolonged exposure of the cells to the 
cytotoxic effects. These benefits may improve further in vivo due to the EPR 
effect.   
Both encapsulation and conjugation of Ag(I)-NHC complexes to polymers were 
successful and produced a range of preliminary results that are worthy of further 
investigation. Both PDCs and PDMs appear to be promising delivery vehicles 
for delivering the Ag(I)-NHC complexes to their site of action, where silver is 
believed will be slowly released leading to a prolonged anticancer activity. The 
use of PDCs and PDMs may improve the bioavailability of the drug, by acting 
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6.7 Future work 
Future work should focus on in vivo testing, to evaluate the efficiency of the 
polymer-Ag(I)-NHC conjugates and micelles in delivering the Ag(I)-NHC 
complexes to the cancerous tissue. This will involve animal studies that will 
determine their safety or toxicity, and whether the polymers improve the 
selectivity of the complexes. In vitro mechanistic studies are currently in 
progress (at the University of Huddersfield) to determine the molecular targets 
e.g. receptors, proteins or enzyme that affect, are affected by or interact with 
the Ag(I)-NHC complexes. Combined in vitro and in vivo results will determine 
future molecular engineering or drug-delivery strategies for selective delivery of 
the complexes to cancerous tissues. 
Recent developments in molecular engineering of an anticancer drug-delivery 
system include engineering of a nanomaterial that can target multi-drug 
resistant cancers.28 This nanomaterial involves adding additional coatings to 
PDMs, the first being siRNA (yellow), followed by positively charged polymer 
(red) and finally a hydrated polysaccharide layer (purple, Figure 6.26).  The 
siRNA acts as the gene blocker that prevents the resistant tumour cells from 
dividing, and due to its negative charge, it can be protected by a positively 
charged polymer. To target this nanoparticle material, it is disguised by adding 
a negatively charged natural hydrated polysaccharide that is found in the body 
and creates a veil of water molecules around the nanoparticle, allowing it to 
travel in the blood stream without elimination by blood enzymes. Tumor-specific 
molecules such as protein, antigens or receptors could be added on its surface 











Nanoparticle core (Ag(I)-NHC-polymer micelle) 
                              
Negatively charged siRNA layer 
Positively charged polymer 
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Chapter 7  
Electrochemical screening of silver(I)-NHC complexes on a 
unique biological sensor 
7.1 Introduction 
Electrochemical biosensors are a subclass of chemical sensors, which consist of 
a molecular sensing device that combines a biological recognition component to 
an electrode transducer. The electrode transducer converts the biological 
recognition event into a measurable electrical signal.1, 2 The past three decades 
have observed an abundance of research on biosensors. This is owed to their 
speed, specificity, low cost, and portability, which allow them to act as alternatives 
to some clinical testing, including home-use devices such as diabetes 
monitoring.3 Electrochemical biosensors are categorised into two classes, 
biocatalytic devices and affinity receptors.2 Biocatalytic devices use enzymes, 
whole cells or tissue slides to produce electroactive species when contacted with 
a target.4 Examples include glucose sensors,5 xanthine sensors6 and lactate 
sensors.7 Affinity biosensors depend on selective binding or interaction of the 
target with a biological component such as an antibody, a protein or a receptor, 
which could assist in detection and monitoring of cancers.2, 8 Examples of affinity 
biosensors include Immunoassays and Immunosensors,9-11 DNA hybridisation 
biosensors12, 13 and receptor-based biosensors.14  
A unique electrochemical biosensor has been developed over the last decade by 
Nelson et al., to detect interactions of compounds with a membrane.15-23 The 
sensing electrode consists of a mercury coated platinum contact (Figure 7.1), 
onto which a phospholipid monolayer (membrane) is deposited. The sensing 
electrode is connected to an on-line high throughput flow system, which utilises 
rapid cyclic voltammograms (RCVs) to display changes in capacitance current 
peaks when a voltage of 40 V s-1 is applied. The electrodes electrochemically 
detect the damage caused to the membrane when in contact with a membrane-
active compound. This unique setup has been used in drug screening of 
membrane-active pharmaceuticals, and in detection of toxins in water supplies.19, 
20, 22 In this study, monolayers of dioleoyl phosphatidylcholine (DOPC) were used 
as the biological membrane, and Ag(I)-NHC complexes were tested as potential 
membrane-active compounds. A correlation between the limit of detection (LoD) 
values of Ag(I)-NHC complexes obtained from this setup and the IC50 values 
obtained from MTT assays, will determine the possible use of this biosensing 
device as a fast, cheap and easy tool for screening of biologically-active 
complexes, prior to or instead of widely-known and more costly biological testing.  
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The biosensor consists of a flow cell with a merged wafer-like device that contains 
eight mercury coated “on chip” Pt disc working electrodes, a Pt auxilary electrode 
and a Ag/AgCl (Figure 7.2, also labelled 4 in Figure 7.1).22 This device was 
attuned to achieve optimum deposition and removal of the phospholipid 
monolayer and compound-interaction response signals. This was achieved by 
minimising the dimensions of the Pt/Hg electrodes using rapid cyclic voltammetry 
to facilitate the deposition of DOPC on the electrode from the DOPC dispersion.19  
 
 
Figure 7.1:Diagram of electrochemical screening device22
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The DOPC monolayer undergoes two potential induced phase transitions, 
translated into two characteristic sharp capacitance current peaks when a 
potential is applied between -0.2 and -1.8 V (Figure 7.3 (a)).18  The two peaks 
correspond to the permeation of the layer to ions, and the re-organisation of the 
layer to form bilayer areas, respectively (Figure 7.3 (b)). Direct measurements of 
structural changes of the DOPC monolayer were later reported using atomic 
force-distance techniques to illustrate the precise changes in the monolayer 
structure (Figure 7.4).15 Interaction of a compound/toxin with the layer is detected 
by changes in the characteristic peak configurations. 
 
  
Figure 7.3: (a). Typical RCV scan of DOPC monolayer (b). Illustration of 
predicted phase transitions18 
 
 
Figure 7.4: Phase transitions of DOPC monolayer15 
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7.2 Organometallic complexes interactions with DOPC 
In this work, Ag(I)-NHC complexes from the xanthine-derived (Chapter 2), 
clotrimazole-derived (Chapter 4) and water-soluble (Chapter 5) groups were 
screened on this electrochemical biosensor using DOPC as the biological 
monolayer. Deposition of dioleoyl phosphatidylcholine (DOPC) on the Pt/Hg is 
performed before the introduction of a complex, and a potential excursion is 
applied from -0.4 V to -3.0 V at 100 V s-1 scan rate. 100-200 µL of DOPC is 
inserted into the flow cell through the solenoid valve, after which the characteristic 
RCV peaks corresponding to phase transitions appear. The potential excursion 
is then changed to -0.4 V to -1.2 V, and the RCV profile of DOPC after repetitive 
cycling in this range is shown in Figure 7.5. Changes to the characteristic RCV 
peaks when subjected to a particular compound are an indication of the 
interaction of the compound with the DOPC. Recovery, or failure of recovery, of 
the characteristic RCV peaks to their normal state after exposure to a compound 
specifies the extent of permanent membrane damage. Results obtained from this 
technique are compared to cytotoxicity data from MTT-based assays, to evaluate 






















Pt/Hg microfabricated electrode 
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7.2.1 Interaction of Cisplatin with DOPC 
Cisplatin was initially screened on the electrochemical biosensor at a 
concentration of 10 µmol dm-3 showing no change in the RCV. Higher 
concentrations were subsequently tested, gradually increasing from 10µmol dm-
3   to 2 mmol dm-3. The results show that cisplatin exhibits no effect on DOPC 
monolayer, indicating no interaction with the membrane is observed including at 
the highest concentration of 2 mmol dm-3 (Figure 7.6). This result is in agreement 
with the mechanism of action of cisplatin reported in the literature,24 in which the 
drug enters the cell via copper transporter Ctr1 as opposed to passive diffusion 
(Figure 7.7).   
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7.2.2 Interaction of xanthine-derived silver(I)-NHCs with DOPC 
Water soluble xanthine-derived Ag(I)-NHC complex C5 was screened for its 
interaction with DOPC, using varying concentrations of the complex. Results 
display no interaction with DOPC, including at a high concentration of 2 mmol dm-
3 (Figure 7.8). We have reported that C5 exhibits anticancer activity against a 
range of cell lines, strongly indicating that it is able to cross a cell membrane.25 
The results from the biomembrane-sensing device suggest that cell entrance of 
C5 is through an alternative mechanism to passive diffusion, i.e. are actively 
transported via channels or transporters across the cell wall. C1, C2, C3 and C4 
were also screened, and similar to C5, displayed no interaction with DOPC. 
Results indicate that xanthine-derived complexes generally have an alternative 
active-transport method to cross cell membranes. This mechanism may be 
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7.2.3 Interaction of water-soluble silver(I)-NHCs with DOPC 
Water-soluble Ag(I)-bis(NHC) complexes C19, C20 and C22-C33 (Chapter 5) 
were screened at a concentration of 50 µmol dm-3 against DOPC. The RCVs of 
the complexes displayed no interaction with DOPC, with the exception of C24, 
C27 and C33 (Figure 7.9).  The three complexes displayed varying degrees of 
interaction with DOPC, with C27 exhibiting the strongest interaction. C27 and 
C33 both contain an anthracene N-substituent, increasing the aromaticity of the 
complex, to which the interaction with DOPC may be attributed.22 The N-
hydroxyethyl substituent in C27 is replaced by a N-carboxylic acid substituent in 
C33, indicating that the N-alcohol substituent improves the interaction with DOPC 
when combined with an aromatic group. The ability of C24 to interact with DOPC 
may be attributed to having both the aromaticity of the N-mesityl substituent and 
the N-alcohol substituent. A relation between Log P values and DOPC interaction 
may be made as C24, C27 and C33 are in the highest four most hydrophobic 
complexes in this group. This suggests that increased hydrophobicity increases 
binding to the DOPC monolayer. The inability of C19, C20, C22, C23 and C25-
C32 to interact with DOPC, regardless of their positive Log P values, and the 
presence of aromatic benzyl rings in complexes C23 and C31, suggests that 
benzyl N-substituents as the aromatic components are not sufficient to enable 
binding to the monolayer. A correlation between membrane activity and 
cytotoxicity was not found for this group of complexes. However, the 
biomembrane sensing results for complexes C19, C20, C22, C23 and C25-C31 
which show no interaction with DOPC, but show potential anticancer activity, 
indicates that active transport may be a route for cell entry. For complexes C24, 
C27 and C33 which exhibited both membrane interaction and anticancer activity, 
a combination of passive diffusion and active transport may together be routes to 
cross the membranes (Table 7.1).  
 
Table 7.1:Summary of potential routes for cell entry for water-soluble Ag(I)-
NHC complexes 
 DOPC interaction Cell Entry 
C19, C20, C22, C23, 
C25-C32 
No Active transport 
C24, C27, C33 Yes Passive diffusion + 
Active transport 
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7.2.4 Interaction of clotrimazole-derived silver(I)-NHCs with DOPC 
Clotrimazole-derived complexes are the most promising group of Ag(I)-NHC 
complexes as potential anticancer agents in this work (Chapter 4). A correlation 
between Log P values and cytotoxicity of these complexes has been observed. 
Ten complexes in this group of varying cytotoxicity, N-substituents and 
counterions were screened on the biomembrane sensor at a concentration of 50 
µmol dm-3 (Figure 7.10). The RCVs show that these complexes have varying 
degrees of interaction with DOPC according to their structural features. The ability 
of these complexes to interact with DOPC suggests that passive diffusion is most 
likely the main route of cell entry for this class of complexes, which is mainly 
attributed to their bulky aromatic triphenyl N-substituents. 
C13A interacts strongly with DOPC, and substituting the Cl on the triphenyl group 
with H in C18A, results in a decrease in interaction.  This indicates that Cl has an 
important role in membrane binding. Substituting the alcohol N-substituent in 
C13A for a benzyl group in C12 leads to an increase in interaction, suggesting 
that the aromaticity of the benzyl group when added to the aromaticity of the 
triphenyl group potentiates its effect in membrane interaction. A change of 
counterion from Cl in C13B to I in C8 slightly increases the interaction with the 
DOPC monolayer. Changing the alcohol N-substituent in C13A for a methyl group 
in C9 noticeably decreases the interaction with the membrane. This suggests that 
the alcohol group has an effect in maintaining a strong interaction with DOPC, 
with hydrophobicity measurements showing that this complex has intermediate 
lipophilicity, which is ideal for optimum anticancer activity.  
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          7.3 Limit of detection (LoD) 
The limit of detection (LoD) of seven clotrimazole-derived complexes was 
calculated. LoD is the lowest concentration of the complex that is detectable by 
the biosensor, which produces a recognisable comparison to the control 
measurement. This is measured by extrapolating the average capacitance 
current (ic) of ten control measurements of DOPC from a calibration curve 
(capacitance current versus concentration of the complex, example shown in 
Figure 7.11), of which the standard deviation (SD) is also calculated. The effect 
relating to three times the SD of the control was read from the calibration curve 
to estimate the detection limit values. The results show that C13B has the lowest 
LoD value, therefore it is considered the most membrane active complex (Table 
7.2). C13B also shows the most promising cytotoxicity and selectivity results with 
an IC50 value against Panc 10.05, lower than that obtained for cisplatin. This 
result implies that it may be possible to use the electrochemical biosensing device 
as a forecasting tool, to determine the most promising anticancer complex within 
a particular class. 
 
Table 7.2: Limit of detection (LoD) values 
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7.4 Interaction of imidazolium salts with DOPC 
The role of the carbene moiety in the anticancer activity of Ag(I)-NHC complexes 
is unknown. They may be involved in damaging the cancerous cells, acting as 
‘carriers’ that transport silver ions into the cells. Screening imidazolium salts 
against DOPC may help in understanding the ability of these compounds to bind 
to cell membranes. Six clotrimazole-derived imidazolium salts were screened at 
50 µmol dm-3 (Figure 7.12), with the results showing strong interactions with the 
monolayer, similar to those observed for the clotrimazole-derived silver 
complexes. Changes to N-substitutents, counterions and Cl on the triphenyl N-
substituent result in the same changes in DOPC interactions as those observed 
for the silver complexes.  These include increase in membrane interaction upon 
either addition of a Cl on the triphenyl group, an N-benzyl or N-alcohol-substituent 
and/or changing the counterion ion to I. This suggests that the carbene moiety in 
the Ag(I)-NHCs is responsible for membrane binding. 
Screening clotrimazole-derived Ag(I)-NHC on DOPC membrane resulted in an 
irreversible change i.e. the membrane did not revert back to its original state as 
the compound is flushed out. Interestingly, the change following exposure to 
imidazolium salts was found to be reversible. This suggest that of silver damages 
the DOPC monolayer, and may translate into its ability to damage cancerous cell 
membranes in vivo. The fact that the DOPC membrane recovers following 
exposure to imidazolium salts indicates that the carbene acts as a carrier for the 
drug across the cell membrane.  
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7.5 Interaction of silver salts with DOPC 
Silver salts AgNO3 and AgOAc were screened at increasing concentrations to 
2mmol dm-3, showing no effect on DOPC (Figure 7.13). This shows the 
necessity of the carbene for membrane interaction, and supports the 




                                   
 
Figure 7.13: Interactions of silver salts with DOPC 
 
Table 7.3: Summary of DOPC recovery 
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A unique electrochemical biosensing device developed by Nelson et al. was used 
to monitor the effects of cisplatin, Ag(I)-NHC complexes, imidazolium salts and 
silver salts on a phospholipid monolayer (DOPC). The measured interactions with 
DOPC can help predict how each complex/salt might behave when it comes into 
contact with a cell membrane in vivo. Comparison of DOPC interactions and IC50 
values revealed the potential application of this technique as a pre-screening 
device for anticancer complexes. DOPC-interaction potentially translates into 
passive diffusion across cell membranes in vivo, and since cisplatin actively 
enters cells via copper transporters, no interaction was observed with DOPC at 
high concentrations. Xanthine-derived complexes also revealed no DOPC-
interaction, with these complexes having exhibited anticancer activity against 
eight cancerous lines, suggesting ‘active transport’ via a channel or transporter 
as the mechanism of cell entry. Screening of water-soluble complexes generally 
displayed no effect on DOPC, with the exception of N-anthracene or N-mesityl 
substituted complexes. This highlights the importance of N-bulky aromatics in 
membrane interactions and possibly a combination of passive diffusion and 
active transport is possible. 
Clotrimazole-derived complexes exhibited strong DOPC interactions, indicating 
that the main route of cell entry for this group of complexes is via passive 
diffusion. Changes in N-substituents affected the degree of interaction, where an 
N-benzyl substituent increases the interaction with DOPC, followed by the N-
alcohol substituent, which appears more effective than N-alkyl substituents in 
membrane interaction. Changes in halide counterions had a minor effect on 
DOPC interaction, however replacing the Cl on the N-triphenyl substituent with H  
decreased DOPC interaction. Determination of the limit of detection (LoD) 
revealed that complex C13B, which displayed the lowest IC50 value, also had the 
lowest LoD value. Further development is required for this device as a 
prescreening tool for anticancer activity, with these preliminary finding providing 
significant promise. Since the imidazolium salts screened revealed strong DOPC 
interactions similar to those of the analogous Ag(I)-NHC complexes, suggests 
that the carbene moiety is responsible for the membrane-interactions of the 
complexes. This further iimplies that Ag(I) is responsible for damaging the 
membrane, which is supported by the inability of the DOPC to recover after 
exposure to Ag(I)-NHC complexes. The hypothesis is that silver ions are 
responsible for the anticancer activity of the complexes, since they irreversibly 
damage the cell membrane, while carbene moiety carries them to the cell, and 
binds to the cell membrane (Table 7.4).  
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DOPC               
recovery 
Cisplatin No Copper transporters - 
Xanthine-derived     
Ag(I)-NHC 
No Active transport - 
Water-soluble           
Ag(I)-NHC 
No Active transport - 
Clotrimazole-derived  
Ag(I)-NHC 
Yes Passive diffusion No 
Clotrimazole-derived 
Imidazolium salts   
Yes Passive diffusion Yes 
Ag salts No Imidazolium                   
NHC salts  
(carbene moiety) 
- 
CHAPTER 7                                                              UNIVERSITY OF LEEDS 
157 
 
7.7 References  
 
1. J. Wang, Biosensors & Bioelectronics, 2006, 21, 1887-1892. 
2. N. J. Ronkainen, H. B. Halsall and W. R. Heineman, Chemical Society 
Reviews, 2010, 39, 1747-1763. 
3. J. D. Newman and A. P. F. Turner, Biosensors & Bioelectronics, 2005, 20, 
2435-2453. 
4. D. Grieshaber, R. MacKenzie, J. Voeroes and E. Reimhult, Sensors, 2008, 
8, 1400-1458. 
5. J. Wang, Analytical Chemistry, 1995, 67, 487-492. 
6. I. Karube and E. Tamiya, Food Biotechnology (New York), 1987, 1, 147-
166. 
7. M. Mascini, F. Mazzei, D. Moscone, G. Calabrese and M. M. Benedetti, 
Clinical chemistry, 1987, 33, 591-593. 
8. J. F. Rusling, C. V. Kumar, J. S. Gutkind and V. Patel, Analyst, 2010, 135, 
2496-2511. 
9. M. Seydack, Biosensors & Bioelectronics, 2005, 20, 2454-2469. 
10. K. Graumann and A. Premstaller, Biotechnology journal, 2006, 1, 164-186. 
11. S. A. Kellermann and L. L. Green, Current opinion in biotechnology, 2002, 
13, 593-597. 
12. S. Takenaka, K. Yamashita, M. Takagi, Y. Uto and H. Kondo, Analytical 
Chemistry, 2000, 72, 1334-1341. 
13. A. D. Ellington and J. W. Szostak, Nature, 1990, 346, 818-822. 
14. N. Matsuno, M. Murawsky, J. Ridgeway and J. Cuppoletti, Biochimica et 
Biophysica Acta (BBA) - Biomembranes, 2004, 1665, 184-190. 
15. A. Vakurov, M. Galluzzi, A. Podesta, N. Gamper, A. L. Nelson and S. D. 
A. Connell, Acs Nano, 2014, 8, 3242-3250. 
16. A. Vakurov, R. Brydson and A. Nelson, Langmuir, 2012, 28, 1246-1255. 
17. D. Bizzotto and A. Nelson, Langmuir, 1998, 14, 6269-6273. 
18. A. V. Brukhno, A. Akinshina, Z. Coldrick, A. Nelson and S. Auer, Soft 
Matter, 2011, 7, 1006-1017. 
19. Z. Coldrick, A. Penezić, B. Gašparović, P. Steenson, J. Merrifield and A. 
Nelson, J Appl Electrochem, 2011, 41, 939-949. 
20. Z. Coldrick, P. Steenson, P. Millner, M. Davies and A. Nelson, 
Electrochimica Acta, 2009, 54, 4954-4962. 
21. A. Nelson, Journal of Electroanalytical Chemistry, 2007, 601, 83-93. 
22. S. Mohamadi, D. J. Tate, A. Vakurov and A. Nelson, Analytica Chimica 
Acta, 2014, 813, 83-89. 
23. A. Nelson, Current Opinion in Colloid & Interface Science, 2010, 15, 455-
466. 
24. D. Wang and S. J. Lippard, Nat Rev Drug Discov, 2005, 4, 307-320. 
25. H. A. Mohamed, B. R. M. Lake, T. Laing, R. M. Phillips and C. E. Willans, 
Dalton transactions, 2015, 44, 7563-7569. 
26. W. Streciwilk, F. Hackenberg, H. Muller-Bunz and M. Tacke, Polyhedron, 









8.1 Methods and Instrumentation 
8.1.1 General  
All reagents were prepared as outlined or used as supplied without need for 
further purification. Compounds previously reported were prepared according to 
literature procedure and fully characterised using NMR spectroscopy and mass 
spectrometry unless otherwise stated. Manipulations were performed using 
standard Schlenk line and Glovebox techniques. Argon and nitrogen were 
passed through a twin-column drying apparatus containing molecular sieves 
(4Å) and phosphorus pentoxide. Anhydrous solvents were passed over 
activated alumina to remove water, copper catalyst to remove oxygen and 
molecular sieves to remove any remaining water via the Dow-Grubbs solvent 
system. 
8.1.2 NMR spectroscopy  
1H and 13C{1H} NMR spectra were recorded on either a Bruker DPX300 
spectrometer (operating frequency 300.1 MHz for 1H and 75.48 MHz for 
13C{1H}), a Bruker Avance 500 spectrometer or a Bruker DRX500 
spectrometer (both with an operating frequency of 500.13 MHz for 1H and 
125.80 MHz for 13C{1H}). All spectra were recorded at 298K (unless otherwise 
stated) in deuterated solvent. Chemical shift values are quoted in parts per 
million (ppm, δ), coupling constants, J, are quoted in Hertz (Hz) and 
assignment of 13C{1H} NMR spectra was aided by 13C{1H} DEPT135 
experiments when necessary. 
8.1.3 Mass spectrometry  
High-resolution mass spectra were collected on a Bruker Daltonics (micro TOF) 
instrument operating in the positive ion electrospray mode. Samples were 
injected directly from feed solutions and acquired over the range m/z 50 – 4000. 
All spectra were recorded using an acetonitrile/water mix as the eluent and a 
sodium formate solution as a calibrant. 
8.1.4 Microanalysis  
Microanalyses were performed in the School of Chemistry, University of Leeds 
by Ms. Tanya Marinko-Covell using a Carlo Erba Elemental Analyser MOD 1106 
spectrometer. 
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8.1.5 X-Ray crystallography 
X-ray diffraction data were collected on an Agilent SuperNova diffractometer 
fitted with an Atlas CCD detector with Mo-Kα radiation (λ = 0.71073 Å) or Cu-
Kα radiation (λ = 1.54184 Å). Crystals were mounted under Fomblin on nylon 
loops. Crystals were held at either 120 or  100 K using an Oxford Cryosystem 
low temperature device during unit cell determination and data collection. Data 
sets were corrected for absorption effects using a multiscan method, and the 
structures were solved either by direct methods using SHELXS-97 or charge 
flipping (Superflip) interfaced through the program Olex2. Refinement was by 
full-matrix least squares on F2 using ShelXL-97, interfaced through either the 
program X-Seed or Olex2. All hydrogen atoms were included at geometrically 
estimated positions using a riding model unless otherwise stated. Graphics of 
the crystal structures outlined in this report were generated using X-seed. 
8.1.6 Hydrophobicity studies 
Equal volumes of octanol and NaCl-saturated water were stirred at room 
temperature for 24 hours, and separated to give octanol-saturated water and 
water-saturated octanol. Five standard concentrations (5, 10, 20, 40 and 60 µM) 
of the complexes were prepared from the octanol-saturated water. Analysis by 
UV / vis spectroscopy was used to obtain a calibration curve of absorbance 
versus concentration for each complex at its maximum absorbance. Accurate 
amounts of the complexes were dissolved in the octanol-saturated water (25 
mL) to make up a concentration of 50 µM. 3 mL of octanol-saturated water 
containing the complex was placed in a centrifuge tube and 3 mL of water-
saturated octanol was layered on top. Six samples prepared in this manner were 
shaken for 4 hours using a vibrax machine at 500 gmin-1. The layers were 
separated and the octanol-saturated water layer was retained for analysis using 
UV / vis spectroscopy. The average concentration of the six runs was calculated 
using the calibration graph and maximum absorbance for each complex. 
Subtraction of the average concentration obtained from the concentration of an 
unshaken sample in octanol-saturated water gave the final [C]org. The [C]org 
and [C]aq were used to determine the partition coefficient Log P. Studies for 
complexes that are more soluble in water-saturated octanol layer were 
performed in that layer. 
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8.1.7 Cytotoxicity studies 
MTT-assay 
In vitro cell tests for all compounds were performed at the Department of 
Pharmacy, University of Huddersfield. Cells were incubated in 96-well plates, at 
2 x 103 cells per well in 200 µL of growth media (RPMI 1640 supplemented with 
10 % foetal calf serum, sodium pyruvate (1mM) and L-glutamine (2mM)). Cells 
were incubated for 24 hours at 37 ºC in an atmosphere of 5 % CO2 prior to drug 
exposure. Silver compounds, imidazolium salts and cisplatin were dissolved in 
dimethylsulfoxide at a concentration of 25 mM and diluted with medium to obtain 
drug solutions ranging from 25 µM to 0.049 µM. The final dimethylsulfoxide 
concentration was 0.1% (v/v) which is non-toxic to cells. Drug solutions were 
applied to cells and incubated for 96 hours at 37 ºC in an atmosphere of 5 % 
CO2. The solutions were removed from the wells and fresh medium added to 
each well along with 20 µL MTT (5 mg/ml), and incubated for 4 hours at 37 ºC 
in an atmosphere of 5 % CO2. The solutions were removed and 150 µL 
dimethylsulfoxide was added to each well to dissolve the purple formazan 
crystals. A plate reader was used to measure the absorbance at 540 nm. Lanes 
containing medium only, and cells in medium only (no drug), were used as 
blanks for the spectrophotometer and 100 % cell survival respectively. Cell 
survival was determined as the absorbance of treated cells divided by the 
absorbance of controls and expressed as a percentage. The concentration 
required to kill 50 % of cells (IC50) was determined from plots of percent survival 
against drug concentration. Each experiment was repeated 3 times and a mean 
value obtained. 
SRB-assay 
In vitro cell tests for Cu(I)-NHC and Ru(II)-NHC complexes were performed at 
the Institute of Pharmacy and Molecular Biotechnology, University of 
Heidelberg, following a literature procedure.1 Cells were seeded in 100 µL 
aliquots into 96-well plates with a density of 5,000 cells/well, and incubated 
overnight. Different concentrations of complexes or respective amounts of DMF 
were added to the cells after incubation, which were further incubated for 
different time periods. Following treatment, 50 µL of ice cold 10 % 
tricholoroacetic acid (TCA) in H2O were added to each well, and the plates were 
kept at 0 °C for 1 h. Subsequently, the solution in the plates was discarded, and 
the plates were washed twice with H2O and dried. 100 µL of 1% acetic acid 
solution containing 0.054 % of sulforhodamine B sodium salt (SRB) were then 
added. The solution was discarded 30 min later, and the plates were washed 
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twice with 200 µL of acetic acid (1 %) into each well. The washing solution of 
acetic acid was quickly discarded after washing. The plates were further dried 
followed by adding 200 µL of 10 mM Tris (pH 10.5) to each well to dissolve the 
SRB dye. The plates were shaken for 15 min, after which time the dye was 
quantified with a plate reader by determining the absorption at 535 nm. The IC50 
values were calculated as the concentrations of the compounds required to 
inhibit 50 % of cell growth. 
8.1.8 Infra-red spectroscopy 
FTIR spectra were recorded using a Spectrum One spectrophotometer 
(PerkinElmer) fitted with diffuse reflectance probe with zinc-selenide window. IR 
Spectra were recorded using a globular light source through KBr beamsplitter 
for the range 4000-400 cm-1 using DLATGS detector with KBr window. 32 scans 
were recorded for each averaged spectrum with a new background recorded 
after each sample. IR spectra were analysed using the spectroscopy software 
package OPUS (v 6.5, Bruker Optiks GmbH). 
8.1.9 Dynamic Light Scattering (DLS) 
Particle size and particle size distribution analyses were obtained by 
perfoming Dynamic Light Scattering (DLS) with three repeats of each sample 
using a Zetasizer Nano ZS series instrument at 37°C, using disposable 
polystyrene cuvettes.  
8.1.10 Scanning Electron Microscopy (SEM) 
Scanning Electron Microscopy (SEM) experiments were performed using a 
Pasteur pipette to extract a drop of the solution and deposit it onto an SEM glass 
cover slip. The sample was allowed to dry in a fume cupboard, after which the 
cover slip was mounted on an SEM stub using conductive tape. The SEM stub 
containing the dried sample was sputter-coated with a thin layer of gold using a 
current of 20 mA for 2 minutes, in a quorum Q150RS sputter-coater. The coated 
samples were analysed for particle size and morphology using a JOEL JSM-
6610LV microscope (Oxford Instruments) equipped with a field emission 
electron gun as an electron source, using a working distance of 11 mm. 
Accelerated voltage was applied between 5 and 15 kV.  
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8.1.11 Confocal Fluorescence Microscopy 
Fluorescence imaging of was performed using a confocal microscope Zeiss 
LSM88o inverted with Airyscan microscope that consists of Axio Observer.Z1, 
Nano Focusing Piezo Stage and Zlmulti S1 incubator box. The images were 
taken at 63 x objective. Lasers include diode 405nm, Argon 458, 488, 514 nm, 
DPSS 561 nm and HeNe 633 nm. Excitation was performed with 405 nm laser 
and detection was in the range 370-500 nm. 
8.1.12 Biomembrane sensing device 
The microfabricated Pt/Hg electrode coated with DOPC lipid was contained in 
a closed flow cell. A constant flow of pH 7.4 PBS was passed over the 
electrode using a peristaltic pump. The flow cell was connected to a 
potentiostat interfaced to a Powerlab signal generator and controlled by 
Scope(c) software. RCVs were obtained by applying a saw-tooth waveform 
from -0.4 to -1.2 V (vs Ag/AgCl) with ramp rate 40 Vs-1 applied to the electrode 
surface. In the absence of faradaic reactions, the current on the RCV plot was 
directly proportional to the capacitance of the surface and is displayed as a 
function of voltage. In response to the applied voltage ramp, the DOPC 
monolayers undergo two pronounced phase transitions characterised by two 
capacitance current peaks. These peaks correspond to the redistribution of 
charges and polar groups on the monolayer interface. All assays were carried 
out in 0.1 mol dm-3 PBS.  The compounds are sampled for 400 seconds after 
which PBS is flushed through for 400 seconds to allow for any recovery of the 
DOPC layer initial structure to take place. 
8.1.13 RCV scans 
Increasing the concentration of the compounds in test media increases the 
response following compound interaction with the DOPC layer. This is shown 
as enhanced peak suppression. The effect of compound dose on the RCV plot 
emphasises the effect of compound type on the nature of and sensitivity of 
interaction with the DOPC coated electrode. When the DOPC coated electrode 
is exposed to a finite concentration of test compound without silver in PBS and 
then flushed for 400 seconds with control PBS, the RCV scan of the lipid layer 
shows a full or partial recovery. The degree of RCV scan recovery is related to 
the degree of DOPC structure restoration which in turn is related to the degree 
of reversibility of the interaction.   
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8.1.14 Limit of Detection (LoD) 
LoD is the minimum concentration of the compound in PBS which has a 
statistically significant effect on the properties of the monolayer. This is 
measured by plotting a calibration graph of capacitance current peak 
height versus compound solution concentration following interaction with 
the respective compound. Subsequently the reproducibility of the 
capacitance current peak height from the RCVs of the DOPC coated Hg 
electrode in PBS was estimated by taking ten replicate measurements. 
The three times standard deviation (SD) of this capacitance peak height 
was calculated as a control. Accordingly the concentration of test 
compound which has an equivalent suppressive effect on the capacitance 
current peak height relating to three times the SD of the control was 
obtained from the calibration curve to estimate the detection limit values. 
The detection limits are estimated and quoted as the minimum 
concentration of compound in water to elicit a response. The LoD is the 
minimum concentration of the compound in PBS which has a statistically 
significant effect on the properties of the monolayer and is inversely 
proportional to the affinity of the compound for the layer. 
8.1.15 Electrochemical synthesis 
The ligand (L1-L3) was added to a flame-dried three-necked round-
bottomed flask with a magnetic stirrer bar. The solid was further dried 
under high vacuum for 1 hour, followed by the addition of 
anhydrous/degassed MeCN (30 mL) was added to the flask.  Two copper 
foils (99.98 % purity, 14 × 11 × 0.025 mm) were connected to an external 
power supply (positive and negative terminals), introduced to the solution 
and a potential range applied (25 – 27 V) to maintain a constant current 
of 30 mA (measured by an in-series ammeter) for 80 minutes. Solid that 
had precipitated out of solution was filtered and dried in vacuo and further 
recrystallised from MeCN/Et2O, washed with Et2O (3 × 30 mL) and filtered 
under N2 (g) to give the Cu(I) complexes as solids. 
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8.2 Experimental details 
8.2.1 Preparation of P2 
Theophylline (5.0 g, 27.8 mmol) was dissolved in MeCN (70 mL), and 
potassium carbonate (4.25 g, 30.8 mmol) and butyl iodide (12.0 mL, 105.5 
mmol) were added. The mixture was heated at reflux for 
48 hours, filtered and washed with MeCN (30 mL x 3) to 
ensure the dissolution of all the product into the filtrate. 
The filtrate is dried in vacuo to yield the product as a white 
solid.  
Yield: 4.7 g, 19.9 mmol (72%) 
1H NMR (300 MHz, DMSO-d6):  8.09 (s, 1H, NCHN), 4.26 (t, J = 7.2 Hz, 2H, 
CH2), 3.42 (s, 3H, CH3), 3.19 (s, 3H, CH3), 1.74 (quin, J = 7.2 Hz, 2H, CH2), 1.24 
(sext, J = 7.2 Hz, 2H, CH2), 0.85 (t, J = 7.2 Hz, 2H, CH3). 13C{1H} NMR (75 MHz, 
DMSO-d6):  155.1 (C=O), 151.7 (C=O),148.9 (C), 140.8 (NCHN), 106.9 (C), 
47.0 (CH2), 32.8 (CH2), 29.7(CH2), 27.9 (CH3), 19.5(CH3), 13.4 (CH3). HRMS 
(ESI+): Calcd for C11H17N4O2 [M + H]+: 237.1351. Found: 237.1345. Anal. Calcd 
for C11H16N4O2∙1/5 H2O: C, 55.08; H, 6.89; N, 23.36. Found: C, 55.40; H, 6.85; 
N, 23.30. 
8.2.2 Preparation of P3 
Theophylline (5.0 g, 27.8 mmol) was dissolved in MeCN (80 mL), and 
potassium carbonate (4.25 g, 30.8 mmol) and benzyl bromide (16.5 mL, 138.7 
mmol) were added. The mixture was heated at reflux for 24 hours, filtered and 
washed with MeCN (30 mL x 3) to ensure the 
dissolution of all the product into the filtrate. The 
filtrate was dried in vacuo to yield the product as a 
white solid, which was further recrystallized from 
MeCN / Et2O. 
Yield: 6.1g, 22.6 mmol (81%).  
1H NMR (300 MHz, CDCl3) : 7.58 (s, 1H, NCHN), 7.43–7.32 (m, 5H, 
aromatic), 5.52 (s, 2H, CH2), 3.60 (s, 3H, CH3), 3.13 (s, 3H, CH3). 13C{1H} NMR 
(75 MHz, CDCl3): 153.4 (C=O), 150.1 (C=O), 139.4 (C), 136.1 (NCHN), 
133.6 (C),127.2, 126.9, 126.6 (CH), 105.1 (C), 48.3 (CH3), 31.8 (CH3), 27.9 
(CH2). HRMS (ESI+): Calcd for C14H15N4O2 [M + H]+: 271.1195. Found: 
271.1188. Anal. Calcd for C14H14N4O2·1/3Et2O: C, 62.43; H, 5.92; N, 18.99. 
Found: C, 62.00; H, 5.50; N, 19.40. 
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8.2.3 Preparation of P4 
Theophylline (4.0 g, 22.2 mmol), copper (I) iodide (1.9 g, 10.0 mmol), cesium 
carbonate (6.52 g, 20.0 mmol) and 2-isobutyrylcyclohexanone (2.2 mL, 13.1 
mmol) were added to a Schlenk flask and degassed. Anhydrous DMSO (17 mL) 
and iodobenzene (3.5 mL, 31.3 mmol) were added to the Schlenk flask. The 
mixture was heated at 130 °C for 24 hours. The solution, which had turned dark 
brown, was dissolved in CH2Cl2 and extracted with H2O (x3). The aqueous 
layers were combined and washed with CH2Cl2 (x3). All the organic layers were 
combined and dried in vacuo to give a dark brown solid. Recrystallisation from 
CH2Cl2 / Et2O furnished the product as a white solid. 
To ensure no copper remained in the product, the solid 
was dissolved in CH2Cl2 and any residual copper was 
separated by addition of a saturated solution of EDTA 
(50 mL x2). The organic layer was extracted and dried 
in vacuo to give a white solid. 
Yield: 1.78 g, 7.0 mmol (32%).  
1H NMR (300 MHz, DMSO-d6):  8.31 (s, 1H, NCHN), 7.71–7.14 (m, J = 7.5 Hz, 
5H, aromatic), 3.46 (s, 3H, CH3), 3.18 (s, 3H, CH3). 13C{1H} NMR (75 MHz, 
DMSO-d6):  153.7 (C=O), 150.9 (C=O),149.2 (C), 142.7 (NCHN), 134.8 (C), 
128.9 (CH), 128.5 (CH),125.1 (CH), 106.1 (C), 29.6 (CH3), 27.8 (CH3). HRMS 
(ESI+): Calcd for C13H13N4O2 [M + H]+: 257.1039. Found: 257.1031. Anal. Calcd 
for C13H12N4O2: C, 60.93; H, 4.72; N, 21.86. Found: C, 60.60; H, 4.85; N, 21.80. 
8.2.4 Preparation of P52  
Theobromine (1.0 g, 5.0 mmol) was dissolved in DMF (15 mL), and iodoethanol 
(0.78 mL, 10.0 mmol) and potassium carbonate (0.84 g, 6.1 mmol) were added. 
The mixture was heated at reflux for 24 hours, filtered 
and washed with Et2O and dried in vacuo to yield a 
pale brown solid.  
Yield: 1.05 g, 4.7 mmol (94%) 
1H NMR (300 MHz, DMSO-d6): 8.00 (s, 1H, NCHN), 4.74 (t, 1H J = 5.0 Hz, 
OH), 3.95 (t, 2H J = 5.0 Hz, CH2), 3.88 (s, 3H, CH3), 3.52 (q, 2H J = 5.0 Hz, 
CH2), 3.41 (s, 3H, CH3). 13C{1H} NMR (75 MHz, DMSO-d6): 154.5 (C=O), 
151.1(C=O), 148.3 (C), 143.0 (CH), 106.5 (C), 58.1 (CH2), 42.3 (CH2), 33.0 
(CH3), 29.4 (CH3). HRMS (ESI+): Calcd for C9H12N4NaO3 [M + Na]+: 247.0807. 
Found: 247.0802.  
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8.2.5 Preparation of P28A3 
Glyoxal (1.07 mL, 22.44 mmol) and formaldehyde (0.82 mL, 22.44 mmol) were 
heated to 50 °C in a round-bottomed flask. At the same time, in another round 
bottomed flask, a mixture of L-alanine (2.0 g, 22.44 mmol), sodium hydroxide 
(0.90g, 22.44 mmol) and ammonium acetate (1.72 g, 22.44 mmol) were stirred 
in water (10 mL) until all components were dissolved. This 
solution was added dropwise to the glyoxal and 
formaldehyde mixture over 30 minutes, and the reaction 
mixture was heated for 24 hours at 50 °C.  The solution 
which had turned yellow was dried in vacuo to furnish 
orange crystals.  
1H NMR (300 MHz, DMSO-d6): 7.71 (s, 1H, NCHN), 7.02 (s, 1H, C=CH), 6.93 
(s, 1H, C=CH), 4.60 (q, 1H J = 7.2 Hz, CH), 1.55 (d, 3H J = 7.2 Hz, CH3). HRMS 
(ESI+): Calcd for C6H8N4NaO3 [M – Na + H]+: 141.0619. Found: 141.0658.  
8.2.6 Preparation of P28B3 
The orange crystals of P5 (4.7 g, 29.0 mmol), were dissolved in MeOH (50 mL) 
and cooled to 0 °C, and thionyl chloride (2.1 mL, 29.0 mmol) was added 
dropwise to the cold solution over 90 minutes.  The mixture was warmed to room 
temperature and stirred for 48 hours. The solution, which turned a light yellow 
colour, was dried in vacuo to yield a sticky yellow solid that 
was dissolved in a saturated solution of NaHCO3 (70 mL), and 
the product extracted with ethyl acetate (50 mL x 3), CH2Cl2 
(50 mL x 3) and Et2O (50 mL x 3). The organic layers were 
combined and dried over magnesium sulfate and further dried 
in vacuo to yield a brown oil. 
Yield: 0.4 g, 2.6 mmol (9%) 
1H NMR (300 MHz, CDCl3):  7.51(s, 1H, NCHN), 6.95 (s, 2H, HC=CH), 4.86 
(q, J = 7.2 Hz, 1H, CH), 3.64 (s, 3H, O-CH3), 1.66 (d, J = 7.2 Hz, 3H, CH3). 
HRMS (ESI+): Calcd for C7H11N2O2 [M + H]+: 155.0776. Found: 155.0783.  
8.2.7 Preparation of P29-314 
1H-Imidazole (2.0 g, 29.4 mmol), potassium hydroxide (3.29 g, 58.8 mmol) and 
tetra-n-butyl ammonium bromide (0.284 g, 0.882 mmol) were suspended in 
water (2 mL) and dissolved by aid of sonication. CH2Br2 (2.06 mL, 29.4 mmol) 
was added dropwise via syringe and the reaction mixture 
stirred overnight, during which time a white crystalline 
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purified by column chromatography (SiO2, ethyl acetate) to give the title product 
as a colourless crystalline solid.     
Yield: 1.8 g, 12.2 mmol (41%) 
1H NMR (300 MHz, DMSO-d6):  7.96 (s, 1H, NCHN), 7.40 (s, 1H, C=CH), 6.93 
(s, 1H, C=CH), 6.23 (s, 2H, N-CH2-N). 13C{1H} NMR (75 MHz, DMSO-d6): 
137.3 (NCHN), 129.0 (C=CH), 119.1 (C=CH), 54.7 (CH2). HRMS (ESI+): Calcd 
for C7H91N4 [M + H]+: 149.0827. Found: 149.0821. 
8.2.8 Preparation of P335 
1H-Imidazole (0.2 g, 2.9 mmol), potassium hydroxide (0.33 g, 5.9 mmol) and 9- 
chloromethyl anthracene (0.66 g, 2.9 mmol) were added to an ampoule. MeCN 
(30 mL) was added and the mixture was heated at 90°C for 24 hours in a sealed 
vessel. The solution, which had turned a dark brown 
colour, was dried in vacuo, washed with distilled H2O (50 
mL) and extracted into Et2O (3 x 50 mL) and CH2Cl2 (3 x 
50 mL). The organic layers were combined and dried over 
magnesium sulfate and dried in vacuo to yield a brown 
solid.  
Yield:  0.7 g, 2.7 mmol (92%) 
1H NMR (300 MHz, CDCl3): 8.52 (s, 1H, NCHN), 8.17 (d, 2H, J = 8.1 Hz, 
aromatic), 8.03 (d, 2H, J = 8.1 Hz, aromatic), 7.56-7.44 (m, 5H, aromatic), 6.96 
(s, 2H, CH2). 13C{1H} NMR (75 MHz, CDCl3): 135.8 (N=CH-N), 130.5, 129.8 
(C, aromatic), 128.5, 128.2, 126.4 (CH, aromatic), 124.3, 123.7 (N-HC=CH-N), 
121.9 (CH, aromatic),  42.3 (CH2). HRMS (ESI+): Calcd for C18H14N2 [M + H]+: 
259.1191, Found: 259.1247 
8.2.9 Preparation of P(PM5)6, 7 
L-Lysine (Z) amino acid (5.02 g, 17.9 mmol) was weighed into a three neck 
round bottomed flask and dried in vacuo. 
Anhydrous ethyl acetate (50 mL) and α-
pinene (4.23 g, 31.1 mmol) were added to 
the amino acid and the mixture was 
heated at reflux for 30 minutes. 
Triphosgene (6.78 g, 22.9 mmol) was 
dissolved in anhydrous ethyl acetate (20 mL) and added into the solution 
dropwise using a dropping funnel. The solution was heated at reflux for 4 hours 
until the initial suspension cleared into a gold colour solution. The solution was 
concentrated by reducing its volume to a third in vacuo, after which it was added 
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dropwise to C7H16 (300 mL) at 0 °C to precipitate the N-carboxy anhydride 
product as a white solid. The product was filtered and washed with C7H16 (3 x 
50 mL) and dried in vacuo to yield a white solid.  
Yield: 4.85 g, 15.8 mmol (89%). 
1H NMR (300MHz, DMSO-d6) : 9.07(s, 1H, NH), 7.39-7.30 (m, 5H, aromatic), 
7.24 (NH-C=O), 5.00 (s, 2H, O-CH2-aromatic), 4.42 (t, 1H, J = 6.1 Hz, CH), 2.98 
(q, 2H, J = 6.1 Hz, CH2-NH), 1.77-1.63 (m, 2H, CH2), 1.44-1.25 (m, 4H, CH2). 
HRMS (ESI+): calcd for C15H18N2NaO5 [M + Na]+: 329.1113. Found: 329.1114. 
Anal. Calcd for C15H18N2O5: C, 58.82; H, 5.92; N, 9.15. Found: C, 58.80; H, 5.90; 
N, 9.10. 
8.2.10 Preparation of P(PM5.A-C)7 
Synthesis of methoxy-poly(polyethylene glycol)-b-poly(L-lysine(Cbz))  
N(epsilon)-Benzyloxycarbonyl-L-lysine 
NCA (380.2 mg, 1.24 mmol) was 
dissolved in anhydrous CH2Cl2 (10 mL). 
This solution was injected into a dry and 
nitrogen-purged Schlenk tube sealed 
with a rubber septum and equipped with 
a magnetic stirrer bar. O-(2-
aminoethyl)-O′-methylpolyethylene 
glycol (155 mg, 0.031 mmol) was 
dissolved in anhydrous CH2Cl2 (10 mL) 
and injected into the Schlenk tube under 
a constant flow of nitrogen and with 
constant stirring. The reaction mass 
was degassed by bubbling N2 through the solution and left to stir at room 
temperature for 120 hours, under a constant stream of nitrogen. The resultant 
polymer was precipitated in cold Et2O (100 mL) for 5 hours. The precipitated 
polymer was isolated from the supernatant by centrifugation (6000 rpm, 20 min, 
-5 °C). The polymer was washed three times using cold Et2O (100 mL) and dried 
in a vacuum oven maintained at 40 °C for 24 hours. 
   






1 (P(PM5 A)) 250 306.3 20 418.0 
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2 (P(PM5 B)) 155 380.2 40 487.1 
3 (P(PM5 C)) 155 712.2 75 691.0 
 
1H NMR (300 MHz, Trifluoroacetic acid-d):  8.37 (s, 8, NH), 7.36-7.28 (broad 
s, aromatic 1), 5.15 (broad s, O-CH2-aromatic 2), 4.56 (broad s, CH 7), 3.90 
(broad s, mPEG), 1.87-1.73 (m, CH2 4), 1.56-1.37 (m, CH2 5 & 6). 
8.2.11 Preparation of PM5.A-C 
Synthesis of methoxy-Poly(polyethylene 
glycol)-b-Poly(L-lysine) mPEG5000-b-
Poly(L-lysine(Cbz)) (480 mg) was dissolved 
in CF3COOH (5 mL). The polymer solution 
was added to a 33 wt.% solution of HBr in 
CH3COOH (1.5 mL). The mixture was 
stirred at room temperature for 24 hours, 
then added dropwise into cold Et2O (150 
mL) to induce the precipitation of the deprotected polymer. The precipitate was 
isolated by centrifugation (3000 rpm, 10 min). The polymer was re-suspended 
in fresh Et2O, stirred for 30 min and centrifuged. This was repeated several 
times until a clear supernatant was obtained. The polymer was dissolved in de-
ionised H2O and dialysed against de-ionised water for 96 hours, with the 
dialysate being substituted with a fresh supply after every 8 hours. The polymer 
was isolated by freeze-drying.  
 
*Estimated from 1H NMR by normalising to mPEG5000 integrals and comparing 
the mPEG signal (3.40 ppm - 3.52 ppm) to the proton signal from α-CH groups 
of poly(L-lysine) (3.25 ppm).   
 
1H NMR (300 MHz, DMSO-d6): 8.03 (broad s, NH 1), 4.27 (broad s, CH 6), 
3.51 (broad s, mPEG), 2.78 (broad s, CH2-NH2 2), 1.66-1.57 (broad m, CH2 3 & 
4), 1.35 (broad s, CH2 5). 
Entry/Polymer   Yield (mg)  Yield (wt.%) Mw (g/mol)* m:n* 
1 (PM5 A) 171.0 43.8 10055.6 1:20 
2 (PM5 B) 369.9 77.1 11464.5 1:40 
3 (PM5 C) 547.8 88.4 22992.6 1:75 
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8.2.12 Preparation of L18 
Caffeine (5.0 g, 33.0 mmol) was dissolved in DMF (40 mL), and methyl iodide 
(9.51 mL, 330.0 mmol) was added. The mixture was 
heated at reflux for 48 hours. Ethyl acetate (200 mL) was 
added to the solution to induce precipitation. Most of the 
solvent was decanted from the precipitate and ethyl 
acetate (200 mL) was added to the solid. This was 
decanted and washed a third time with ethyl acetate. The solid was filtered and 
washed with ethyl acetate (300 mL), and dried in vacuo to yield the product as 
a white solid. 
Yield: 5.4 g, 16.0 mmol (49%) 
1H NMR (300 MHz, DMSO-d6):  9.27 (s, 1H, NCHN), 4.14 (s, 3H, CH3), 4.05 
(s, 3H, CH3), 3.73 (s, 3H, CH3), 3.27 (s, 3H, CH3).13C{1H} NMR (75 MHz, DMSO-
d6): 153.3 (C=O), 150.2 (C=O), 141.1 (C=C), 138.1 (NCHN), 107.8 (C=C), 36.6, 
35.9, 30.4, 25.5 (NCH3). HRMS (ESI+): Calcd for C9H13N4O2 [M - I]+: 209.1033. 
Found: 209.1029. M.P: 186.4-188.1°C 
8.2.13 Preparation of L1.19 
Caffeine (1.0 g, 5.0 mmol) was dissolved in toluene (15 mL) and (CH3)2SO4 (0.5 
mL, 5.3 mmol) was added. The mixture was heated 
at reflux for 48 hours. Excess Et2O (150 mL) was 
added to the solution which had turned a brown 
colour, and the brown oil that precipitated out of 
solution was filtered and washed with Et2O, and 
dried in vacuo. The sticky product was not used in 
subsequent reactions. 
1H NMR (300 MHz, D2O):  8.89 (s, 1H, NCHN), 4.11 (s, 6H, CH3), 3.78 (s, 3H, 
CH3), 3.73 (s, 3H, CH3), 3.33 (s, 3H, CH3).  HRMS (ESI+): calcd for C9H13N4O2 
[M - OSO3CH3]+: 209.1033. Found: 209.1038. 
8.2.14 Preparation of L1.29  
Caffeine (2.0 g, 10.0 mmol) was dissolved in toluene (30 mL), and p- SO3CH3 
(C6H5)CH3 (7.8 mL, 50.0 mmol) was added. The mixture was heated to reflux 
for 48 hours. Excess Et2O (300 mL) was added 
to the solution which had turned a yellow 
colour, and the yellow solid that precipitated out 
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and dried in vacuo. The product was not used in subsequent reactions. 
Yield: 1.48 g, 3.9 mmol (39%) 
1H NMR (300 MHz, DMSO-d6):  9.25 (s, 1H, NCHN), 7.44 (d, J = 7.2 Hz, 2H, 
aromatic), 7.09 (d, J = 7.2 Hz, 2H, aromatic), 4.12 (s, 3H, CH3), 4.03 (s, 3H, 
CH3), 3.72 (s, 3H, CH3), 3.26 (s, 3H, CH3), 2.28 (s, 3H, CH3). HRMS (ESI+): 
Calcd for C9H13N4O2 [M – tolSO3]+: 209.1033. Found: 209.1050.  
8.2.15 Preparation of L2 
P2 (4.5 g, 19.1 mmol), was dissolved in DMF (10 mL) and CH3I (23.7 mL, 381.0 
mmol) was added. The mixture was heated at 70°C for 24 
hours in a sealed ampoule. Excess Et2O (150 mL) was 
added to the solution resulting in the precipitation of a 
yellow solid. The solid was recrystallised from CH2Cl2/ 
Et2O and dried in vacuo to yield a bright yellow solid.  
Yield: 6.3 g, 16.7 mmol (87%) 
1H NMR (300 MHz, DMSO-d6):  9.41 (s, 1H, NCHN), 4.45 (t, J = 7.3 Hz, 2H, 
CH2), 4.16 (s, 3H, CH3), 3.76 (s, 3H, CH3), 3.26(s, 3H, CH3), 1.82 (quin, J = 7.3 
Hz, 2H, CH2), 1.31 (sext, J = 7.3 Hz,  2H, CH2), 0.91 (t, J = 7.3 Hz,  3H,CH3). 1H 
NMR (300 MHz, CDCl3):  10.50 (s, 1H, NCHN), 4.58 (t, J = 7.3 Hz, 2H, CH2), 
4.48 (s, 3H, CH3), 3.87 (s, 3H, CH3), 3.40 (s, 3H, CH3), 1.99 (quin, J = 7.3 Hz, 
2H, CH2), 1.45 (sext, J = 7.3 Hz, 2H, CH2), 0.98 (t, J = 7.3 Hz, 3H,CH3).13C{1H} 
NMR (75 MHz, CDCl3): δ 153.1(C=O), 149.9 (C=O), 139.5 (C), 138.6 (CH), 
107.8(C), 49.7(CH3), 38.9(CH2), 32.3 (CH2), 32.1 (CH3), 28.7 (CH2), 19.4(CH3), 
13.3(CH3).HRMS (ESI+): Calcd for C12H19N4O2 [M - I]+: 251.1503. Found: 
251.1589. Anal. Calcd for C12H19IN4O2: C, 38.11; H, 5.06; N, 14.81. Found: C, 
37.80; H, 5.00; N, 14.60. M.P: 142.4-144.7°C 
8.2.16 Preparation of L3 
P3 (2.6 g, 9.6 mmol), was dissolved in DMF (3 mL) and CH3I (11.9 mL, 191.0 
mmol) was added. The mixture was heated at 70 °C for 
24 hours in a sealed ampoule. Excess Et2O (150mL) 
was added to the solution which had turned an orange 
colour resulting in the precipitation of an orange powder. 
The powder was recrystallised from CH2Cl2 / Et2O and 
dried in vacuo to yield the product as a yellow solid.  
Yield: 0.8 g, 1.9 mmol (20%) 
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1H NMR (300 MHz, DMSO-d6):  9.49 (s, 1H, NCHN), 7.46-7.37 (m, 5H, 
aromatic), 5.75 (s, 2H, CH2), 4,16 (s, 3H, CH3),  3.73 (s, 3H, CH3), 3.26 (s, 3H, 
CH3).13C{1H} NMR (75 MHz, DMSO-d6):  153.1(C=O), 150.1 (C=O), 139.8 (C), 
139.4 (CH), 134.4 (C-arom), 128.8, 128.7, 128.2 (CH, aromatic), 106.9 (C), 
51.1(CH3), 37.2 (CH3), 31.3 (CH3), 28.4(CH2). HRMS (ESI+): Calcd for 
C30H33N8O4 [2M - I]+: 569.2614. Found: 569.2619. Anal. Calcd for C15H17IN4O2 
∙
1/4 Et2O: C, 44.61; H, 4.56; N, 13.01. Found: C, 44.80; H, 4.30; N, 12.70. M.P: 
200.2-203.4 °C 
8.2.17 Preparation of L3.1 
P3 (0.85 g, 3.2 mmol) was dissolved in DMF (15 mL) and p- SO3CH3(C6H5)CH3 
(4.74 mL, 31.5 mmol) was added. The mixture 
was heated at reflux for 24 hours. Excess ethyl 
acetate (150 mL) was added to the solution 
which had turned a reddish-brown clear colour 
to precipitate a yellow solid. The yellow solid 
was filtered and washed with ethyl acetate 
(200 mL) and dried in vacuo. The product was 
not used in subsequent reactions. 
Yield: 0.3 g, 0.7 mmol (21%) 
1H NMR (300 MHz, DMSO-d6):  9.47 (s, 1H, NCHN), 7.68-7.12 (m, 9H, 
aromatic), 5.69 (s, 2H, CH2), 4.13 (s, 3H, CH3), 3.70 (s, 3H, CH3), 3.09 (s, 3H, 
CH3), 2.28 (s, 3H, CH3). 13C{1H} NMR (75 MHz, CDCl3):  171.3,156.4, 143.4, 
139.8, 129.8, 127.8, 126.6, 124.2, 122.3 (CH, aromatic), 103.8 (C), 60.6(CH3),   
55.7 (CH3), 21.6 (CH3), 14.3(CH2). HRMS (ESI+): Calcd for C15H17N4O2 [M - 
tos]+: 285.3265. Found: 285.3211. 
8.2.18 Preparation of L4 
P4 (0.2 g, 0.8 mmol) was dissolved in DMF (4 mL), and CH3I (0.91 mL, 15.6 
mmol) was added. The mixture was heated at 70 °C in a 
sealed ampoule for 24 hours. Excess Et2O (90 mL) was 
added to the solution, which had turned an orange colour, 
to furnish the product as a yellow solid that was filtered 
and dried in vacuo. 
Yield: 0.15 g, 0.4 mmol (50%) 
1H NMR (300 MHz, DMSO-d6):  9.75 (s, 1H, NCHN), 8.17 (broad s, 5H, 
aromatic), 4.25 (s, 3H, CH3), 3.82 (s, 3H, CH3), 3.40 (s, 3H, CH3).13C{1H} NMR 
(75 MHz, DMSO-d6):  154.1(C), 151.9(C), 140.3(C), 132.7(C), 130.7(CH), 
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129.3(CH), 125.8(CH), 109.5(CH), 54.4(C), 35.7(CH3), 28.5(CH3), 26.3(CH3). 
HRMS (ESI+): Calcd for C14H15N4O2 [M - I]+: 271.1190. Found: 271.1188. Anal. 
Calcd for C14H15IN4O2 ∙3H2O: C, 37.18; H, 4.68; N, 12.39. Found: C, 36.80; H, 
4.20; N, 12.20. M.P: 168.1-169.4 °C 
8.2.19 Preparation of L58 
P5 (0.3 g, 1.3 mmol) was dissolved in DMF (3 mL) and CH3I (5.1 mL, 80.1 mmol) 
was added. The mixture was heated at 70°C for 48 
hours in a sealed ampoule. Excess Et2O (90 mL) was 
added to the solution which had turned turbid yellow to 
yield a yellow solid. Recrystallisation from MeOH / ethyl 
acetate furnished the product as a light yellow solid. 
Yield: 0.15 g, 0.4 mmol (31%) 
1H NMR (300 MHz, DMSO-d6):  9.27 (s, 1H, NCHN), 4.15 (s, 3H, CH3), 4.06 
(s, 3H, CH3), 3.99 (t, J = 6.4 Hz, 2H, CH2), 3.55 (t, J = 6.4 Hz, 2H, CH2). 13C{1H} 
NMR (125 MHz, DMSO-d6):  153.3(C=O), 150.2(C=O), 139.7(CH), 139.2(C), 
107.7(C), 57.2(CH2), 43.5(CH2), 36.9(CH3), 35.6(CH3), 31.1(CH3). HRMS 
(ESI+): calcd for C10H15N4O3 [M - I]+: 239.1139. Found: 239.1180 M.P: 180.1-
181.7 °C 
8.2.20 Preparation of L6 
Clotrimazole (0.20 g, 0.58 mmol) was dissolved in CH2Cl2 (3 mL) and methyl 
iodide (0.72 mL, 11.60 mmol) was added. The mixture was heated at 45 °C in 
the microwave for 15 minutes. Excess Et2O (30 mL) was 
added to the pale yellow solution, prompting 
precipitation of the product as an off-white solid. The 
product was filtered, washed with Et2O (100 mL), and 
dried in vacuo. 
Yield: 0.21 g, 0.4 mmol (74%).  
1H NMR (300 MHz, CDCl3):  9.10 (s, 1H, NCHN), 7.75 (s, 1H, NCH), 7.50-7.11 
(m, 14H, aromatic), 6.95 (s, 1H, NCH), 4.25 (s, 3H, CH3). 13C{1H} NMR (75 MHz, 
CDCl3):  138.0 (CH), 137.9 (C), 137.4 (C), 135.1 (C), 132.9 (CH), 131.7 (CH), 
131.5 (CH), 130.1 (CH), 192.5 (CH), 129.2 (CH), 128.1 (CH), 124.1 (CH), 123.6 
(CH), 79.5 (C), 38.8 (CH3). HRMS (ESI+): Calcd. for C23H20ClN2 [M - I]+: 
359.1310. Found: 359.1311.  C23H26ClIN2∙1/3 H2O: C, 56.75; H, 4.14; N, 5.75; 
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8.2.21 Preparation of L7 
Clotrimazole (0.20 g, 0.58 mmol) was dissolved in CH2Cl2 (3 mL) and and butyl 
iodide (0.67 mL, 5.80 mmol) was added. The mixture was heated to 45 °C in the 
microwave for 15 minutes. Excess Et2O (30 mL) 
was added to the pale yellow solution, inducing 
precipitation of the product as a white solid.  The 
product was filtered, washed with Et2O, and dried 
in vacuo.  
Yield: 0.18 g, 0.34 mmol (59%). 
 1H NMR (300 MHz, CDCl3): 9.18 (s, 1H, NCHN), 7.71(s, 1H, NCH), 7.51-6.91 
(m, 14H, aromatic), 6.74 (s, 1H, NCH), 4.63 (t, J = 7.3 Hz, 2H, CH2), 1.86 (m, 
2H, CH2), 1.37 (m, 2H, CH2), 0.93 (t, J = 7.3 Hz, 3H, CH3). 13C NMR (CDCl3, 75 
MHz):  140.3 (C), 138.1 (C), 137.1 (CH), 135.5 (C), 132.1 (CH), 131.4 (CH), 
130.0 (CH), 129.7 (CH), 129.0 (CH), 127.9 (CH), 127.0 (CH), 123.6 (CH), 121.5 
(CH), 79.1 (C), 50.9 (CH2), 32.3 (CH2), 19.2 (CH2), 13.5 (CH3). HRMS (ESI+): 
Calcd. for C26H26ClN2 [M - I]+: 401.1785. Found: 401.1778. M.P.: 103.1-104.9 
°C. Anal. Calcd for C26H24ClIN2∙1/2H2O: C, 58.06; H, 5.06; N, 5.21; found: C, 
58.30; H, 4.90; N, 5.30. 
8.2.22 Preparation of L8 
Clotrimazole (0.50 g, 1.45 mmol) was dissolved in CH2Cl2 (3 mL) and 2-
iodoethanol (0.23 mL, 2.9 mmol) was added. The mixture was heated at reflux 
for 48 hours. Ethyl acetate (30 mL) was added to 
the resulting brown solution which induced 
precipitation of a yellow solid. This was filtered 
and washed with ethyl acetate. Trituration with 
(CH3)2CO gave the product as a white solid. 
Yield: 0.38 g, 0.74 mmol (51%). 
1H NMR (300 MHz, CDCl3):  9.04 (s, 1H, NCHN), 7.75 (s, 1H, NCH), 7.52-7.10 
(m, 14H, aromatic), 7.02 (s, 1H, NCH), 4.64 (t, J = 4.9 Hz, 2H, CH2), 3.99 (t, J = 
4.9 Hz, 2H, CH2), 2.82 (broad s, 1H, OH). 13C{1H} NMR (75 MHz, CDCl3):  
138.1 (C), 137.8 (CH), 137.4 (C), 135.3 (C), 133.0 (CH), 131.5 (CH), 131.4 (CH), 
130.0 (CH), 129.5 (CH), 129.2 (CH), 128.1 (CH), 123.5 (CH), 123.4 (CH) 79.3 
(C), 59.9 (CH2), 52.8 (CH2). HRMS (ESI+): Calcd. for C24H22ClN2O [M - I]+: 
389.1421. Found: 389.1419. M.P.: 155.6-156.2 °C. Anal. Calcd for 
C24H22ClIN2O: C, 55.78; H, 4.29; N, 5.42; found: C, 56.00; H, 4.40; N, 5.80. 
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8.2.23 Preparation of L9 
2-Chlorotrityl chloride (0.50 g, 1.60 mmol) and 1-methylimidazole (0.50 mL, 6.27 
mmol) were dissolved in MeCN (10 mL) and heated 
at reflux for 24 hours. The solution was cooled to 
room temperature and Et2O (90 mL) was used to 
precipitate the product as a white solid. 
Yield: 0.53 g, 1.35 mmol (85%). 
1H NMR (300 MHz, CDCl3):  9.10 (s, 1H, NCHN), 7.75 (s, 1H, NCH), 7.50-7.11 
(m, 14H, aromatic), 6.95 (s, 1H, NCH), 4.25 (s, 3H, CH3). 13C{1H} NMR (75 MHz, 
CDCl3):  139.1 (CH), 138.4 (C), 137.6 (C), 135.4 (C), 133.0(CH), 131.7 (CH), 
131.4 (CH), 130.0 (CH), 129.5 (CH), 129.1 (CH), 127.9 (CH), 123.7 (CH), 123.4 
(CH), 79.3 (C), 37.8 (CH3). HRMS (ESI+): Calcd. for C23H20ClN2 [M - Cl]+: 
359.1310. Found: 359.1311. M.P.: 190.1-190.8 °C. Anal. Calcd for C23H20Cl2N2: 
C, 69.88; H, 5.10; N, 7.09; found: C, 69.80; H, 5.10; N, 7.20.  
8.2.24 Preparation of L10 
2-Chlorotrityl chloride (0.50 g, 1.60 mmol) and 1-allylimidazole (0.48 mL, 4.40 
mmol) were dissolved in MeCN (10 mL) and heated at reflux for 24 hours. The 
yellow solution was allowed to cool to room 
temperature and addition of Et2O (90 mL) was used 
to precipitate a yellow oil. The solution was 
decanted from the oil which was washed with ethyl 
acetate. Trituration in (CH3)2CO yields the product 
as a white solid that was dried in vacuo. 
Yield: 0.37 g, 0.9 mmol (55%). 
1H NMR (CDCl3, 300 MHz):  9.84 (s, 1H, NCHN), 7.71 (s, 1H, NCH), 7.51-7.06 
(m, 14H, aromatic), 6.96 (s, 1H, NCH), 6.08-5.95 (m, 1H, CH), 5.41-5.35 (m, 
4H, N-CH2CHCH2). 13C{1H} NMR (CDCl3, 75 MHz):  138.8 (CH), 138.4 (C), 
137.5 (C), 135.4 (C), 132.9 (CH), 131.8 (CH), 131.5 (CH), 130.8 (CH), 130.0 
(CH), 129.5 (CH),129.1 (CH), 127.9 (CH), 123.5 (CH), 122.2 (CH), 121.9 (CH2) 
79.4 (C), 52.9 (CH2). HRMS (ESI+): Calcd. for C25H22ClN2 [M - Cl]+: 385.1466. 
Found: 385.1471. M.P.: 157.8-159.1 °C. Anal. Calcd for C25H22Cl2N2∙1/4 H2O: C, 
70.26; H, 5.35; N, 6.55; found: C, 70.20; H, 5.30; N, 6.80. 
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8.2.25 Preparation of L11 
2-Chlorotrityl chloride (0.50 g, 1.60 mmol) dissolved in CH2Cl2 (5 mL) and 
1-butylimidazole (0.21 mL, 1.60 mmol) was 
added. The mixture was heated at 45 °C 
for 24 hours in a sealed ampoule. Excess 
Et2O (60 mL) was added to the solution 
which had turned a yellow colour to obtain 
the product as a white solid. 
Yield: 0.3 g, 0.7 mmol (43%). 
1H NMR (300 MHz, CDCl3):  9.60 (s, 1H, NCHN), 8.19 (s, 1H, HC=C), 
7.47-6.98 (m, 15H, aromatic + C=CH), 4.63 (t, J = 7.3 Hz, 2H, CH2), 1.85-
1.74 (m, 2H, CH2), 1.28 (dt, J = 17.4, 7.3Hz, 2H, CH2), 0.86 (t, J = 7.3 Hz, 
3H, CH3). 13C{1H} NMR (CDCl3, 75 MHz): δ 138.5 (C-arom), 138.2 (CH), 
137.5, 135.3 (C-arom), 132.9, 131.8, 131.4, 129.8, 129.3, 129.0, 127.9 
(CH-arom), 123.6, 122.7(CH), 79.1 (C), 50.5, 32.5, 19.4 (CH2), 13.6 (CH3). 
HRMS (ESI+): Calcd. for C26H26ClN2 [M - Cl]+: 401.1779. Found: 
401.1764. M.P.: 161.3-162.9°C. Anal. Calcd for C26H26Cl2N2: C, 71.39; H, 
5.99; N, 6.90; found: C, 71.10; H, 6.20; N, 6.60. 
8.2.26 Preparation of L12 
2-Chlorotrityl chloride (0.50 g, 1.60 mmol) and 1-benzylimidazole (0.25 mL, 1.93 
mmol) were dissolved in MeCN (10 mL). The mixture was heated at reflux for 
24 hours. The solution was allowed to cool to 
room temperature and excess Et2O (90 mL) was 
added to precipitate a yellow solid. This was 
filtered and washed with ethyl acetate (100 mL) 
and (CH3)2CO (50 mL) to give the product as a 
white solid which was dried in vacuo. 
Yield: 0.14 g, 0.3 mmol (20%).  
1H NMR (300 MHz, CDCl3):  9.92 (s, 1H, NCHN), 7.49 (s, 1H, NCH), 7.44-7.02 
(m, 19H, aromatic), 6.88 (s, 1H, NCH), 5.90 (s, 2H, CH2). 13C{1H} NMR (CDCl3, 
75 MHz): 157.7 (C), 138.9 (CH), 138.5 (C), 137.5 (C), 135.4 (C), 133.7 (CH), 
132.9 (CH), 131.9 (CH), 131.4 (CH), 129.9 (CH),129.4 (CH), 129.3 (CH), 129.1 
(CH), 129.1 (CH), 127.9 (CH), 123.5 (CH), 122.1 (C), 79.3 (C), 54.1 (CH2). 
HRMS (ESI+): Calcd. for C29H24ClN2 [M - Cl]+: 435.1623. Found: 435.1630. M.P.: 
125.8-127.6 °C. Anal. Calcd for C25H22Cl2N2∙3/5H2O: C, 69.74; H, 5.65; N, 
5.61; found: C, 69.90; H, 5.30; N, 6.00. 
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8.2.27 Preparation of L13 
2-Chlorotrityl chloride (1.0 g, 3.20 mmol) was dissolved in CH2Cl2 (5 mL) and 1-
(2-hydroxyethyl)imidazole (0.30 mL, 3.20 mmol) was added. The solution was 
heated at 45 °C for 24 hours in a sealed 
ampoule. Excess C5H12 (100 mL) was added to 
the solution which had turned yellow, yielding a 
yellow oil. This was recrystallised from MeOH / 
C5H12 to obtain the product as a yellow solid. 
Yield: 1.32 g, 3.1 mmol (97%).  
1H NMR (300 MHz, acetone-d6):  8.98 (s, 1H, NCHN), 7.68, 6.91 (s, 1H, 
HC=CH), 7.87-7.12 (m, 14H, aromatic), 4.41 (t, J = 5.1 Hz, 2H, CH2), 3.87 (t, J 
= 5.1 Hz, 2H, CH2). 1H NMR (300 MHz, MeOD):  9.00 (s, 1H, NCHN), 7.83 (s, 
1H, C=CH), 7.64-7.20 (m, 15H, Ar + HC=C), 4.41 (t, J = 5.1 Hz, 2H, CH2), 3.89 
(t, J = 5.1 Hz, 2H, CH2). 13C{1H} NMR (125 MHz, acetone-d6): 139.0 (C), 138.2 
(CH), 135.4,133.2 (C-arom), 132.1, 131.8, 130.4, 129.8, 129.3, 128.5, 127.8 
(CH-arom), 124.6 , 123.8 (CH=CH), 120.6 (C), 79.2 (C), 61.6 (CH2), 60.2 (CH2). 
HRMS (ESI+): Calcd. for C24H22ClN2O [M - Cl]+: 389.1421. Found: 389.1425. 
M.P.: 172.2-174.6°C. Anal. Calcd for C24H22Cl2N2O∙1/3 H2O: C, 66.83; H, 5.30; 
N, 6.49. Found: C, 67.20; H, 5.25; N, 6.70. 
8.2.28 Preparation of L14 
Trityl chloride (6.80 g, 24.40 mmol) and 1-methylimidazole (2.0 g, 24.40 mmol) 
were dissolved in MeCN (20 mL). The mixture was 
heated at reflux for 24 hours. The white solution was 
allowed to cool and addition of excess Et2O (150 mL) 
furnished the product as a white solid. 
Yield: 6.1 g, 16.9 mmol (69%). 
1H NMR (300 MHz, CDCl3):  9.50 (s, 1H, imH), 7.90 (s, 1H, N-CH), 7.42-7.12 
(m, 15H, aromatic), 6.97 (s, 1H, N-CH), 4.29 (s, 3H, CH3). 13C{1H} NMR (125 
MHz, CDCl3):  147.0(CH), 139.6, 138.0, 135.9 (C-arom), 129.7, 129.3, 129.0, 
128.0, 127.9, 127.2, 124.1, 123.8, (CH-arom), 122.1 (CH), 119.9 (CH), 79.5(C), 
36.2 (CH3). HRMS (ESI+): Calcd. For C23H21N2 [M - Cl]+: 325.1699. Found: 
325.1701. M.P.: 162.3-164.5°C. Anal. Calcd for C23H21ClN2∙2H2O: C, 69.60; H, 
6.35; N, 7.06; found: C, 69.80; H, 6.30; N, 7.40. 
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8.2.29 Preparation of L15 
Trityl chloride (5.15 g, 18.50 mmol) and 1-allyl-1H-
imidazole (0.58 g, 1.49 mmol) were dissolved in 
CH2Cl2 (20 mL) and heated at reflux for 24 hours. 
Addition of excess Et2O (150 mL) yields the 
product as a white solid that was dried in vacuo. 
Yield: 3.0 g, 8.4 mmol (45%). 
1H NMR (300 MHz, CDCl3):  9.62 (s, 1H, NCHN), 7.81 (s, 1H, N-CH), 7.41-
7.11 (m, 15H, aromatic), 6.98 (s, 1H, N-CH), 6.10-5.97 (m, 1H, C=CHallyl), 5.43- 
5.35 (m, 4H, CH2=CH=CH2). 13C{1H} NMR (125 MHz, CDCl3):  139.6 (CH), 
138.5 (C), 138.0 (CH), 130.6 (CH), 130.3, 129.6, 129.6, 129.1, 128.9, 128.6, 
127.9, 127.6, 126.6, 126.4, 125.7 (C-arom), 123.8 (CH=CH2), 122.2 (CH2), 52.8 
(CH=CH2). HRMS (ESI+): Calcd. For C25H23N2 [M - Cl]+: 351.1856. Found: 
351.4187. M.P.: 104.8-106.1 °C. Anal. Calcd for C25H23ClN2: C, 72.02; H, 6.37; 
N, 6.72; found: C, 71.80; H, 6.30; N, 6.90. 
8.2.30 Preparation of L16 
Trityl chloride (4.50 g, 16.12 mmol) and 1-butylimidazole (2.0 g, 16.12 mmol) 
were dissolved in CH2Cl2 (20 mL) and heated at reflux for 24 hours. Excess 
Et2O was added to the solution to furnish an off white solid. A saturated solution 
of NaHCO3 (20 mL) was added to the solid and 
the product was extracted into CH2Cl2 (20 mL x 
3). The organic layers were combined and 
filtered over magnesium sulfate. 
Recrystallisation from CH2Cl2 / Et2O yielded the 
product as a white solid which was dried in vacuo.  
Yield: 3.41 g, 8.5 mmol (53%).  
1H NMR (300 MHz, CDCl3):  9.46 (s, 1H, NCHN), 7.99 (s, 1H, HC=C), 7.43-
7.03 (m, 15H, aromatic), 7.01 (s, 1H,C=CH), 4.69 (t, J = 7.3 Hz, 2H, CH2), 1.85 
(pent, J = 7.3 Hz, 2H, CH2), 1.31 (sext, J = 7.3 Hz,  2H, CH2), 0.97 (t, J = 7.3 
Hz,3H, CH3) . 13C NMR (75 MHz, CDCl3):  139.6(CH), 138.1(C), 137.6(CH), 
136.3, 135.3, 133.5, 131.3, 130.4, 129.6, 129.3, 128.9, 127.7, 126.3, 125.7, 
124.3 (Ar), 123.9, (CH), 50.5, 32.3, 19.5 (CH2), 13.5 (CH3). HRMS (ESI+): Calcd. 
For C26H27N2 [M - Cl]+ : 367.2169. Found: 367.2119. M.P.: 109.1-111.3 °C. Anal. 
Calcd for C26H27ClN2∙4/3 H2O: C, 73.14; H, 7.00; N, 6.56; found: C, 73.10; H, 
6.90; N, 6.80. 
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8.2.31 Preparation of L17 
Trityl chloride (0.50 g, 1.78 mmol) and 1-benzylimidazole (0.28 g, 1.78 mmol) 
were dissolved in CH2Cl2 (5 mL). The solution was heated at 45 °C for 24 hours 
in a sealed ampoule. Excess Et2O (60 mL) was added to the solution to give an 
off white solid which was dried in vacuo. A saturated solution of NaHCO3 (20 
mL) was added to the solid and the product 
was extracted into CH2Cl2 (20 mL x 3). The 
organic layers were combined and filtered over 
magnesium sulfate, and excess Et2O was 
added to the solution furnishing the product as 
a white solid, which was dried in vacuo. 
Yield: 0.51 g, 1.2 mmol (65%).  
1H NMR (500 MHz, CDCl3):  9.82 (s, 1H, NCHN), 7.71, 6.93 (s, 1H, HC=CH), 
7.46-7.11 (m, 20H, aromatic), 5.94 (s, 2H, CH2). 13C{1H} NMR (75 MHz, CDCl3): 
138.2(CH), 135.5(C), 129.6, 129.5, 129.4, 129.3, 129.2, 128.9, 127.9, 127.2, 
123.7 (Ar),122.0 (CH), 121.0 (CH), 52.93(CH2). HRMS (ESI+): Calcd for 
C29H25N2 [M - Cl]+: 401.2012. Found: 401.2016. M.P.: 108.4-110.2°C. Anal. 
Calcd for C29H25ClN2∙5/4H2O: C, 75.80; H, 6.03; N, 6.10; found: C, 76.10; H, 
5.90; N, 6.50. 
8.2.32 Preparation of L18 
Trityl chloride (0.5 g, 1.8 mmol) was dissolved in CH2Cl2 (5 mL) and 1-(2-
hydroxyethyl) imidazole (0.17 mL, 1.80 mmol) 
was added. The solution was heated at 45°C for 
72 hours in a sealed ampoule. A white solid 
precipitated out of solution, which was filtered off 
and recrystallised from MeOH / C5H12 (5 mL / 50 
mL) furnishing the product as a white solid, which was dried in vacuo.  
Yield: 0.66 g, 1.7 mmol (94%). 
1H NMR (300 MHz, MeOD):  8.89 (s, 1H, NCHN), 8.24, 7.79 (s, 1H, HC=CH), 
7.50-7.24 (m, 15H, Ar), 4.37 (t, 2H, J = 5.1 Hz, CH2), 4.24 (t, 2H, J = 5.1 Hz, 
CH2). 13C{1H} NMR (75 MHz, MeOD):  141.4 (C), 139.4 (C), 130.8, 130.3, 129.9 
(CH-Ar), 125.5, 123.9 (NCH=CHN), 60.9 (CH2), 53.5 (CH2). HRMS (ESI+): Calcd 
for C24H23N2O [M - Cl]+ : 355.1810. Found: 355.1813. M.P.: 156.9-159.1°C. 
Anal. Calcd for C24H23ClN2O∙1/3H2O∙1/3CH2Cl2: C, 68.73; H, 5.77; N, 6.59; found: 
C, 69.00; H, 6.00; N, 6.36. 
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8.2.33 Preparation of L19 
2-Hydroxyethyl imidazole (0.17 mL, 1.78 mmol) was dissolved in MeCN (2 mL), 
and 2-chloroethanol (1.0 mL, 14.90 mmol) was 
added. The mixture was heated at 90 °C for 144 
hours in a sealed ampoule. Et2O was added to 
precipitate the product as a yellow oil which was 
dried in vacuo.  
Yield: 0.27 g, 1.4 mmol (79%)  
1H NMR (300 MHz, MeOD):  9.31 (s, 1H, NCHN), 7.95 (s, 1H, HC=C), 7.94 (s, 
1H, C=CH), 4.60 (t, J = 5.0 Hz, 4H, CH2), 4.13 (t, J = 5.0 Hz, 4H, CH2). 13C{1H} 
NMR (75 MHz, MeOD): 138.0 (NHCN), 124.0 (HC=CH), 61.1, 53.3 (CH2). 
HRMS (ESI+): Calcd for C7H13N2O2 [M - Cl]+ : 157.0972. Found: 157.0993. IR 
νmax / cm-1 3289 (OH), 2957, 1157, 1060.  
Ligands L19-L25 are hygroscopic and are mostly oils, hence elemental analysis 
was not obtained. 
8.2.34 Preparation of L2010, 11 
1-Methyl imidazole (1.84 mL, 24.4 mmol) and 2-chloroethanol (1.63 mL, 24.4 
mmol) were heated at 100°C in a sealed ampoule for 72 hours. The clear 
mixture turned dark brown after 24 hours. Excess Et2O 
(30 mL) was added to the mixture and precipitation of 
the product as a brown oil was aided by sonication. The 
Et2O was decanted and the product was subsequently 
dried in vacuo.  
Yield: 3.0 g, 18.5 mmol (76%)  
1H NMR (300 MHz, D2O): 8.81 (s, 1H, NCHN), 7.57 (s, 1H, C=CH), 7.51 (s, 
1H, C=CH), 4.37 (t, J = 5.0 Hz, 2H, CH2), 3.98 (t, J = 5.0 Hz, 2H, CH2), 3.96 (s, 
3H, CH3). 13C{1H} NMR (75 MHz, D2O): 136.2 (NCHN), 123.6 (C=C), 122.1 
(C=C), 59.8 (CH2), 51.6 (CH2), 35.9 (CH3). HRMS (ESI+): Calcd for C6H11N2O 
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8.2.35 Preparation of L21 
1-(Prop-2-enyl) imidazole (0.48 mL, 5.31 mmol) was dissolved in MeCN (2 mL), 
and 2-chloroethanol (0.31 mL, 4.62 mmol) was 
added. The mixture was heated to 90 °C for 24 
hours in a sealed ampoule. Addition of Et2O (30 
mL) precipitates the product as a yellow oil. which 
was subsequently dried in vacuo.       
Yield: 0.32 g, 1.7 mmol (32%)  
1H NMR (300 MHz, MeOD): 9.15 (s, 1H, NCHN), 7.76 (s, 1H, HC=C), 7.70 (s, 
1H, C=CH), 6.20-6.09 (m, 1H, C=CH,CH2), 5.51-5.45 (m, 2H, HC=CH2), 4.96 
(d, J = 6.2 Hz, 2H, CH2), 4.40 (t, J = 5.0 Hz, 2H, CH2), 3.92 (t, J = 5.0 Hz, 2H, 
CH2). 13C{1H} NMR (75 MHz, MeOD): 137.8 (NHCN), 132.3 (HC=CH3), 124.4, 
123.7 (HC=CH), 122.0 (N-CH2), 61.2, 53.5 (CH2), 52.9 (C=CH2). HRMS (ESI+): 
Calcd for C8H13N2O [M – Cl + MeOH]+ : 185.1285. Found: 185.1254. IR νmax / 
cm-1 3333 (OH), 2878, 1645, 1159, 1068. 
8.2.36 Preparation of L22 
1-Butyl imidazole (0.32 mL, 2.4 mmol) was dissolved in MeCN (2 mL), and 2-
chloroethanol (0.16 mL, 2.4 mmol) was added. The 
mixture was heated at 90 °C for 24 hours in a 
sealed ampoule. Addition of Et2O (30 mL) 
precipitates the product as a yellow oil. The Et2O 
was decanted and the product was subsequently 
dried in vacuo.  
Yield: 0.26 g, 1.3 mmol (53%)  
1H NMR (300 MHz, MeOD): 9.34 (s, 1H, NCHN), 7.92-7.89 (m, 2H, HC=CH), 
4.55 (t, J = 5.0 Hz, 2H, CH2), 4.46 (t, J = 7.4 Hz, 2H, CH2), 4.06 (t, J = 5.0 Hz, 
2H, CH2), 2.06 (quin, J = 7.4 Hz, 2H, CH2), 1.53 (sext, J = 7.4 Hz, 2H, CH2), 
1.44 (t, J = 7.4 Hz, 3H, CH3). 13C{1H} NMR (75 MHz, MeOD): 137.6 (NHCN), 
124.3, 123.7 (HC=CH), 61.2, 53.4 (CH2), 50.7 (CH2), 33.2 (CH2), 20.5 (CH2), 
14.0 (CH3). HRMS (ESI+):  Calcd for C9H17N2O [M – Cl]+ : 169.1335. Found: 
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8.2.37 Preparation of L2310 
1-Benzyl imidazole (0.5 g, 3.2 mmol) dissolved in MeCN (2 mL) and 2-
chloroethanol (0.21 mL, 3.2 mmol). The mixture 
is at 90 °C for 24 hours in a sealed ampoule. 
Excess Et2O (30 mL) was added to the solution 
to yield the product as a colourless oil. The Et2O 
was decanted and the product was dried in 
vacuo.  
 Yield: 0.26 g, 1.1 mmol (34%)  
1H NMR (300 MHz, MeOD):  9.26 (s, 1H, NCHN), 7.74 (s, 1H, C=CH), 7.70 (s, 
1H, C=CH), 7.53-7.41 (m, 5H, aromatic), 5.52 (s, 2H, benzyl-CH2), 4.39 (t, J = 
5.0 Hz, 2H, CH2), 3.93 (t, J = 5.0 Hz, 2H, CH2). 13C{1H} NMR (75 MHz, MeOD): 
137.7 (NCHN), 135.3 (C-arom), 130.3, 130.2, 129.7 (CH-arom), 124.4, 123.5 
(HC=CH), 61.0 (CH2-benzyl), 54.0, 53.3 (CH2). HRMS (ESI+):  Calcd for 
C12H15N2O [M – Cl]+ : 203.1184. Found: 203.1184. 
8.2.38 Preparation of L2410 
1-Mesityl Imidazole (0.5 g, 2.7 mmol) was dissolved in MeCN (7 mL) and 2-
chloroethanol (0.18 mL, 2.7 mmol) added. The 
mixture was heated at 90°C for 48 hours in a 
sealed ampoule. Excess Et2O (100 mL) was 
added to the solution which had turned brown 
yielding a brown solid. The Et2O was decanted 
and the brown solid was dried in vacuo. 
Yield: 0.22 g, 0.8 mmol (31%) 
1H NMR (300 MHz, DMSO-d6):  9.42(s, 1H,NCHN),  8.05 (s, 1H, C=CH), 7.92 
(s, 1H, C=CH), 7.14 (s, 2H, aromatic), 4.33 (t, 2H, CH2), 3.80 (broad s, 2H, CH2), 
2.33 (s, 3H, CH3), 2.02 (s, 6H, CH3). 1H NMR (300 MHz, MeOD): 9.27 (s, 1H, 
NCHN), 7.99 (s, 1H, HC=C), 7.75 (s, 1H, C=CH), 7.15 (s, 2H, Ar), 4.51 (t, J = 
5.0 Hz, 2H, CH2), 3.98 (t, J = 5.0 Hz, 2H, CH2), 2.38 (s, 3H, CH3), 2.12 (s, 6H, 
CH3). 13C{1H} NMR (75 MHz, MeOD):  139.1 (NHCN), 130.7 (HC-Ar), 125.3, 
124.7 (HC=CH), 60.9, 53.6 (CH2), 21.2 (Ar-CH3), 17.4 (Ar-CH3). HRMS (ESI+):  
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8.2.39 Preparation of L25 
2-(1H-imidazol-1-ylmethyl)pyridine (0.5 g, 3.1 mmol) was dissolved in MeCN (2 
mL), and 2-chloroethanol (0.20 mL, 3.1 mmol) 
was added. The mixture was heated at 90 °C for 
72 hours in a sealed ampoule. Addition of Et2O 
(50 mL) precipitates the product as a brown oil.  
The Et2O was decanted and the brown oil was 
dried in vacuo.  
Yield: 0.29 g, 1.2 mmol (39%) 
1H NMR (300 MHz, MeOD): 9.27 (s, 1H, NCHN), 9.02-8.98 ( m, 1H, HC=C), 
8.58-8.55 (m, 1H, C=CH), 7.93-7.87 (m, 1H, HCN-Ar), 7.76-7.71 (m, 1H, Ar), 
7.63-7.58 (m, 1H, Ar), 7.45-7.40 (m, 1H, Ar), 5.64 (s, 2H, CH2), 5.05 (s, 1H, OH), 
4.42-4.36 (m, 2H, CH2), 3.94-3.90 (m, 2H, CH2). 13C{1H} NMR (75 MHz, MeOD): 
  154.4 (CN-Ar), 150.9 (HCN-Ar), 139.2 (HC-Ar), 138.5 (NCHN), 125.3, 124.3 
(HC=CH), 123.7 (HC-Ar), 120.8 (HC-Ar), 54.8 (CH2), 53.5 (CH2). HRMS (ESI+):  
Calcd for C11H14N3O [M – Cl]+ : 204.1131. Found: 204.1131. IR νmax / cm-1 
3319(OH), 2952, 1476, 1289, 1158, 1065. 
8.2.40 Preparation of L26 
5-fluoro-2-(1H-imidazol-1-yl)pyridine (0.25 g, 1.53 mmol) was dissolved in 
MeCN (4 mL), and 2-chloroethanol (0.41 mL, 4.24 mmol) was added. The 
mixture was heated to 90 °C for 144 hours in a 
sealed ampoule. Addition of Et2O (60 mL) 
precipitates a green oil. The Et2O was decanted 
and the green oil was recrystallised from MeOH 
/ Et2O to furnish the product as a pale green solid that was dried in vacuo.      
Yield: 0.13 g, 0.5 mmol (35%) 
1H NMR (300 MHz, MeOD): 9.79 (s, 1H, NCHN), 8.47 (d, J = 6.0 Hz, 1H, 
HC=C), 8.30 (d, J = 6.0 Hz, 1H, C=CH), 7.99-7.89 (m, 3H, Ar), 4.39 (t, J = 5.1 
Hz, 2H, CH2), 3.90 (t, J = 5.1 Hz, 2H, CH2). 13C{1H} NMR (75 MHz, MeOD): 
138.8 (FCCHN), 138.4 (NHCN), 136.4 (NCN), 128.5, 128.2 (HC=CH), 125.2 
(C-F), 120.8 (HC-Ar), 117.1 (HC-Ar), 60.9, 54.0 (CH2). HRMS (ESI+):  calcd for 
C10H11FN3O [M – Cl]+ : 208.0881. Found: 208.0888. IR νmax / cm-1 3355(OH), 
2835, 1546, 1483, 1271, 1078, 1020. Anal. Calcd for C10H11ClFN3O.H2O. ½ 
MeCN: C, 46.82; H, 5.18; N, 17.37; found: C, 46.80; H, 4.80; N, 17.70. 
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8.2.41 Preparation of L27 
9-(Chloromethyl) anthracene P8 (0.5 g, 2.2 mmol) was dissolved in MeCN (30 
mL) and transferred to an ampoule. 1-(2-
hydroxyethyl) imidazole (0.21 mL, 2.2 mmol) 
was added. The mixture was heated at 90 °C for 
24 hours. Excess Et2O (200 mL) was added to 
the orange solution to yield the product as an 
orange solid. The Et2O was decanted and the 
solid was dried in vacuo.  
Yield: 0.71 g, 2.1 mmol (95%) 
1H NMR (300 MHz, CDCl3):  10.23 (s, 1H, NCHN), 8.61 (s, 1H, aromatic), 8.39 
(d, 2H, J = 5.3 Hz, aromatic), 8.08 (d, 2H, J = 5.3 Hz, aromatic), 7.66 (t, 2H, J = 
4.7 Hz, aromatic), 7.53 (t, 2H, J = 4.7 Hz, aromatic), 7.14 (s, 1H, C=CH), 6.77 
(s, 1H, HC=C), 6.55 (s, 2H, CH2), 4.41 (t, 2H, J = 5.6 Hz, CH2), 4.04 (t, 2H, J = 
5.6 Hz, CH2). 13C{1H} NMR (75 MHz, CDCl3):  137.5 (C), 131.4 (C), 131.1 (C), 
130.7 (CH), 129.5 (CH), 128.5 (CH), 125.7 (CH), 122.9 (CH), 122.0 (CH), 121.0 
(CH), 59.9 (CH2),  52.9 (CH2),  46.0 (CH2). HRMS (ESI+):  Calcd for C20H19N2O 
[M – Cl]+ : 303.1492. Found: 303.1483. IR νmax / cm-1 3233 (OH), 1548-1402 (C-
C arom).  Anal. Calcd for C20H19ClN2O∙4/3 H2O∙1/3 MeCN: C, 65.92; H, 6.07; N, 
8.68; found: C, 66.25; H, 5.90; N, 8.40. 
8.2.42 Preparation of L28 
2-(1-imidazoyl)-propionic acid methyl ester P28B (0.4 g, 2.6 mmol) was 
dissolved in MeOH (5 mL) and methyl iodide (1.0 mL, 34.4 
mmol) was added.  The mixture was heated at 70 °C in a 
sealed ampoule for 24 hours. The solvent was removed in 
vacuo to yield the product as a brown oil. 
Yield: 0.21 g, 0.7 mmol (27%) 
1H NMR (300 MHz, MeOD):  9.51 (s, 1H, NCHN), 8.07 (s, 1H, C=CH), 7.96 (s, 
1H, HC=C), 5.83 (q, J = 4.4 Hz, 1H, CH), 4.28 (s, 3H, CH3), 4.07 (s, 3H, O- 
CH3), 2.14 (d, J = 4.4 Hz, 3H, CH3). 1H NMR (300 MHz, CD3CN): 9.27 (s, 1H, 
NCHN), 7.68 (s, 1H, C=CH), 7.58 (s, 1H, HC=C), 5.59 (q, 1H, CH), 3.95 (s, 3H, 
CH3), 3.70 (s, 3H, O- CH3), 1.80 (d, 3H, CH3). 13C{1H}  NMR (75 MHz, MeOD): 
170.8 (C=O), 139.4 (NCHN), 126.1 (C=C), 122.1 (C=C), 52.4 (N-C- CH3), 49.9 
(O-CH3), 32.0 (N-CH3). HRMS (ESI+):  calcd for C8H13IN2O2 [M – I]+ : 169.0972. 
Found: 169.0969. IR νmax / cm-1 : 1742 (ester C=O), 1222(ester C-O), 1173, 
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1076, 747, 658.  Anal. Calcd for C8H13IN2O2∙3/2 H2O: C, 29.74; H, 4.99; N, 8.79; 
found: C, 29.70; H, 4.70; N, 8.50. 
8.2.43 Preparation of L29 
1.1’-methylene-bis-1H-imidazole (0.2 g, 1.35 mmol) dissolved in MeCN (3 mL) 
and methyl chloroacetate (0.23 mL, 2.7 mmol) was added. The mixture heated 
at 90°C in a sealed ampoule for 20 hours. 
The solvent was removed from the solution 
in vacuo to yield a brown oil. Recrystallisation 
from MeOH / Et2O furnished the product as a 
sticky yellow solid (very hygroscopic). 
Yield: 0.35 g, 1.0 mmol (71%) 
1H NMR (300 MHz, MeOD):  9.78 (s, 2H, NCHN), 8.20 (s, 2H, C=CH), 7.87 (s, 
2H, HC=C), 7.03 (s, 2H, N-CH2-N), 5.50-5.25 (m, 4H, N-CH2-C=O), 3.85 (s, 6H, 
O- CH3). 1H NMR (300 MHz, DMSO-d6):  9.87 (s, 2H, NCHN), 8.30 (s, 2H, 
C=CH), 7.91 (s, 2H, HC=C), 7.04 (s, 2H, N-CH2-N), 5.39 (s, 4H, N-CH2-C=O), 
3.13 (s, 6H, O- CH3).13C{1H}  NMR (75 MHz, MeOD):  170.0 (C=O), 140.9 
(NCHN), 126.2, 123.2 (C=C), 63.2 (N-CH2-N), 53.5 (N-CH2-C=O), 49.9 (O-CH3). 
HRMS (ESI+):  Calcd for C13H17N4O4 [M – 2Cl]2+ : 147.0659. Found: 147.0657. 
IR νmax / cm-1 :1746 (ester C=O), 1223 (ester C-O), 1167, 748, 619. Anal. Calcd 
for C13H18Cl2N4O4∙3.5 H2O. MeCN: C, 38.39; H, 6.01; N, 14.92; found: C, 38.10; 
H, 5.60; N, 15.30. 
8.2.44 Preparation of L30 
1.1’-methylene-bis-1H-imidazole (0.3 g, 2.0 mmol) dissolved in MeCN (5 mL) 
and tert-butyl chloroacetate (0.58 mL, 4.0 mmol) added. The mixture was 
heated at 90°C in a sealed ampoule for 72 hours. Excess Et2O (80 mL) was 
added to the solution which had turned a bluish purple colour to yield a sticky 
light yellow solid. The Et2O was 
decanted and recrystallisation of the 
yellow solid from MeCN / Et2O furnishes 
a white solid that is hygroscopic and 
became sticky within a few minutes after 
being exposed to air.  
Yield: 0.6 g, 1.9 mmol (93%) 
1H NMR (300 MHz, CD3CN): 10.65 (s, 2H, NCHN), 8.72 (s, 2H, C=CH), 7.51 
(s, 2H, HC=C), 7.39 (s, 2H, N-CH2-N), 5.02 (s, 4H, N-CH2-C=O), 1.48 (s, 18H, 
CH3). 13C{1H}  NMR (125 MHz, CD3CN): 165.9 (C=O), 140.5 (NCHN), 
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125.0(C=C), 123.6 (C=C), 84.9(C-(CH3)3), 58.4 (N-CH2-N), 51.9 (N-CH2-C=O), 
28.2 (C-(CH3)3). HRMS (ESI+):  Calcd for C11H14N4O4 [M – Cl-OH]2+ : 133.0502. 
Found: 133.0534. IR νmax / cm-1 : 3080, 2977, 2930, (carboxylic acid OH), 
1740(carboxylic acid C=O), 1153, 749, 615. Anal. Calcd for C11H15ClN4O5∙ 
3/2Et2O∙1/2 H2O: C, 46.52; H, 7.12; N, 12.77; found: C, 46.30; H, 7.30; N, 12.40. 
8.2.45 Preparation of L31 
1.1’-methylene-bis-1H-imidazole (0.3 g, 2.0 mmol) was dissolved in MeCN (5 
mL) and benzyl chloroacetate (0.62 mL, 4.0 mmol) was added. The mixture was 
heated at 90°C in a sealed ampoule for 24 hours. Excess Et2O (80 mL) was 
added to the solution which had turned a bluish purple colour to yield a sticky 
light yellow solid. 
Recrystallisation from 
MeCN / Et2O furnishes a 
white solid that is 
hygroscopic and becomes 
sticky within a few minutes 
after being exposed to air.  
Yield: 0.62 g, 1.2 mmol (59%) 
1H NMR (300 MHz, MeOD): 9.66 (s, 2H, NCHN), 8.07 (s, 2H, C=CH), 7.86 (s, 
2H, HC=C), 7.43-7.40 (m, 10H, aromatic), 6.92 (s, 2H, N-CH2-N), 5.37 (s, 4H, 
N-CH2-C=O), 5.32 (s, 4H, CH2). 13C{1H}  NMR (125 MHz, MeOD): 167.4 
(C=O), 136.3 (NCHN), 126.3(C=C), 123.1 (C=C), 69.3(N-CH2-N), 60.2 (N-CH2-
C=O), 51.4 (CH2). HRMS (ESI+):  Calcd for C16H17N4O2 [M – benzyl acetate- 
2Cl]+ : 297.1346. Found: 297.1347. IR νmax / cm-1 :3060 (aromatic C=C), 1747 
(ester C=O), 1638 (aromatic C-C), 1167 (ester C-O). Anal. Calcd for 
C25H26Cl2N4O4: C, 58.03; H, 5.07; N, 10.83; found: C, 58.40; H, 5.10; N, 10.80. 
8.2.46 Preparation of L32 
1H-imidazole (0.2 g, 2.9 mmol), potassium carbonate (0.66 g, 4.8 mmol) and 
chloroacetic acid (0.56 g, 5.88 mmol) were added. MeCN (30 mL) was added 
to the mixture and heated at 90°C for 48 hours in 
a sealed ampoule. The solution was filtered and 
the solid was washed with CH2Cl2 (30 mL x 3) and 
MeOH (30 mL x 3). The filtrates were combined 
and the solvent was removed in vacuo to yield the 
product as a white solid (very hygroscopic).                                                                                                                                                                                                                                                                                                                                
Yield: 0.46 g, 2.1 mmol (70%) 
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1H NMR (300 MHz, MeOD):  9.04 (s, 1H, NCHN), 8.44 (s, 2H, HC=CH), 7.43 
(broad s, 4H, CH2).  13C{1H}  NMR (125 MHz, MeOD): 179.4, 174.9, 171.7, 
124.0. HRMS (ESI+):  Calcd for C7H9N2O4 [M + H]+ : 185.0557. Found: 185.0559. 
IR νmax / cm-1 :  3009, 2923 (carboxylic acid OH), 1692 (carboxylic acid C=O), 
1594, 1380. Anal Calcd for C7H9ClN2O4∙5/2CH2Cl2: C, 26.36; H, 3.26; N, 6.47; 
found: C, 26.20; H, 3.10; N, 6.45.  
8.2.47 Preparation of L33 
P33 (0.15 g, 0.58 mmol) and chloroacetic acid (0.06 g, 0.58 mmol) were 
dissolved in MeCN (30 mL) and the mixture was heated at 90°C for 24 hours in 
a sealed ampoule. A yellow solid precipitated out of solution after one hour of 
heating. The solution was filtered, and the yellow solid was washed with Et2O 
(90 mL) and dried in vacuo. Recrystallisation 
from CH2Cl2 / Et2O and MeCN / Et2O 
precipitated the yellow solid which was filtered 
and dried in vacuo to furnish the product. The 
product is very hygroscopic and becomes sticky 
within a few minutes after being exposed to air.  
Yield: 0.09 g, 0.3 mmol (46%) 
1H NMR (300 MHz, CDCl3): 11.30 (s, 1H, NCHN), 8.62 (s, 1H, aromatic), 8.31 
(d, J = 8.9 Hz, 2H, aromatic), 8.08 (d, J = 8.9 Hz, 2H, aromatic), 7.69 (t, J = 6.6 
Hz, 2H, aromatic), 7.69 (t, J = 6.6 Hz, 2H, aromatic), 6.60 (s, 2H, CH2), 5.23 (s, 
4H, CH2). 13C{1H}  NMR (75 MHz, DMSO-d6): 129.9, 129.1, 129.0, 127.5, 
127.0, 125.3, 125.1, 123.7, 123.4, 123.1, 122.3, 121.9, 49.9 (CH2), 44.8(CH2).  
HRMS (ESI+):  Calcd for C20H17N2O2 [M - Cl]+ : 317.1285. Found: 317.1288. IR 
νmax / cm-1 :  3049, 2833 (carboxylic acid OH), 1711 (carboxylic acid C=O), 1256, 
1156. Anal Calcd for C20H17ClN2O2.CH2Cl2.CH3CN∙1/3H2O. C, 56.98; H, 4.71; N, 
8.67; found: C, 56.90; H, 4.80; N, 8.70. 
8.2.48 Preparation of L3412 
1-Methyl imidazole (2.91 mL, 36.5 mmol) was dissolved in CH2Cl2 (5 mL) and 
benzyl bromide (4.35 mL, 36.5 mmol), was added. The 
mixture was heated at reflux for 24 hours. Et2O (50 mL) 
was added to the solution to furnish a yellow oil. The 
Et2O was decanted and the yellow oil was dried in 
vacuo. 
Yield: 7.0 g, 27.7 mmol (76%) 
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1H NMR (300 MHz, CDCl3):  9.61 (s, 1H, NCHN), 7.19 (s, 1H, C=CH), 7.14 (s, 
1H, C=CH), 6.95 (m, 2H, aromatic), 6.70 (m, 3H, aromatic), 5.05 (s, 2H, CH2), 
3.41(s, 3H, CH3). HRMS (ESI+):  Calcd for C11H13N2 [M - Br]+ : 174.1107. Found: 
174.1111. 
8.2.49 Preparation of L35 
Anthracene-methylene benzimidazole (0.1 g, 
0.32 mmol) and 2-chloroethanol    (2.0 mL, 19.8 
mmol) were heated at 90°C for 24 hours. Excess 
Et2O was added to the mixture to yield a yellow 
solid which was dried in vacuo. 
Yield: 0.05 g, 0.13 mmol (40 %) 
1H NMR (300 MHz, CDCl3):  10.00 (s, 1H, NCHN), 8.65 (s, 1H, aromatic), 8.47 
(m, 2H, aromatic), 8.11 (m, 2H, aromatic), 7.70-7.45 (m, 8H, aromatic), 6.69 (s, 
2H, CH2), 4.55 (m, 2H, CH2), 4.05 (m, 2H, CH2). HRMS (ESI+):  Calcd for 
C24H21N2O [M - Cl]+ , calcd: 353.1654, found: 353.1681. Anal Calcd for 
C24H21ClN2O; C, 74.12; H, 5.44; N, 7.20, Found: C,73.90; H, 5.60; N,7.35. 
8.2.50 Preparation of L36 
Anthracene methylene benzimidazole (0.1g, 0.32 mmol) was dissolved in 
CH2Cl2 (5 mL) and transferred to an ampoule. A large excess of methyl iodide 
(1 mL, 16 mmol) was added, and the mixture was heated at 50°C in the sealed 
ampoule for 24 hours. Excess Et2O (100 mL) is added 
to the solution which had turned a clear orange colour 
yielding a yellow solid. The solution was filtered, and the 
solid recrystallised from MeCN/ Et2O to obtain the 
product as a bright yellow solid. The solvents were 
decanted and the solid dried in vacuo. 
Yield: 0.1 g, 0.2 mmol (69%)  
1H NMR (500 MHz, CDCl3): 10.40 (s, 1H, NCHN),  8.62 (s, 1H, aromatic), 8.49-
8.46 (m, 2H, aromatic), 8.09-8.07 (m, 2H, aromatic), 7.51-7.41(m, 8H, aromatic),  
6.71 (s,2H, CH2), 4.41 (s, 3H, CH3). HRMS (ESI+):  Calcd for C23H19N2 [M - I]+  
calcd: 323.1543 found: 323.1547. Anal Calcd for C23H19IN2∙1/4CH2Cl2∙1/4 CH3CN, 
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8.2.51 Preparation of L37 
P7 (0.1 g, 0.67 mmol) and 9-chloromethylanthracene (0.305 g, 1.35 mmol) were 
dissolved in MeCN (30 mL).  The mixture was heated at 90 °C for 24 hours in a 
sealed ampoule. A yellow solid 
precipitated out of solution after one 
hour of heating. The solution was 
filtered and the yellow solid was 
washed with Et2O (30 mL x 3) and 
dried in vacuo. 
Yield : 0.62 g,  1.0 mmol (77%). 
1H-NMR (300MHz, DMSO-d6):  8.94 (s, 2H, NCHN), 7.89 (s, 2H, HC=C), 7.55 
(d, 4H, J = 8.0 Hz, aromatic), 7.40 (s, 2H, aromatic), 7.34 (d, 4H, , J = 8.0 Hz, 
aromatic), 6.85-6.72 (m, 10H, aromatic), 5.95 (s, 2H, CH2), 5.70 (s, 4H, CH2). 
HRMS (ESI+):  calcd for C36H29N4 [M - 2Cl]+ calc : 530.2459; found: 530.2426. 
Anal Calcd for C37H30Cl2N2∙2/3CH2Cl2∙1/3 CH3CN. C, 59.21; H, 4.24; N, 6.54, 
Found: C, 59.00; H, 4.20; N,6.70. 
 
8.2.52 Preparation of C18 
L1 (0.5 g, 2.4 mmol) was added to silver acetate (0.8 g, 4.8 mmol) in anhydrous 
MeOH (20 mL). The mixture was stirred for 40 
minutes in the dark, at room temperature. The 
mixture was subsequently filtered and washed 
with MeOH, and the filtrate dried in vacuo to give 
the product as a white solid. 
Yield: 0.5 g, 1.3 mmol (54%) 
1H NMR (300 MHz, D2O): 4.23 (s, 3H, CH3), 4.17 (s, 3H, CH3), 3.85 (s, 3H, 
CH3), 3.41 (s, 3H,CH3), 1.94 (s, 3H,C=OCH3). 13C{1H}  NMR (75 MHz, DMSO-
d6):   173.9(C=O), 153.2(C=O), 150.5(C=O), 140.4(C=C), 108.9(C=C), 33.5, 
31.4, 30.4, 28.2(N-CH3), 23.0 (COCH3). HRMS (ESI+):  Calcd for C11H15AgN4O4 
[M + H]+ : 377.1453. Found: 377.2954. Anal. Calcd for C11H15AgN4O4: C, 35.13; 
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8.2.53 Preparation of C1.Cu 
L1 (0.4 g, 1.2 mmol) was placed in a three-necked round bottomed flask and 
dried in vacuo. Two copper electrodes were inserted and anhydrous MeCN (50 
mL) was cannula transferred into the flask and degassed for 1 hour. A voltage 
was applied to achieve a current of 30 mA that was 
maintained for a duration of 1 hour 20 mins by 
periodically altering the voltage. The product 
precipitated as a greyish yellow solid which was 
filtered, washed with MeCN and dried in vacuo to yield 
a pale green solid. 
Yield: 0.23 g, 0.6 mmol (48%) 
1H NMR (300 MHz, DMSO-d6): 3.35, 3.18, 2.90, 2.41 (s, 3H, CH3). 13C{1H}  
NMR (75 MHz, DMSO-d6): 153.1(C=O), 150.3(C=O), 140.0(C=C), 
108.3(C=C), 38.0, 36.7, 31.4, 28.1 (N-CH3), Anal. Calcd for C9H12CuIN4O2: C, 
27.11; H, 3.03; N, 14.05. Found: C, 27.90; H, 3.10, N, 14.20.  
8.2.54 Preparation of C1.Ru 
L1 (0.05 g, 0.15 mmol), silver oxide (0.018g, 
0.075 mmol) and [Ru(p-cymene)Cl2]2 (0.046 g, 
0.075 mmol) were added to a Schlenk flask with 
activated 4Å molecular sieves and degassed. 
Anhydrous MeCN (8 mL) and CH2Cl2 (10 mL) 
were transferred to the Schlenk flask and the 
mixture was heated at 40°C for 2 hours. The solution which had turned a clear 
orange colour was filtered through celite, and the solvent was removed in vacuo 
to yield the product as an orange solid. 
Yield: 0.025 g, 0.05 mmol (30%) 
1H NMR (300 MHz, CDCl3): 5.48 (d, J = 6.0 Hz, 2H, aromatic), 5.24 (d, J = 6.0 
Hz, 2H, aromatic), 4.34 (s, 3H, CH3), 4.29 (s, 3H, CH3), 3.78 (s, 3H, CH3), 3.40 
(s, 3H, CH3), 2.15 (s, 3H, CH3), 2.97 (sept, J = 6.0 Hz, 1H, CH), 1.30 (d, J = 6.0 
Hz, 6H, CH(CH3)3). HRMS (ESI+):  Calcd for C19H26Cl2N4O2Ru [M - Cl]+ : 
479.0788. Found: 479.0810. Anal. Calcd for C19H26Cl2N4O2Ru∙2H2O: C, 41.46; 
H, 5.49; N, 10.18. Found: C, 41.70; H, 5.10, N, 10.20. 
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8.2.55 Preparation of C2 
L2 (0.10 g, 0.26 mmol) and silver acetate (0.09 g, 1.54 mmol) were dissolved in 
a solvent mixture anhydrous MeOH (5 mL) and CH2Cl2 (5 mL). The mixture was 
stirred for two hours in the dark. The solution was filtered and washed with 
CH2Cl2, and the filtrate dried in vacuo to give a 
white sticky solid. Recrystallisation from CH2Cl2 
/ C5H9 rendered the product as a white solid 
which was dried in vacuo.  
Yield: 0.06 g, 0.14 mmol (55%) 
1H NMR (300 MHz, CDCl3): 4.44 (t, J = 7.4 Hz, 2H, CH2), 4.21 (s, 3H, CH3), 
3.81 (s, 3H, CH3), 3.39 (s, 3H, CH3), 1.79 (quin, J = 7.35 Hz, 2H, CH2), 1.37 
(sext, J = 7.4 Hz, 2H, CH2), 0.93 (t, 3H,CH3). 13C{1H}  NMR (75 MHz, CDCl3):  
152.8(C=O), 150.4 (C=O), 140.2 (C), 109.2 (C), 53.2(C=O, acetate), 
51.5(CH3), 39.6 (CH2), 33.5 (CH3), 32.0 (CH3), 28.4(CH2), 22.04(CH2),  
19.4(CH3), 13.8(CH3). 13C{1H}  NMR (75 MHz, DMSO-d6):  185.2 (Ag-C), 
152.7(C=O), 150.3 (C=O), 140.6 (C), 107.9 (C), 53.2(C=O, acetate), 50.0 (CH3), 
39.6 (CH2), 32.9 (CH3), 31.3 (CH3), 28.4 (CH2), 22.04 (CH2),  18.9 (CH3), 
13.4(CH3). ). HRMS (ESI+):  Calcd for C24H36AgN8O4 [2M + H]+ : 608.1910. 
Found: 608.1939. Anal. Calcd for C14H22AgN4O4: C, 40.21; H, 5.30; N,13.40. 
Found: C, 39.90; H, 5.30, N, 13.10.  
8.2.56 Preparation of C2.Cu 
L2 (0.3g, 0.79 mmols) was placed in a 3 necked round bottomed flask. Two 
copper electrodes were inserted and anhydrous MeCN (15 mL) was cannula 
transferred into the flask and degassed for one hour. A voltage was applied to 
achieve a current of 30 mA that was maintained 
for a duration of 1 hour 20 mins by periodically 
altering the voltage. After one hour the complex 
started to precipitate out of solution. The solution 
filtered through celite and the solvent was 
removed from the filtrate in vacuo yielding the 
product a light grey solid. 
Yield: 0.07 g, 0.16 mmol (20%)  
1H NMR (300 MHz, DMSO-d6): 4.42 (t, J = 7.5 Hz ,2H, CH2  ), 4.17(s, 3H, CH3), 
3.73 (s, 3H, CH3), 3.24 (s, 3H, CH3), 1.75 (quin, J = 7.5 Hz, 2H, CH2  ), 1.35 
(sext, J = 7.5 Hz, 2H, CH2), 0.91 (t, J = 7.5 Hz ,3H, CH3). 13C{1H}  NMR (75 MHz, 
DMSO-d6): 152.9(C=O), 152.4(C=O), 151.1(C=C), 150.2(C=C), 41.3, 38.1, 
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32.9, 27.7 (N-CH3), 31.3, 31.1, 29.9 (CH2) . HRMS (ESI+):  calcd for 
C12H18CuN4O2 [M – I + MeCN]+ : 355.1070. Found: 355.0985.  Anal. Calcd for 
C12H18CuIN4O2: C, 32.70; H, 4.12; N, 12.71. Found: C, 32.77; H, 4.12, N,12.40.  
8.2.57 Preparation of C2.Ru 
L2 (0.1g, 0.26 mmol), silver oxide (0.031g, 0.135mmol) and [Ru(p-cymene)Cl2]2 
(0.081g, 0.135 mmol) were added to an ampoule with activated molecular 
sieves 4Å and degassed. Anhydrous CH2Cl2 
(20 mL) were transferred to the ampoule and 
the mixture was heated at 40°C for 1.5 hours. 
The solution which was a golden orange 
colour was filtered through celite, and the 
solvent was removed from filtrate in vacuo to 
yield the product as a golden orange solid. 
Yield: 0.065 g, 0.11 mmol (44%) 
1H NMR (300 MHz, CDCl3): 5.45 (d, J = 6.0 Hz, 2H, aromatic), 5.17 (d, J = 6.0 
Hz, 2H, aromatic), 4.57 (t, J = 7.5 Hz, CH2),  4.25(s, 3H, CH3), 3.73 (s, 3H, CH3), 
3.37 (s, 3H, CH3), 2.94 (sept, J = 7.5 Hz, 1H, CH), 2.06 (s, 3H, CH3), 1.79 (broad 
s, 2H, CH2), 1.44 (broad s, 2H, CH2), 1.28 (d, J = 6.0 Hz, 6H, CH(CH3)3), 0.95 
(t, J = 7.50 Hz, CH3) . HRMS (ESI+):  calcd for C22H32ClN4O2Ru [M - Cl]+ : 
521.1257. Found: 521.1347. Anal. Calcd for C22H32Cl2N4O2Ru∙H2O: C, 45.99; 
H, 5.97; N, 9.75. Found: C, 46.10; H, 5.70, N, 9.90. 
8.2.58 Preparation of C3 
L3 (0.25 g, 0.61 mmol) was added to silver acetate (0.2 g, 1.2 mmol) in a solvent 
mixture of anhydrous CH2Cl2 (5 mL) and 
MeOH (5 mL). The mixture was stirred at 
room temperature for two hours in the dark. 
The solution was filtered and the solid washed 
with CH2Cl2 (30 mL). The solvent was 
removed from the filtrate in vacuo to give the 
product as a white solid.  
Yield: 0.11 g, 0.25 mmol (40%) 
1H NMR (300 MHz, CDCl3):  7.45 (d, 2H, aromatic), 7.30-7.23 (m, 3H, 
aromatic), 5.63 (s, 2H, CH2), 4.18 (s, 3H, CH3), 3.76 (s, 3H, CH3), 3.34 (s, 3H, 
CH3). 13C{1H} NMR (75 MHz, CDCl3):  185.5 (Ag-C),  178.2 (C=O), 
153.1(C=O), 150.6 (C=O), 140.3 (C), 135.5(C-arom), 129.0, 128.7, 128.4, (CH, 
aromatic), 109.2 (C), 54.2(CH3),   40.0 (CH3), 32.0 (CH3), 28.8(CH2), 22.3 (CH3). 
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HRMS (ESI+):  Calcd for C30H32AgN8O4 [Ag(NHC)2]+ : 675.1597. Found: 
675.1616. Anal. Calcd for C17H20AgN4O4: C, 45.25; H, 4.24; N, 12.42. Found: 
C, 45.30; H, 4.20, N, 12.20  
8.2.59 Preparation of C3.Cu 
L3 (0.2 g, 0.49 mmols) was placed in a three-necked round bottomed flask and 
degassed. Two copper electrodes were inserted and anhydrous MeCN (70 mL) 
was transferred into the flask and degassed for 1h. 
A voltage was applied to achieve a current of 30 mA 
that was maintained for a duration of 1hour 20 mins 
by periodically altering the voltage. After 1h the 
complex started to precipitate out of solution. The 
solution was filtered through celite and filtrate dried 
in vacuo yielding a pale grey solid. 
Yield: 0.16 g, 0.34 mmol (69%)  
1H NMR (300 MHz, DMSO-d6): 7.39-7.27 (m, 5H, aromatic), 5.64 (s, 2H, 
CH2),  4.14 (s, 3H, CH3), 3.71 (s, 3H, CH3), 3.20 (s, 3H, CH3).13C{1H}  NMR 
(75 MHz, DMSO-d6): 156.2(C=O), 153.0(C=O), 141.1(C=C), 137.0(C=C), 
129.4,128.4,127.6,117.9 (aromatic), 51.3(CH2), 38.3, 31.5, 28.1 (N-CH3). 
HRMS (ESI+):  Calcd for C15H16CuN4O2 [M – I + MeCN]+ : 389.0913. Found: 
389.0832.  Anal. Calcd for C15H16CuIN4O2: C, 37.95; H, 3.40; N, 11.80. Found: 
C, 38.00; H, 3.62, N, 11.79.  
8.2.60 Preparation of C3.Ru 
L3 (0.05g, 0.12 mmol), silver oxide (0.014g, 0.062mmol) and [Ru(p-
cymene)Cl2]2 (0.038 g, 0.062 mmol) were added to an ampoule with activated 
molecular sieves 4Å and degassed. 
Anhydrous CH2Cl2 (10 mL) was transferred to 
the ampoule and the mixture was heated at 
40°C for 1.5 hours. The solution which was a 
golden orange colour was filtered through 
celite, and the filtrate was dried in vacuo to 
yield the product as a golden orange solid. 
Yield: 0.021 g, 0.035 mmol (29%)  
1H NMR (300 MHz, CDCl3): 7.40-7.01 (m, 5H, aromatic) 5.48 (d, J = 6.0 Hz,  
2H, CH2), 5.28 (broad s, 4H, aromatic),  4.38 (s, 3H, CH3), 3.83 (s, 3H, CH3), 
3.32 (s, 3H, CH3), 2.90 (sept, J = 6.0 Hz, 1H, CH), 2.04 (s, 3H, CH3), , 1.23 (d, 
J = 6.0 Hz, 6H, CH(CH3)3), 0.95 (t, J = 7.50 Hz, CH3) . HRMS (ESI+):  calcd for 
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C25H30ClN4O2Ru [M - Cl]+ : 555.1101. Found: 555.1358. Anal. Calcd for 
C19H26Cl2N4O2Ru∙2H2O: C, 47.92; H, 5.47; N, 8.94. Found: C, 47.60; H, 5.10, 
N, 8.60. 
8.2.61 Preparation of C4 
L4 (0.15 g, 0.38 mmol) was added to silver acetate (0.125 g, 0.75 mmol) in a 
solvent mixture of anhydrous MeCN (5 mL) and 
MeOH (5 mL). The mixture was stirred at room 
temperature for two hours in the dark. The 
mixture was filtered and the filtrate dried in vacuo 
to yield the product as a white solid.  
Yield: 0.115 g, 0.26 mmol (69%)  
1H NMR (300 MHz, DMSO-d6):  7.52-7.34 (m, 5H, aromatic), 4.28 (s, 3H, CH3), 
3.81 (s, 3H, CH3), 3.71 (s, 3H, CH3), 3.62 (s, 3H, CH3). 13C{1H} NMR (75 MHz, 
CDCl3):  186.1(Ag-C), 175.5 (C=O, acetate), 152.0(C=O), 150.0 (C=O), 141.1 
(C=C),137.6(C-aromatic), 129.3(CH-aromatic), 128.8 (CH-aromatic),126.5(CH-
aromatic), 109.2 (C=C), 31.6(CH3), 28.3(CH3), 23.2(CH3). HRMS (ESI+):  Calcd 
for C28H28AgN8O4 [2M-AgI]+ : 647.1279. Found: 647.1297. Anal. Calcd for 
C16H17AgN4O4 : C, 43.96; H,3.92; N,12.82. Found: C, 44.70; H, 4.40, N,12.60.  
8.2.62 Preparation of C5 
L5 (0.1g, 0.27 mmol) was added to silver acetate (0.09g, 0.54 mmol) in a solvent 
mixture of anhydrous CH2Cl2 (5 mL) and 
MeOH (5 mL). The mixture was stirred at 
room temperature for two hours in the dark. 
The mixture was filtered and washed with 
CH2Cl2 and the filtrate dried in vacuo to give 
a white solid. Recrystallisation from MeOH / 
Et2O furnishes the product as a white solid. 
Yield: 0.03 g, 0.07 mmol (28%) 
1H NMR (300 MHz, MeOD):  4.47 ( broad s,1H,OH), 4.18 (s,3H,CH3), 4.15 (t, 
J = 6.0 Hz, 2H, CH2),  4.09 (s,3H,CH3), 3.79 (s,3H,CH3), 3.75 (t, J = 6.0 Hz, 2H, 
CH2), 3.53 (s,3H,CH3). 13C NMR (75 MHz, d4-MeOD):  179.7 (C=O, acetate), 
143.9 (C), 123.8(C), 82.8 (CH2), 60.2 (CH2), 40.3 (CH3), 34.5(CH3), 32.9(CH3), 
23.6 (CH3-acetate). HRMS (ESI+): Calcd for C20H28AgN8O6 [2M-AgI]+  Calc: 
585.3625, found: 585.1187. Anal. Calcd for C11H17AgN4O5 ∙¼ Et2O : C, 36.85; 
H,4.64; N,13.22. Found: C,36.50; H,4.50, N,13.60.  
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8.2.63 Preparation of C6 
L6 (0.40 g, 0.84 mmol) and silver oxide (0.19g, 0.84 mmol) were dissolved in 
CH2Cl2 (40 mL) and heated at reflux for 24 hours in 
the dark. The solution was filtered through celite, 
and the solid washed with CH2Cl2 (30 mL). The 
filtrate was dried in vacuo to give the product as a 
white crystalline solid. 
Yield: 0.21 g, 0.35 mmol (42%).  
1H NMR (300 MHz, CDCl3):  7.34 – 6.95 (m, 16H, aromatic), 3.88 (s, 3H, CH3). 
13C{1H} NMR (75 MHz, DMSO-d6):  139.8 (C), 134.8 (C), 132.2 (C), 131.0 (CH), 
130.2 (CH), 128.2 (CH), 128.1 (CH), 127.8 (CH), 123.2 (CH), 121.1 (CH), 118.5 
(CH), 76.8 (CH), 40.1 (CH3). HRMS (ESI+): Calcd for C46H38AgCl2N4 [2M – AgI2]+ 
calcd: 825.1521 found: 825.1532. Anal. Calcd for C23H19AgClIN2.3/2 CH2Cl2: C, 
40.81; H, 3.08; N, 3.89. Found: C, 40.90; H,3.20; N,4.10. 
8.2.64 Preparation of C7 
L7 (0.15 g, 0.28 mmol) and silver oxide (0.07g, 0.28 mmol) were dissolved in 
CH2Cl2 (15 mL) and heated at reflux for 24 hours in the dark. The solution was 
filtered through celite, and the solid washed with 
CH2Cl2 (20 mL). The filtrate was dried in vacuo to 
give a yellow solid. The solid was recrystallised 
from CH2Cl2/C5H9, the solvent was decanted and 
the solid was dried in vacuo to yield the product 
as a yellow solid. 
Yield: 0.08 g, 0.13 mmol (47%).  
1H NMR (300 MHz, CDCl3):  7.45-7.09 (m, 15H, Ar + N-CH), 6.96 (s, 1H, N-
CH), 4.15 (t, J = 7.5 Hz, 2H, N-CH2CH2CH2CH3), 1.80 (quin, J = 7.5 Hz, 7.3Hz, 
2H, CH2), 1.32 (sext,  J = 7.5 Hz, 2H, CH2), 0.94 (t,  J = 7.5 Hz, 3H, CH3). 13C{1H} 
NMR (75 MHz, CDCl3):  141.1 (C), 140.0 (C), 135.8 (C), 131.6 (CH), 130.7 
(CH), 130.6 (CH), 128.5 (CH), 128.2 (CH), 128.1 (CH), 123.6 (CH),118.2 (CH),  
77.8 (C), 53.6 (CH2), 33.5 (CH2) 19.7 (CH2), 13.8 (CH3). HRMS (ESI+): calcd for 
C52H50AgCl2N4 [2M-AgI2]+  calcd: 909.2460 found: 909.2609. Anal. Calcd for 
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8.2.65 Preparation of C8 
L8 (0.32 g, 0.63 mmol) and silver oxide (0.14g, 
0.63 mmol) were dissolved in CH2Cl2 (30 mL) 
and heated at reflux for 24 hours in the dark. 
The solution was filtered through celite, and 
the solid washed with CH2Cl2. The solvent was 
removed from the filtrate in vacuo to yield the 
product as a white solid. 
Yield: 0.12 g, 0.13 mmol (21%).  
1H NMR (300 MHz, DMSO-d6):  8.63 (s, 1H, HC=CH) 7.59-6.96 (m, 15H, 
aromatic + HC=CH), 4.24 (t, J = 6.0 Hz, 2H, CH2), 3.67 (t, J = 6.0 Hz, 2H, CH2). 
13C{1H} NMR (75 MHz, CDCl3):  138.6 (C), 136.2 (C), 135.6 (C), 133.1 (CH),  
131.3 (CH), 130.9 (CH),129.9 (CH), 129.5 (CH), 129.0 (CH), 127.7 (CH), 122.9 
(CH) 120.7 (CH), 78.4 (C), 61.0 (CH2), 54.4 (CH2). HRMS (ESI+): Calcd for 
C48H42AgCl2N4O2 [2M-AgI2]+  887.1883. Found: 887.1864. Anal. Calcd for 
3(C48H42AgCl2IN4O2)∙1(C24H21AgClIN2O): C, 55.22; H, 4.11; N, 5.31; found: 
C,55.11; H,4.05; N,5.36. 
8.2.66 Preparation of C9 
L12 (0.50 g, 1.27 mmol) and silver oxide (0.29 g, 1.27 mmol) were dissolved in 
CH2Cl2 (10 mL) and heated at reflux for 24 hours in 
the dark. The mixture was allowed to cool before it 
was filtered through celite, and the solid washed with 
CH2Cl2. The solvent was removed from the filtrate in 
vacuo to give the product as a white crystalline solid.  
Yield: 0.40 g, 0.8 mmol (62%).  
1H NMR (300 MHz, CDCl3):  7.44-7.42 (m, 2H, C=CH + aromatic), 7.36-7.09  
(m, 14H, aromatic), 6.95 (m, 1H, HC=C), 3.88 (s, 3H, CH3). 13C{1H} NMR 
(75MHz, CDCl3):  140.9 (C), 140.0 (C), 135.7 (C), 132.5 (CH), 131.5 (CH), 
130.6 (CH), 130.5 (CH), 128.4 (CH), 128.1 (CH), 127.8 (CH), 123.6 (CH), 119.7 
(CH), 77.7 (C), 40.2 (CH3). HRMS (ESI+): calcd for C46H38AgCl2N4 [2M-AgCl2]+ 
: 825.1521. Found: 825.1520. Anal. Calcd for C23H19AgClN2∙3/2 H2O: C, 52.20; 
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8.2.67 Preparation of C10 
L10 (0.30g, 0.71 mmol) and silver oxide (0.17 g, 0.71 mmol) were dissolved in 
CH2Cl2 (8 mL) and heated at reflux for 24 hours in 
the dark. The mixture was allowed to cool before it 
was filtered through celite, and the solid washed with 
CH2Cl2 (20 mL). The filtrate was dried in vacuo to 
give the product as a white solid. 
Yield: 0.14 g, 0.27 mmol (37%). 
 1H NMR (300 MHz, CDCl3):  7.36-7.04 (m, 15H, aromatic+ HC=C), 6.88 (s, 
1H, C=CH), 5.87 (m, 1H, N-CH2CHCH2), 5.24-5.12 (m, 2H, N-CH2CHCH2), 4.7 
(d, J = 4.7 Hz, 2H, N-CH2CHCH2). 13C{1H} NMR (125 MHz, CDCl3):  139.9 (C), 
135.8 (C), 132.7 (CH), 132.6 (CH), 131.7 (CH), 130.7 (CH), 130.6 (C), 128.5 
(CH), 128.2 (CH), 128.0 (CH), 123.9 (CH), 119.5 (CH), 118.5 (CH2), 77.6 (C), 
55.6 (CH2). HRMS (ESI+): Calcd for C50H44AgCl2N4 [2M-AgCl2]+: 877.1834. 
Found: 877.1830. Anal. Calcd for C25H21AgCl2N2∙½ H2O: C, 55.89; H, 4.13; N, 
5.21; found: C, 55.50; H, 4.20; N, 5.00. 
8.2.68 Preparation of C11 
L11 (0.02 g, 0.05 mmol) and silver oxide (0.006 g, 0.03 mmol) were dissolved 
in a solvent mixture of anhydrous MeOH (3 mL) and CH2Cl2 (3 mL) in a Schlenk 
flask. The mixture was stirred at room 
temperature for 24 hours in the dark. The 
solution was filtered through celite, and the 
solvent was removed from the filtrate in vacuo 
to yield the product as a light yellow solid. 
Yield: 0.005g, 0.001 mmol (20%).  
1H NMR (300 MHz, CDCl3):  7.61-6.88 (m, 16H, aromatic + HC=CH), 4.15 (t, J 
= 7.2 Hz, 2H, CH2), 1.83 (dt, J = 14.4, 7.2 Hz, 2H, CH2), 1.57 (m, 2H, CH2), 0.92 
(dd, J = 9.0, 5.7 Hz, 3H,CH3). 13C{1H} NMR (75 MHz, CDCl3):  141.2, 139.6, 
138.4, 135.4, 132.4, 131.4, 130.3, 129.7, 129.0, 128.4, 128.1, 127.8, 123.6, 
118.2, 77.4, 53.2, 33.2, 19.5, 13.7. HRMS (ESI+): Calcd for C52H50AgCl2N4 
[2M-AgCl2]+: 909.2460. Found: 909.2609. Anal. Calcd for 
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8.2.69 Preparation of C12 
L12 (0.10 g, 0.21 mmol) and silver oxide (0.05 g, 0.21 mmol) were dissolved in 
CH2Cl2 (8 mL) and heated at reflux for 24 
hours in the dark. The mixture was filtered 
through celite and the solid washed with 
CH2Cl2. The solvent was removed from the 
filtrate in vacuo to give the product as an off 
white solid. 
Yield : 0.06 g, 0.1 mmol (50 %).  
1H NMR (300 MHz, CDCl3):  7.46-7.10 (m, 20H, Ar+ HC=C), 6.87 (s, 1H, 
C=CH), 5.35 (s, 2H, CH2). 13C{1H} NMR (75 MHz, CDCl3):  141.0 (C), 139.9 
(C), 135.8 (C), 135.6 (C), 132.7 (CH), 131.7 (CH), 130.7 (CH), 129.2 (CH), 128.8 
(CH), 128.6 (CH),128.2 (CH), 128.1 (CH), 127.8 (CH), 127.1 (CH), 78.0 (C), 
57.2 (CH2). HRMS (ESI+): Calcd for C58H46AgCl2N4 [2M-AgCl2]+ : 977.2147. 
Found: 977.2170. Anal. Calcd for C29H23AgCl2N2∙2 H2O: C, 56.70; H, 4.43; N, 
4.56; found: C, 56.80; H, 4.60; N, 4.20. 
8.2.70 Preparation of C13A 
L13 (0.2 g, 0.47 mmol) and silver oxide (0.13g, 0.47 mmol) were dissolved in 
CH2Cl2 (20 mL). The mixture was stirred at room 
temperature for 24 hours in the dark. The mixture 
was filtered through celite, and the filtrate dried in 
vacuo to yield a orange solid. Recrystallisation 
from CH2Cl2 / Et2O yields the product as a white 
solid. The solvent was decanted and the solid 
dried in vacuo.  
Yield: 0.23 g, 0.43 mmol (92 %).  
1H NMR (300 MHz, MeOD):  7.41-7.04 (m, 14H, aromatic), 6.90-6.88 (m, 2H, 
HC=CH), 4.25 (t, 2H, J = 6.0 Hz, CH2), 3.76 (t, 2H, J = 6.0 Hz, CH2).13C{1H} 
NMR (75 MHz, d4-MeOD): δ 187.9, 185.1 (Ag-C), 142.0, 141.6, 137.1 (C-Ar), 
133.5, 132.4, 131.9, 130.3, 129.0, 128.0, 127.8(CH-aromatic), 124.9, 120.6 
(CH), 78.6 (C), 62.7, 56.6 (CH2). HRMS (ESI+): Calcd for C48H42AgCl2N4O2 [2M-
AgCl2]+: 885.1732. Found: 885.1762. Anal. Calcd for C24H21AgCl2N2O: C, 54.16; 
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8.2.71 Preparation of C13B 
L13 (0.2 g, 0.47 mmol) and silver oxide (0.065g, 0.28 mmol) were dissolved in 
solvent mixture of anhydrous MeOH (10 mL) 
and anhydrous CH2Cl2 (5 mL) in a Schlenk flask 
with activated molecular sieves 4Å. The mixture 
was stirred at RT for 24 hours in the. The 
mixture was filtered through celite, and the 
solvent was removed from the filtrate in vacuo. 
The solid was recrystallised from CH2Cl2 / Et2O 
yielding the product as a white solid. The 
solvents were decanted and the solid dried in 
vacuo. 
Yield: 0.13 g, 0.14 mmol (30 %).  
1H NMR (300 MHz, d4-MeOD):  7.52-6.99 (m, 16H, Ar + HC=CH), 3.65-3.60 
(m, 4H, CH2). 13C{1H} NMR (75 MHz, d4-MeOD): δ 142.3, 141.6, 137.2 (C-Ar), 
133.8, 132.5, 131.9, 131.6, 129.6, 129.1, 128.1, 124.9, 120.6 (CH), 78.7 (C), 
62.5, 56.6 (CH2). HRMS (ESI+): Calcd for C48H42AgCl2N4O2 [2M-AgCl2]+: 
885.1732. Found: 885.1747. Anal. Calcd for C48H42AgCl3N4O2∙½ Et2O: C, 
62.59; H, 4.60; N, 6.08; found: C, 62.68; H, 4.94; N, 5.85. 
8.2.72 Preparation of C14 
L14 (0.50 g, 1.38 mmol) and silver oxide (0.32 g, 1.38 mmol) were dissolved in 
CH2Cl2 (30 mL) and heated at reflux for 18 hours in 
the dark. The mixture was filtered through celite, 
and the solvent was removed from the filtrate in 
vacuo to give a brown solid. Recrystallisation from 
CH2Cl2 / Et2O yielded the product as a white solid. 
The solvents were decanted and the solid dried in 
vacuo. 
Yield: 0.4 g, 0.85 mmol (62%). 
1H NMR (300 MHz, CDCl3): δ 7.34-7.20 (m, 15H, Ar), 7.04 (s, 1H, C=CH), 6.98 
(s, 1H, HC=C), 3.84 (s, 3H, CH3). 13C{1H} NMR (75MHz, CDCl3): δ 140.5 (C), 
129.6, 128.5,128.2, 127.9 (Ar), 122.0(HC=C), 119.8 (C=CH), 36.12 (CH3). 
HRMS (ESI+): Calcd for C46H40AgN4 [2M-AgCl2]+ : 757.2301. Found: 757.2314. 
Anal. Calcd for C23H20AgClN2∙½ H2O: C, 57.94; H, 4.44; N, 5.88; found: C, 




CHAPTER 8                                                                UNIVERSITY OF LEEDS 
200 
 
8.2.73 Preparation of C15 
L15 (0.58 g, 1.49 mmol) and silver oxide (0.35 g, 1.49 mmol) were dissolved in 
CH2Cl2 (30 mL) and heated at reflux for 18 hours 
in the dark. The mixture was filtered through celite, 
and the solvent was removed from the filtrate in 
vacuo to give a colourless oil. Recrystallisation 
from CH2Cl2 / Et2O yielded the product as a white 
solid. The solvents were decanted and the solid 
dried in vacuo. 
Yield: 0.41 g, 0.83 mmol (56 %).  
1H NMR (300 MHz, CDCl3):  7.37-7.19 (m, 15H, Ar), 7.07 (s, 1H, C=CH), 6.95 
(s, 1H, HC=C), 6.00 (m, 1H, N-CH2CHCH2), 5.24 (m, 2H, N-CH2CHCH2), 4.75 
(dt, J = 5.8, 1.4 Hz, 2H, N-CH2CHCH2). 13C{1H} NMR (75MHz, CDCl3):  142.1 
(C), 132.6 (HC=C), 130.6(HC=C), 129.6, 128.9,128.6, 127.7(aromatic), 
119.5(HC=CH2), 117.5 (C=CH2), 55.6 (CH2). HRMS (ESI+): Calcd for 
C50H44AgN4 [2M-AgCl2]+: 809.2614. Found: 809.2616. Anal. Calcd for 
C25H22AgClN2: C, 60.81; H, 4.49; N, 5.67; found: C, 60.61; H, 4.50; N, 5.60. 
8.2.74 Preparation of C16 
L16 (0.62 g, 1.53 mmol) and silver oxide (0.36 g, 1.53 mmol) were dissolved in 
CH2Cl2 (30 mL) and heated at reflux for 18 hours 
in the dark. The mixture was filtered through 
celite, and the solvent was removed from the 
filtrate in vacuo to give a colourless oil. 
Recrystallisation from CH2Cl2 / Et2O yielded the 
product as a white solid. The solvents were 
decanted and the solid dried in vacuo. 
Yield: 0.21 g, 0.41 mmol (27 %). 
1H NMR (300 MHz, CDCl3):  7.37-7.18 (m, 15H, aromatic), 7.05 (s, 1H, C=CH), 
6.93 (s, 1H, HC=C), 4.13 (t, J = 7.3 Hz, 2H, CH2), 1.80 (quin, J = 7.3 Hz, 2H, 
CH2), 1.31 (sext, J = 7.3 Hz, 2H, CH2), 0.93 (t, J = 7.3 Hz, 2H, CH3). 13C{1H} 
NMR (75 MHz, CDCl3):  147.0 (C), 137.2, 129.7, 129.4, 129.1, 128.0, 127.8, 
124.0, 122.6 (CH), 79.7 (C) 50.6, 32.4, 19.6 (CH2), 13.6 (CH3). HRMS (ESI+): 
Calcd for C52H52AgN4 [2M-AgCl2]+ : 841.3240. Found: 841.3245. Anal. Calcd for 
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8.2.75 Preparation of C17 
L17 (0.086 g, 0.19 mmol) and silver oxide (0.027g, 0.12mmol) were dissolved 
in a mixture of anhydrous MeOH (5 mL) and CH2Cl2 (5 mL) in a Schlenk flask 
with activated molecular sieves 4Å. The 
mixture was stirred at room temperature for 
24 hours in the dark. The solution was filtered 
through celite, and the solvents were 
removed from the filtrate dried in vacuo to 
yield the product as a light yellow solid. 
Yield : 0.01g, 0.013 mmol (7 %). 
1H NMR (300 MHz, CDCl3):  7.45-6.88 (m, 22H, Ar + HC=CH), 4.54 (s, 2H, 
CH2). 13C{1H} NMR (125 MHz, CDCl3):  186.6, 184.1 (Ag-C), 142.3, 135.8 (C-
Ar), 130.1, 129.9, 129.0, 128.5, 128.3, 127.4, (CH- Ar), 124.3, 119.6 (CH), 77.4 
(C), 65.9 (CH2). HRMS (ESI+): Calcd for C58H48AgN4 [2M-AgCl2]+: 909.2927. 
Found: 909.2964. Anal. Calcd for (C29H24AgClN2)∙(C58H48AgClN4): C, 70.22; H, 
4.88; N, 5.65; found: C, 70.30; H, 5.30; N, 5.60. 
8.2.76 Preparation of C18A 
L18 (0.2 g, 0.26 mmol) and silver oxide (0.08 g, 0.26 mmol) were dissolved in 
CH2Cl2 (20 mL). The mixture was stirred at room 
temperature for 24 hours in the dark. The mixture 
was filtered through celite, and the solvent was 
removed from the filtrate in vacuo to yield a white 
solid. Recrystallisation from CH2Cl2 / Et2O yields 
the product as a white solid. The solvents were 
decanted and the solid dried in vacuo. 
Yield: 0.09g, 0.18 mmol (70%).  
1H NMR (300 MHz, CDCl3):  7.23-7.08 (m, 15H, aromatic), 6.94 (broad s, 2H, 
HC=CH), 4.23-4.18 (m, 2H, CH2), 3.77-3.61(m, 2H, CH2). 13C{1H} NMR (75 
MHz, CDCl3):  141.5 (C-Ar), 130.1, 128.1, 127.8 (CH-Ar), 122.6, 120.7 (CH), 
77.4 (C), 55.3, 53.2 (CH2). HRMS (ESI+): Calcd for C48H44AgN4O2 [2M-AgCl2]+  
calcd: 817.2512. Found: 817.2544. Anal. Calcd for C24H22AgClN2O: C, 57.91; 
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8.2.77 Preparation of C18B 
L18 (0.1 g, 0.26 mmol) and silver oxide (0.04 g, 0.15 mmol) were dissolved in a 
solvent mixture of anhydrous MeOH (10 mL) 
and anhydrous CH2Cl2 (5 mL) in a Schlenk 
flask. The mixture was stirred at room 
temperature for 24 hours in the dark under 
anhydrous conditions. The solution was filtered 
through celite, and the solvent was removed 
from the filtrate in vacuo yielding the product as 
a white solid. 
Yield: 0.018g, 0.031 (12%).  
1H NMR (300 MHz, MeOD):  7.63 (broad s, 1H, C=CH), 7.48-7.00 (m, 15H, 
Ar), 6.86 (broad s, 1H, HC=C), 4.12 (t, J = 5.10 Hz, 2H, CH2), 3.81(t, J = 5.10 
Hz, 2H, CH2). 13C{1H} NMR (75 MHz, MeOD):  144.0 (C-Ar), 131.4, 129.4, 
129.2 (CH-Ar), 124.5, 120.8 (CH), 78.6 (C), 62.4, 56.3 (CH2). HRMS (ESI+): 
Calcd for C48H44AgN4O2 [2M-AgCl2]+  calcd: 817.2512. Found: 817.2529. Anal. 
Calcd for 4(C24H22AgClN2O)∙1(C48H44AgClN4O2): C, 60.83; H, 4.68; N, 5.91; 
found: C, 60.80; H, 4.50; N, 5.80.  
8.2.78 Preparation of C19 
L19 (0.1g, 0.52 mmol), silver oxide (0.12g, 0.52 mmol) were dissolved in MeOH 
(10 mL) were stirred at room temperature, in the 
dark for 4 hours. The mixture was filtered through 
celite and Et2O (50 mL) was added to the filtrate 
precipitating a light brown solid. The solvent was 
decanted and the solid dried in vacuo.  
Yield: 0.115 g, 0.25 mmol (49%) 
1H NMR (300 MHz, MeOD): 7.23 (s, 4H, HC=CH), 4.16 (t, J = 5.4, 8H, CH2), 
3.79 (t, J = 5.4, 8H, CH2). 13C{1H} NMR (75 MHz, MeOD): 123.0 (HC=CH), 
63.0, 55.4 (CH2). HRMS (ESI+): calcd for C14H24AgN4O4 [M - Cl]+: calcd: 
419.0843. Found: 419.0845. Anal. Calcd for C14H24AgClN4O4: C, 36.90; H, 5.31; 
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8.2.79 Preparation of C2010, 11 
L20 (0.8 g, 4.9 mmols) was dissolved in MeOH (30 mL) and silver oxide (0.87 
g, 3.8 mmols) was added. The mixture was heated at reflux for 8 hours. The 
solution was filtered through celite, and the 
solvent was removed from the filtrate in vacuo to 
yield a brown solid. Recrystallisation from MeOH 
/ Et2O furnished the product as a light yellow solid. 
The solvents were decanted and the solid dried in 
vacuo. 
Yield: 0.42 g, 1.06 mmol (22 %) 
1H NMR (300 MHz, DMSO-d6):  7.40 (s, 1H, C=CH), 7.36 (s, 1H, C=CH), 4.07 
(t, J = 6.0 Hz, 2H, CH2), 3.66 (t, J = 6.0 Hz, 2H, CH2), 3.13 (s, 3H, CH3). 13C{1H} 
NMR (125 MHz, DMSO-d6):  122.0,121.8 (HC=CH), 61.5(CH2), 54.0(CH2), 
37.8 (CH3). HRMS (ESI+): calcd for C12H21AgN4O2 [M - Cl]+  calcd: 360.071 
found: 360.066. Anal. Calcd for C12H20AgClN4O2: C, 36.43; H, 5.10; N, 14.16. 
Found: C, 36.80; H, 5.30; N, 13.80.  
8.2.80 Preparation of C21 
L21 (0.1g, 0.52 mmols) was dissolved in MeOH (10 mL) and silver oxide (0.13g, 
0.52 mmols) was added and the mixture was heated at reflux for 4 hours. The 
solution which had turned a grey colour was 
filtered through celite and the solvent was 
removed from the filtrate in vacuo to yield a brown 
oil, which decomposes to a dark grey colour when 
upon recrystallisation from MeOH / Et2O and 
further drying in vacuo.  
Challenging to analyse due to fast decomposition. 
1H NMR (300 MHz, MeOD):  7.38 (d, 2H, C=CH), 7.30 (d, 2H, C=CH),6.15-
6.03 (m, 2H, C=CH-CH2), 5.33-5.19 (m, 4H, HC=CH2), 4.82 (m, 4H, CH2), 4.30-
4.27 (m, 4H, CH2), 3.92-3.89 (m, 4H, CH2). 
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8.2.81 Preparation of C22 
L22 (0.1g, 0.49 mmol), silver oxide (0.11 mg, 0.49 mmol) and MeOH (10 mL) 
were stirred at room temperature, in the dark 
for 4 hours. The mixture was filtered through 
celite, and the solvent was removed from the 
filtrate in vacuo to yield a yellow oil. 
Recrystallisation from MeOH / Et2O furnishes 
the product as a yellow solid. 
Yield: 0.20 g, 0.44 mmol (88 %) 
1H NMR (300 MHz, MeOD):    7.25 (m, 4H, HC=CH), 4.18 (t, J = 5.1 Hz, 4H, 
CH2), 4.10 (t, J = 7.2 Hz, 4H, CH2), 3.79 (t, J = 5.1 Hz, 4H, CH2), 1.78 (m, 4H, 
CH2), 1.29 (m, 4H, CH2), 0.83 (t, J = 7.2, 6H, CH3). 13C{1H} NMR (75 MHz, 
MeOD):  123.2, 122.6 (HC=CH), 62.9, 55.4 (CH2), 52.6 (CH2), 34.9 (CH2), 20.9 
(CH2), 14.1 (CH3). HRMS (ESI+): calcd for C18H32AgN4O2 [M - Cl]+  calcd: 
443.1571, found:443.1576. Anal. Calcd for C18H32AgClN4O2∙4/5MeOH: C, 44.68; 
H, 7.01; N, 11.09. Found: C, 44.30; H, 7.20; N, 10.70.  
8.2.82 Preparation of C23 
L23 (0.1g, 0.42mmol) was dissolved in MeOH 
(10 mL) and silver oxide (0.097g, 0.42mmol) 
was added. The mixture heated to reflux for 24 
hours in the dark. The solution was filtered 
through celite, and the solvent was removed 
from the filtrate in vacuo to yield the product as 
a brown solid.  
Yield: 0.15 g, 0.27 mmol (65 %) 
1H NMR (300 MHz, MeOD):  7.27 -7.12 (m, 14H, Ar, HC=CH), 5.18 (s, 4H, 
CH2), 4.10 (t, J = 5.4 Hz, 4H, CH2), 3.74 (t, J = 5.4 Hz, 4H, CH2). 13C{1H} NMR 
(125 MHz, MeOD): 182.3 (Ag-C), 138.4 (C-Ar), 130.0, 129.3, 128.7 (HC-Ar), 
123.5, 123.2 (HC=CH), 62.4, 56.0 (CH2), 55.5 (CH2). HRMS (ESI+): Calcd for 
C24H28AgN4O2 [M - Cl]+  calcd: 511.1258, found: 511.1257. Anal. Calcd for 
C24H28AgClN4O2: C, 52.62; H, 5.15; N, 10.23. Found: C, 52.90; H, 5.55; N, 9.85.  
 
 
CHAPTER 8                                                                UNIVERSITY OF LEEDS 
205 
 
8.2.83 Preparation of C2410 
L24 (0.1 g, 0.38 mmol) was dissolved in MeOH 
(15 mL) and silver oxide (0.09 g, 0.38mmol) 
was added. The mixture was stirred for 6 hours 
at room temperature. The solution was filtered 
through celite and the solvent was removed 
from the filtrate in vacuo to obtain a brown 
solid. The solid was recrystallised from MeOH 
/ Et2O, the solvents decanted and the solid was dried in vacuo.  
Yield: 0.16 g, 0.26 mmol (70%) 
1H NMR (300 MHz, MeOD):  7.51 (s, 1H, C=CH), 7.21 (s, 1H, C=CH), 7.01(s, 
2H, aromatic), 4.21 (t, J = 5.4 Hz, 2H, CH2), 3.84 (t, J = 5.4 Hz, 2H, CH2), 2.43 
(s, 3H, CH3), 1.85 (s, 6H, CH3). 13C{1H} NMR (75 MHz, CDCl3):  
138.7,135.7,135.0 (C-arom), 129.0 (CH-arom), 122.7,121.9 (HC=CH), 61.6, 
54.6 (CH2), 21.1 (p-CH3), 17.4 (o-CH3). HRMS (ESI+): calcd for C28H36AgN4O2 
[M - Cl]+  calcd: 567.1884 found: 567.1889. Anal. Calcd for 
C28H36AgClN4O2∙3/2H2O: C, 53.39; H, 6.08; N, 8.89. Found: C, 53.00; H, 6.10; 
N, 8.50.  
8.2.84 Preparation of C25 
L25 (0.1g, 0.42 mmol) and silver oxide (0.097 g, 0.42 mmol) were dissolved in 
MeOH (10 mL) and the mixture was stirred at 
room temperature for 4 hours, in the dark. The 
solution was filtered through celite, and excess 
Et2O was added to precipitate a brown oil. The 
brown oil was recrystallised from MeOH / Et2O to 
furnish the product as a brown solid. The solvent 
was decanted and the solid dried in vacuo. 
Yield: 0.15 g, 0.27 mmol (64%)  
1H NMR (300 MHz, MeOD):  8.43-8.41 (m, 2H, HCN-Ar), 7.72 (td, J = 7.7 Hz, 
2H, HC=CH), 7.59-7.57 (m, 2H, Ar), 7.31 (q, J = 7.7 Hz, 4H, Ar), 5.38 (s, 4H, 
CH2), 4.28-4.22 (m, 4H, CH2), 3.82-3.78 (m, 4H, CH2); 13C{1H} NMR (125 
MHz, MeOD):  182.9 (Ag-C), 150.5 (HC-Ar), 139.1 (HC-Ar), 125.2, 124.8 
(HC=CH), 123.7 (HC-Ar), 123.4 (HC-Ar), 62.7 (CH2), 57.2 (CH2), 55.4 (CH2); 
HRMS (ESI+): calcd for C22H26AgN6O2 [M - Cl]+ : 513.1163, found 513.1167. 
Anal. Calcd for C22H26AgN6O2.H2O∙MeOH: C, 46.05; H, 5.38; N, 14.01, Found: 
C, 46.30; H, 5.60; N, 13.70. 
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8.2.85 Preparation of C26 
L26 (0.08g, 0.33 mmol), silver oxide (0.076 g, 
0.33 mmol) were dissolved in MeOH (10 mL), 
and the mixture was stirred at room temperature 
for 4 hours, in the dark. The mixture was filtered 
through celite and Et2O (80 mL) was added to 
precipitate the product as an off-white solid. The 
solvent was decanted and the solid was dried in vacuo. 
Yield: 0.03g, 0.06 mmol (17 %) 
 1H NMR (300 MHz, MeOD):   8.22 (broad s, 2H, C=CH), 7.94-7.87 (m, 4H, 
Ar), 7.71-7.63 (m, 2H, Ar), 7.51 (broad s,  2H, C=CH), 4.32 (t, J = 5.2 Hz, 2H, 
CH2), 3.88 (t, J = 5.2 Hz, 2H, CH2); 13C{1H} NMR (75 MHz, MeOD): 
137.9,137.6,127.8,127.5,124.4,121.3,118.3, 62.8 (CH2),56.10(CH2); HRMS 
(ESI+): Calcd for C20H20AgN6O2F2 [M – Cl]+, 521.0667, Found 521.0656. Anal. 
Calcd for C20H20AgF2N6O2∙2/3 H2O: C, 42.47; H, 3.97; N, 14.61, Found: C, 42.80; 
H, 3.85; N, 14.30.  
8.2.86 Preparation of C27 
L27 (0.3 g, 0.89 mmol) and silver oxide (0.12 
g, 0.53 mmol) were added to a Schlenk flask 
with activated 4Å molecular sieves and 
degassed. Anhydrous MeCN (20 mL) and 
MeOH (14 mL) were transferred to the 
Schlenk flask, and the mixture was stirred at 
RT for 18 hours. The solution was filtered 
through celite and the solvents removed in 
vacuo rendering the product as a light yellow 
solid.  
Yield: 0.24 g, 0.32 mmol (36%) 
1H NMR (300 MHz, CDCl3):  8.53(s, 1H, aromatic), 8.32 (d, 2H, J = 8.4 Hz, 
aromatic), 8.05 (d, 2H, J = 8.4 Hz, aromatic), 7.54-7.44 (m, 4H, aromatic), 6.89 
(s, 1H, C=CH), 6.50 (s, 1H, HC=C), 6.24 (s, 2H, CH2), 4.33 (m, 2H, CH2), 3.94 
(m, 2H, CH2). 13C{1H} NMR (75 MHz, CDCl3): 134.1 (C), 131.4 (C), 131.0 (C), 
129.7 (CH), 129.5 (CH), 129.5 (CH), 127.6 (CH), 122.9 (CH), 125.5 (CH), 123.3 
(CH), 121.7(CH), 61.6 (CH2), 55.0 (CH2), 47.6 (CH2). HRMS (ESI+): Calcd for 
C40H36AgN4O2 [M-Cl]+ , calcd: 711.1884, found: 711.1879. Anal. Calcd for 
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C40H36AgClN4O2∙2H2O: C, 61.27; H, 5.14; N, 7.15, Found: C, 60.90; H, 5.00; N, 
7.50.  
8.2.87 Preparation of C28 
L28 (0.15 g, 0.53 mmol) and silver oxide 
(0.12g, 0.51mmol) were added to activated 
molecular sieves 4Å in a Schlenk flask and 
dried in vacuo. Anhydrous MeOH (10 mL) were 
transferred to the Schlenk flask and the 
mixture was stirred at room temperature for 24 
hours. The solution was filtered through celite, 
and the solvents removed from the filtrate in 
vacuo to yield the product as an off-white solid.  
Yield: 0.025g, 0.06 mmol (11 %). 
1H NMR (300 MHz, MeOD): 7.99 (s, 1H, a), 7.72 (s, 5H, a), 7.58 (s, 5H, b), 
7.18 (s, 6H, b), 6.93 (s, 6H, b), 4.94-4.89 (m, 9H, d), 4.72 (q, J = 4.30 Hz, 6H, 
g), 3.93 (s, 3H, c), 3.70 (s, 1H, e), 3.00 (s, 3H, e), 2.87 (s, 3H, f), 1.81-1.79 (m, 
23H, h/i), 1.69 (d, J = 4.3 Hz, 18H, h), 1.30 (d, J = 4.3 Hz, 18H, i). 13C{1H} NMR 
(125 MHz, MeOD):  183.2 (Ag-C), 177.4 (C=O), 174.7(C=O), 137.8(C=C), 
128.3 (C=C), 122.3 (C=C), 120.0 (C=C), 61.9 (N-CH-CH3), 59.7 (N-CH-CH3), 
53.0(CH), 36.8 (O- CH3), 21.8 (N- CH3), 19.9 (CH3), 19.2 (CH3). HRMS (ESI+): 
calcd for C14H22AgN4O4 [M – Ag + H]+ calcd: 419.0684, found: 419.0914. Anal. 
Calcd for C21H30Ag2N6O6 ∙3H2O∙3/4MeOH: C, 33.99; H, 5.30; N, 11.19. Found: 
C, 34.10; H, 4.96; N,10.80. 
8.2.88 Preparation of C29 
L29 (0.075 g, 0.25 mmol) and silver oxide (0.12 g, 0.51 mmol) were added to a 
Schlenk flask and dried in vacuo. Anhydrous 
MeOH (15 mL) was transferred to the 
Schlenk flask and the mixture was stirred at 
room temperature for 18 hours. The solution, 
which had turned grey, was filtered through 
celite, and the solvent removed from the 
filtrate in vacuo to yield the product as a white 
solid.  
Yield: 0.05 g, 0.06 mmol (24 %)  
1H NMR (300 MHz, MeOD):  7.59 (s, 4H, C=CH), 7.33 (s, 4H, HC=C), 7.24 (s, 
4H, N-CH2-N), 5.02-4.58 (m, 8H, N-CH2-C=O), 3.22 (s, 6H, O- CH3). 13C{1H} 
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NMR (125 MHz, MeOD):  125.1(C=O), 122.2, 121.7(C=C), 65.1, 56.4 (CH2), 
49.6 (CH3). HRMS (ESI+): calcd for C25H31Ag2N8O9 [M-2OH]2+ calcd: 388.0215, 
found: 388.0258. IR νmax / cm-1: 3371(OH), 3100, 2966 (carboxylic acid OH), 
1741(ester C=O), 1368, 1230, 727. Anal. Calcd for C24H36Ag2N8O11∙3/2H2O: C, 
34.59; H, 4.00; N, 13.45. Found: C, 34.70; H, 4.40; N,13.60.  
8.2.89 Preparation of C30 
L30 (0.2 g, 0.42 mmol) and Silver oxide (0.19 g, 0.84 mmol) were added to 
activated molecular sieves 4Å in a Schlenk flask and dried in vacuo. Anhydrous 
MeCN (10 mL) and anhydrous MeOH (10 
mL) were transferred to the Schlenk flask 
and the mixture was stirred at room 
temperature for 24 hours. The solution, 
which had turned grey, was filtered 
through celite, and the solvent removed 
from the filtrate in vacuo to yield the 
product as a white solid. 
Yield: 0.15 g, 0.2 mmol (46 %)  
1H NMR (300 MHz, MeOD):  7.60 (s, 4H, C=CH), 7.33 (s, 4H, HC=C), 7.24 (s, 
4H, N-CH2-N), 6.48(broad s, 6H, OH), 4.60 (s, 8H, N-CH2-C=O). 13C{1H} NMR 
(125 MHz, MeOD):  124.1(C=O), 121.3,120.4 (C=C), 55.5, 51.8 (CH2). HRMS 
(ESI+): calcd for C23H29Ag2N8NaO9 [M-2OH+H2O +MeCN]2+, calc: 399.4982, 
found: 399.5605. IR νmax / cm-1 :  3366(OH), 3099, 2966(carboxylic acid OH), 
1742(carboxylic acid C=O), 1368, 1170, , 727. Anal. Calcd for 
C22H30Ag2N8O10∙CH3OH: C, 34.04; H, 3.73; N,13.83. Found: C, 34.20; H,3.90; 
N,13.50. 
8.2.90 Preparation of C31 
L31 (0.3 g, 0.58 mmol) and silver oxide (0.27 g, 1.16 mmol) were added to 
activated molecular sieves 4Å in a Schlenk flask and dried in vacuo. Anhydrous 
MeOH (10 mL) was transferred to the Schlenk flask and the mixture was stirred 
at room temperature for 24 
hours. The solution, which 
had turned grey, was 
filtered through celite. Et2O 
(60 mL) was added to the 
filtrate to precipitate the 
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product as a white solid. The solvent was decanted and the solid was dried in 
vacuo.  
Yield : 0.1 g, 0.1 mmol (18%) 
1H NMR (300 MHz, MeOD): 7.69 (s, 2H, C=CH), 7.59 (s, 2H, HC=C), 7.49-
7.23(m, 10H, aromatic), 4.71 (s, 2H, N-CH2-N), 4.62 (s, 4H, N-CH2-C=O), 3.37 
(s, 4H, CH2). 13C{1H} NMR (125 MHz, MeOD): 173.6, 170.1 (Ag-C), 142.6 
(C=O), 129.3,125.2, 127.9, 125.2 (aromatic), 123.9(C=C), 122.2 (C=C), 65.1(N-
CH2-N), 56.6 (N-CH2-C=O), 53.3 (CH2). HRMS (ESI+): calcd for C36H35Ag2N8O8 
[M-2OH-H]+, Calcd: 923.0671, found : 923.0701. IR νmax / cm-1 :  3254 (OH), 
3092, 3001 (carboxylic acid OH) , 1745 (ester), 1604 (C-C benzene). Anal. 
Calcd for C40H48Ag2N8O11 ∙Et2O: C: 46.53 H: 4.69 N: 10.85, found: C: 46.50 H: 
4.30 N: 10.70 
8.2.91 Preparation of C32 
L32 (0.10g, 0.45 mmol) and silver oxide (0.11g, 0.45 mmol) were added to an 
ampoule with activated molecular sieves 4Å and dried in vacuo. Anhydrous 
CH3CN (12 mL) and MeOH (15 mL) were transferred to the ampoule and the 
mixture was stirred at room temperature for 24 hours. The solution was filtered 
through celite, and the solvents were removed 
from the filtrate in vacuo to yield the product 
as a sticky white solid. Recrystallisation from 
MeOH / C5H12 and MeCN/ C5H12 , decantation 
of the solvents and drying of the solid in vacuo 
renders a sticky white solid (very 
hygroscopic). 
Yield: 0.08 g, 0.13 mmol (30 %) 
1H-NMR (300MHz, MeOD): 8.44 (s, 1H, CH), 7.49 (s, 2H, CH), 6.95 (s, 2H, 
CH), 6.81 (s, 2H, CH), 4.45 (s, 4H, CH2). 13C{1H}-NMR (75MHz, MeOD): 179.9 
(Ag-C), 171.7 (C=O), 124.0 (CH), 63.0 (CH2). HRMS (ESI+): calcd for 
C16H18AgN5NaO8 [M–H+MeCN+Na]+: 539.2044, Found: 539.3042. Anal. Calcd 
for C14H16AgClN4O8 . 3 MeCN. 2/3 C5H12: C: 41.04 H: 4.80 N: 14.36, found: C: 
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8.2.92 Preparation of C33 
L33 (0.05 g, 0.14 mmol) and silver oxide (0.42 g, 1.81 mmol) were added to an 
ampoule with 4Å activated molecular sieves, and dried in vacuo. Dry CH2Cl2 (7 
mL) and MeOH (7 mL) were transferred to the 
ampoule and the mixture was stirred at RT for 24 
hours. The solution which had turned an orange 
colour was filtered through celite, and the 
solvents were removed from the filtrate in vacuo 
to yield the product as a red/orange solid. The 
solid is very hygroscopic and turns to an oil when 
exposed to air. Recrystallisation from MeCN / 
Et2O yields the product as an orange solid. The 
solvents were decanted and the solid dried in 
vacuo. 
 Yield: 0.02 g, 0.024 mmol (18 %)  
1H-NMR (300 MHz, MeOD):  8.34 (m, 4H, aromatic), 8.20 (m, 4H, aromatic), 
7.77-7.25 (m, 10H, aromatic), 6.46 (broad s, 4H, CH2), 6.11 (broad s, 4H, CH2). 
13C{1H}-NMR (75 MHz, MeOD): 132.1,131.5, 130.3,130.1, 128.8, 128.3, 
126.1, 126.0 (aromatic), 123.5, 122.7 (HC=CH), 69.4 (CH2), 30.9 (CH2). HRMS 
(ESI+): calcd for C40H32AgN4O4 [M - Cl]+ calc : 741.1466; found: 741.1474. Anal. 
Calcd for C40H32AgClN4O4 ∙3/2 MeCN∙3/2 CH2Cl2: C: 55.27 H: 4.33 N: 7.97, found: 
C: 55.50 H: 4.40 N: 8.35. 
8.2.93 Preparation of C3412 
L34 (0.58 g, 2.29 mmols) was dissolved in 
CH2Cl2 (7 mL), and silver oxide (0.27g, 1.15 
mmol) was added. The mixture was stirred at 
room temperature for 18 hours. Filter solution 
over celite, dried in vacuo to give a white solid. 
Recrystallisation from CH2Cl2 / Et2O yields the 
product as a white solid. 
Yield: 0.76 g, 1.06 mmol (46 %) 
1H NMR (300 MHz, CDCl3):  7.28-7.17 (m, 10H, aromatic), 6.91 (s, 2H, C=CH), 
6.86 (s, 2H, C=CH), 5.22 (s, 4H, CH2), 3.41(s, 6H, CH3). 13C{1H} NMR (500 
MHz, CDCl3):  182.4 (Ag-C), 135.8(C), 129.1(CH), 128.5(CH), 127.9(CH), 
122.6(CH), 121.2(CH), 55.6(CH2), 38.9(CH3). HRMS (ESI+): Calcd for [M-
AgBr2]+, calc: 453.1043, found: 453.1031. Anal. Calcd for C22H24Ag2BrN4 ∙¼ 
Et2O: C, 37.41; H, 3.62; N, 7.59. Found: C, 37.65; H, 3.50, N, 7.90. 
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8.2.94 Preparation of C35 
L35 (0.01 g, 0.026 mmol) and silver oxide 
(0.006 g, 0.026 mmol) were dissolved in a 
solvent mixture of MeOD (0.5 mL) and CDCl3 
(0.5 mL). The mixture was stirred at RT for 4 
hours. The solution was filtered through celite 
and the solvents were removed in vacuo to 
yield a yellow solid. 
Yield: 0.015 g, 0.018 mmol (68 %) 
1H NMR (300 MHz, CDCl3): 8.45-7.16(m, 13H, CH-aromatic), 6.19(s, 2H, 
CH2), 4.40 (broad s, 2H, CH2), 3.91 (broad s, 2H, CH2).13C{1H} NMR (75 MHz, 
CDCl3): 131.5, 129.6,127.7, 125.5, 124.0, 123.7, 111.7(CH-aromatic), 53.5, 
(CH2), 30.4 (CH3).  HRMS (ESI+): Calcd for C48H40AgN4O2 [2M - Cl]+ , calcd: 
813.2199, found: 813.2180. Anal. Calcd for C48H40AgClN4O2: C, 67.97; H, 4.75; 
N, 6.61. Found: C, 67.80; H, 4.85, N, 6.80. 
8.2.95 Preparation of C36 
L36 (0.09g, 0.20 mmol) and silver oxide (0.046g, 
0.20mmol) were added to a Schlenck flask with 
activated 4Å molecular sieves and dried in vacuo. 
Anhydrous CH2Cl2 (10 mL) and MeOH (10 mL) were 
transferred to the Schlenk flask. The mixture was 
stirred at RT for 24 hours. The solution was filtered 
through celite and the solvents were removed in 
vacuo to yield a dark orange solid. 
Yield: 0.01 g, 0.011 mmol (6%) 
1H NMR (300 MHz, CDCl3):  8.46 (s, 1H, aromatic), 8.18-7.93 (m, 4H, 
aromatic), 7.47-7.31 (m, 8H, aromatic), 6.26 (s,2H, CH2), 4.96 (s, 3H, CH3). 
13C{1H} NMR (75 MHz, DMSO-d6):  HRMS (ESI+): Calcd for C46H36AgN4 [2M - 
I]+  calcd: 751.1991 found: 751.1985. Anal. Calcd for C46H36AgIN4: C, 62.81; H, 
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8.2.96 Preparation of C37 
L37 (0.1g, 0.16 mmol) and silver oxide (0.036g, 0.16mmol) were added to an 
ampoule dried in vacuo, evacuated and purged with Argon (x3). Dry CH2Cl2 (10 
mL) was transferred to the ampoule 
and the mixture was heated at 50°C 
for 24 hours. To improve the solubility 
of the mixture, dry MeOH (10 mL) was 
added after 24 hours and the mixture 
was heated for an additional 24 hours. 
The solution was filtered through 
celite; excess Et2O (300 mL) was 
added to the filtrate and the product 
precipitated out of solution as a yellow 
solid which was filtered and dried in 
vacuo.  
Yield: 0.05 g, 0.04 mmol (22 %). 
1H NMR (300 MHz, DMSO-d6):  8.75 (s, 2H, C=CH), 8.11-7.18(m, 20H, 
aromatic + HC=C), 6.04-5.76 (broad m, 4H, CH2), 4.04 (broad s, 2H, CH2). 
13C{1H} NMR (75 MHz, DMSO-d6): 131.8, 131.0,129.9, 127.7, 126.0 (CH, 
aromatic), 124.8, 123.7 (CH=CH), 65.8, 15.1 (CH2). HRMS (ESI+): Calcd for 
C74H56Ag2N8 [M - 2Cl]2+ calc : 636.1358; found: 636.1376. Anal. Calcd for 
C74H56Ag2Cl2N8. 2/3 CH2Cl2: C: 61.63; H: 4.04; N: 7.62, found: C: 61.60; H: 4.40; 
N: 7.80 
8.2.97 Preparation of PDC1 
PM1 (0.3 g, 0.78 mmol) and silver oxide (0.5g, 2.16 mmol) were added to a 
Schlenk flask and dried in vacuo for one hour. 
Anhydrous MeOH (14 mL) was cannula 
transferred to the Schlenk flask and the mixture 
was stirred at RT for 24 hours. The solution, 
which had turned brown, was cannula filtered 
through celite, and the solvent removed from the 
filtrate in vacuo to furnish a brown solid.  
Yield: 0.21g, 0.37 mmol (48 %) 
1H NMR (300 MHz, MeOD):  7.39-6.62 (broad m, aromatic + CH), 5.12 (broad 
s, CH2), 3.88 (broad s, CH3). 13C{1H} NMR (125 MHz, MeOD):  170.2, 164.9, 
146.8(broad), 139.1 137.3, 135.7, 135.6, 129.3 (broad), 127.1(broad), 124.3, 
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123.3(broad), 55.6, 41.9, 38.9, 37.1, 35.2, 31.9, 23.3, 14.8. Anal. Calcd for 
C30H34AgClN2: C: 63.67; H: 6.06; N: 4.95, found: C: 63.40; H: 6.00; N: 5.00 
8.2.98 Preparation of PDC2 
PM2 (0.3 g, 0.66 mmol) and silver oxide (0.46 g, 1.96 mmol) were added to a 
Schlenk flask and dried in vacuo for one hour, 
evacuated and purged with N2 (x3). Anhydrous 
MeOH (15 mL) was cannula transferred to the 
Schlenk flask and the mixture was stirred at 
room temperature for 72 hours. The solution, 
which had turned brown, was cannula filtered 
through celite, and the solvent removed from the 
filtrate in vacuo to yield a brown solid.  
Yield: 0.18 g, 0.28 mmol (43%) 
1H NMR (300 MHz, MeOD):  7.43-6.59 (broad m, aromatic + CH), 5.28 (broad 
s CH2). 13C{1H} NMR (125 MHz, MeOD): 170.3, 138.4, 137.3, 130.2(broad), 
129.5(broad), 128.7(broad), 127.0(broad), 123.6(broad), 56.1(broad), 
41.9(broad), 35.5, 23.6, 14.5. Anal. Calcd for C37H40AgClN2: C: 67.74; H: 6.15; 
N: 4.27, found: C: 68.10; H: 6.00; N: 4.60 
8.2.99 Preparation of PDC3 
Poly- (L)-glutamic acid PM3 (0.05g, 0.21mmol), C20 (0.11g, 0.21mmol) and 4-
Dimethylaminopyridine (DMAP) (0.0026g, 
0.021mmol) were added to a Schlenk flask and 
dried in vacuo for one hour. Anhydrous DMF (10 
mL) was transferred to the Schlenk flask and the 
mixture was cooled to 0°C in an ice bath, at 
which point Dicyclohexylcardodiimide (DCC, 
0.044 g, 0.21 mmol) was added. The mixture 
was stirred for 5 minutes at 0°C, warmed to room 
temperature and stirred for 5 hours. The solution 
was cannula filtered, and the the solvents were 
removed from the filtrate in vacuo to yield a 
sticky brown solid. 
Yield : 0.06 g, 0.1 mmol  (45 %)  
1H NMR (300 MHz, DMSO-d6):  8.50 (s, NH, a), 8.08-7.83 (m, aromatic, b), 
7.48 , 7.43 (s, HC=CH, c), 4.96 (d, J = 8.3 Hz, arom-CH2-NH, d), 4.41(broad t, 
CH2, e), 4.21 (broad q, CH, f), 3.73 (t, J = 5.1 Hz, CH2, g), 2.89, 2.73 (s, CH3, h 
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& i), 1.63-1.52 (broad m, CH2, j, k & l), 1.26-1.09 (broad m, CH2 + NH, m + n). 
HRMS (ESI+): calcd for C24H33AgN5O4 [M-Cl-NH2]+ calc: 565.1653; found: 
565.2416. Anal. Calcd for C29H43AgClN7O6∙ 2/3 Et2O: C: 48.86; H: 6.43; N: 12.60, 
found: C: 48.90; H: 6.80; N: 13.00. 
8.2.100 Preparation of PDM4a 
Two stock solutions of PM4 (mPEG5000P(Phe)) 
(1mg/mL) in DMF, and of C20 (0.25mg/mL) in 
H2O, were prepared by serial dilution. 20, 40 
,200 and 400µl of the PM4 solution (1mg/mL) 
were added to 2mL of the solution of C20 using 
a micropipette.  The solutions were shaken on a 
vibrax machine, and the average particle size 
and polydispersity index (PDI) were measured 
using dynamic light scattering (DLS).  






























8.2.101 Preparation of PDM4b 
Two stock solutions of PM4 (mPEG
5000
P(Phe)) (1mg/mL) in CH2Cl2, and of C27 
(1mg/mL) in CH2Cl2, were prepared with the aid 
of sonication. Equal volumes (2.9 mL) of the two 
solutions were combined, and an equivalent 
volume of nanopure H2O (5.8 mL) was added to 
the mixture.  The solutions were shaken on a 
vibrax machine for 15 minutes, left to stand for 4 
hours before the organic layer was removed in 
vacuo. The average particle size and 
polydispersity index (PDI) were measured using 
dynamic light scattering (DLS).  
C27:PM4 = 1:1 
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8.2.102 Preparation of PDM5 
Solutions in HPLC grade water of concentration 1mg/mL were prepared of 
PM5A-C, L30, L32, L33, C30, C32 and 
C33. The solutions of the three polymers, 
ligands and complexes were filtered 
through 0.45µm and 0.2µm filters and 
analysed using DLS to confirm no 
particles were present before 
encapsulation. Equal volumes of 
solutions (1mL) of polymer and of ligand 
or complex were mixed to form solutions 
of 1:1 ratio, and agitated on vibrax 
machine. The particles in solution were 
analysed using DLS at 37°C to mimic the 
body temperature.  
PM5 A : mPEG5000: poly(lysine) = 1:39         1: L30    3: L32   5: L33 
PM5 B : mPEG5000: poly(lysine) = 1:50         2: C30   4: C32   6: C33 
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Summary, conclusions and future work 
Thirty seven Ag(I)-NHC complexes were designed and synthesised for 
chemotherapeutic purposes. The complexes are categorised into three classes 
according to their precursors, which are either naturally derived or biologically 
relevant. The three classes are: 1, xanthine-derived, 2, clotrimazole-derived, 
and 3, water-soluble Ag(I)-NHC complexes. Full characterisation of the 
complexes included NMR spectroscopy, HRMS, elemental analysis and X-ray 
diffraction analysis. The Log P values of the complexes were determined, 
followed by in vitro cytotoxicity testing against various cancerous and non-
cancerous cells. Structure-activity relationships were determined for each 
individual class from the IC50 and Log P values, from which a general SAR was 
observed across the classes. It was clear that combining a hydrophilic N-
substituent and a hydrophobic N-substituent in the same complex which renders 
‘intermediate lipophilicity’, increases the antiproliferative activity.     
1. Xanthine-derived (Chapter 2): 
 
Lipophilicity trend: C2 > C3 > C4 > C1 > C5 
Most cytotoxic: C4 & C5 (C4 > C5, C4 Log P = 0.15) 
 
2. Clotrimazole-derived (Chapter 4): 
 
Lipophilicity trend: R: Bn > nBu > allyl > Me > (CH2)2OH, X: I > Cl, Y: Cl > H 
Most cytotoxic: C13 & C18 (Log P values between 0.25 - 0.30) 
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3. Water-soluble complexes (Chapter 5): 
A.                                                                                B. 
 
C.                                                  D. 
   
Most cytotoxic: C23 & C27 & C31 (C23 > C27 > C31, Log P values between 0.02 - 0.50) 
Figure 9.1: Summary of Ag(I)-NHC complexes investigated for anticancer 
properties 
The steric bulk provided by the hydrophobic N-substituent appears to improve 
anticancer activity, i.e. the bulkier the hydrophobic N-substituent the lower the 
IC50 value. This can be observed with groups like phenyl group in C4 and the 
triphenyl group in C13 and C18. The steric bulk possibly leads to a slower 
release of the Ag+ ions, leading to a prolonged duration of action.  The bulky N-
triphenyl substituent present in the clotrimazole-derived complexes is possibly 
behind the overall general higher cytotoxicity results of this class of complexes 
over the other classes. In particular, the N-hydroxyethyl containing complexes 
C13 and C18 are very promising anticancer drugs as they revealed IC50 values 
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similar to those obtained for cisplatin, with a higher selectivity to a number of 
cancerous cell lines over a non-cancerous cell line (Chapter 4).  
Xanthine-derived Cu(I)- and Ru(II)-NHC complexes were synthesised and the 
results from in vitro studies revealed minimal or non-existent anticancer activity 
of these complexes (IC50 > 100µM, Chapter 3).  The corresponding Ag(I)-NHC 
complexes (Chapter 2) are therefore superior as potential anticancer drugs, 
possibly due to the weaker Ag-C bond that can release Ag+ ions in solution 
responsible for cytotoxicity. 
Anticancer activity: 
 
             Figure 9.2: Xanthine-derived Cu(I)- & Ru(II)-NHC showed low or no 
cytotoxicity 
In vivo delivery of the complexes to the cancerous tissue without enzymatic 
degradation and with high selectivity were major concerns that had to be 
addressed. Tacke and co-workers reported poor selectivity of a Ag(I)-NHC 
complex (with previously reported promising in vitro results) to cancerous tissue 
in vivo animal models, as the complex revealed toxicity to non-tumour bearing 
mice.1 Therefore, developing polymer-based carriers was rationalised for the 
delivery of the Ag(I)-NHC complexes to cancerous tissue in vivo by avoiding 
enzymatic inactivation and by selectivity to cancerous tissue (Chapter 6). 
Polymer-drug conjugates (PDCs) of various polymers conjugated to Ag(I)-NHC 
complexes were chemically synthesised, however, the linear nature of the PDCs 
does not eliminate the possibility of enzymatic attack and inactivation of the 
Ag(I)-NHC complex. Formation of polymer-drug micelles (PDMs) with physically 
encapsulated Ag(I)-NHC complexes was performed through two methods, the 
first being the self-assembly of polymer when a solution of the polymer in DMF 
is added to a solution of the Ag(I)-NHC complex in water and the second by 
electrostatic interaction of negatively charged Ag(I)-NHC complex to a positively 
charged polymer. The particles were analysed using Dynamic light scattering 
(DLS) to determine the average particle size and Polydispersity index (PDI) of 
the particles. Scanning electron microscopy (SEM) was used to image the 
particles and Energy dispersive X-ray spectroscopy (EDX) was used to map the 
position of Ag ions in the sample, suggesting successful encapsulation of the 
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complexes. Confocal fluorescence microscopy was used to locate the position 
of the fluorescent complex C27 in the PDM. 
A unique bio-membrane sensing device was used to screen the effect of the 
Ag(I)-NHC complexes on a phospholipid monolayer (Chapter 7). Interactions 
with the membrane reflects potential interactions with cellular membranes in 
vivo. The monolayer is deposited on a Hg coated Pt electrode, which is 
connected to a flow cell, and the interactions with the monolayer are detected 
using rapid cyclic voltammetry (RCV). Complexes that are membrane-active 
can pass biological membranes via passive diffusion, while complexes which 
do not interact with the membrane enter cells via active transport. Cisplatin and 
xanthine-derived Ag(I)-NHC complexes did not interact with the monolayer, only 
water-soluble Ag(I)-NHC complexes with bulky N-aromatic groups, N-mesityl 
and N-anthracenyl were membrane active, and all clotrimazle-derived 
complexes were able to interact with the membrane in varying degrees 
according to the N-substituents, counterions and phenyl substituents.  
For the clotrimazole-derived membrane-active complexes, a correlation 
between the limit of detection (LoD) calculated using this technique and IC50 
values was observed. This result displays the potential of using this technique 
as a ‘prescreening’ tool to reduce or eliminate the use of expensive in vitro 
cytotoxicity testing. The role of each portion of the Ag(I)-NHC complex in cell 
entry was investigated using this device, by testing the ability of each portion to 
interact with the membrane, and the membranes ability to recover. The 
imidazolium salts displayed membrane-interactions similar to those observed 
for the Ag(I)-NHCs, however, the unlike with Ag(I)-NHCs, the membrane was 
able to recover to its normal state after exposure to the imidazolium salts. Silver 
salts did not interact with the membrane, supporting the hypothesis that the role 
of the NHC moiety is to carry Ag to the cancerous tissue and for the interaction 
with the membrane, while the role of the Ag portion is to damage the membrane. 
Future work regarding this technique may involve developing a procedure for 
deposition of cancerous cells or tissue on the microfabricated chip and using 
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The promising cytotoxicity results of the clotrimazole-derived Ag(I)-NHC 
complexes, including promising selectivity to cancerous cells, may encourage 
the future use of  other imidazole- and triazole-based antifungal agents such as 
Ketoconazole and Fluconazole. It will be interesting to investigate the effect of 
the presence of dihalides in both compounds on the anticancer activity, in 
addition to the effects of other groups such as ether, ketone and alcohol that 
were not present in clotrimazole.  Mechanistic studies are currently being 
conducted at the University of Huddersfield to help determine the biological 
targets of the Ag(I)-NHC complexes, such as thioredoxin reductase and 
topoisomerase. Future work will possibly include in vivo animal testing of the 
Ag(I)-NHC complexes, and the PDCs and PDMs formed, in order to evaluate 
the effect of encapsulation on the delivery of the complexes to the cancerous 
tissue. Tacke and co-workers reported the selective antibacterial activity of a 
benzyl-substituted Ag(I)-NHC complex  in vivo using Galleria mellonella larvae, 
observed through the high survival rate of the larvae after treatment.2 Hence, 
future work can also include antibacterial testing of the complexes, especially 
antifungal-derived complexes, e.g. clotrimazole-derived Ag(I)-NHC complexes, 
as the antibacterial properties of both the silver and the antifungal precursor 
may combine to give a synergistic antibacterial effect.  
                          
                         Ketoconazole                                           Fluconazole 
 
Figure 9.3: Ag(I)-NHC complexes derived from antifungal agents for future 
work 




1. I. Fichtner, J. Cinatl, M. Michaelis, L. C. Sanders, R. Hilger, B. N. 
Kennedy, A. L. Reynolds, F. Hackenberg, G. Lally, S. J. Quinn, I. McRae and 
M. Tacke, Letters in Drug Design & Discovery, 2012, 9, 815-822. 
2. N. Browne, F. Hackenberg, W. Streciwilk, M. Tacke and K. Kavanagh, 
Biometals, 2014, 27, 745-752. 
 
 




Crystal data and structure refinement for L2 
Empirical formula C12H19N4O2I 
Formula weight 378.21 
Temperature/K 99.98(14) 
Crystal system monoclinic 












Crystal size/mm3 0.21 × 0.17 × 0.06 
2Θ range for data collection 6.7 to 54.2° 
Index ranges -8 ≤ h ≤ 12, -24 ≤ k ≤ 29, -9 ≤ l ≤ 8 
Reflections collected 4777 
Independent reflections 2369[R(int) = 0.0372] 
Data/restraints/parameters 2369/289/159 
Goodness-of-fit on F2 1.085 
Final R indexes [I>=2σ (I)] R1 = 0.0564, wR2 = 0.1407 
Final R indexes [all data] R1 = 0.0593, wR2 = 0.1439 
Largest diff. peak/hole / e Å-3 2.11/-1.31 
Flack parameter 0.28(8) 
Appendix                                                                  UNIVERSITY OF LEEDS 
224 
 
Crystal data and structure refinement for L3 
Empirical formula C15H17N4O2I 
Formula weight 412.23 
Temperature/K 100.00(10) 
Crystal system orthorhombic 












Crystal size/mm3 0.05 × 0.03 × 0.02 
2Θ range for data collection 9.78 to 133.18° 
Index ranges -20 ≤ h ≤ 20, -12 ≤ k ≤ 10, -9 ≤ l ≤ 10 
Reflections collected 9250 
Independent reflections 2736[R(int) = 0.0828] 
Data/restraints/parameters 2736/1/202 
Goodness-of-fit on F2 1.017 
Final R indexes [I>=2σ (I)] R1 = 0.0491, wR2 = 0.1024 
Final R indexes [all data] R1 = 0.0921, wR2 = 0.1211 
Largest diff. peak/hole / e Å-3 0.84/-0.83 
Flack parameter 0.084(14) 
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Crystal data and structure refinement for L3.1 
Empirical formula C44H48N8S2O10 
Formula weight 913.02 
Temperature/K 99.99(10) 
Crystal system triclinic 












Crystal size/mm3 0.12 × 0.05 × 0.04 
2Θ range for data collection 4.28 to 52.74° 
Index ranges -9 ≤ h ≤ 9, -11 ≤ k ≤ 11, -18 ≤ l ≤ 13 
Reflections collected 7315 
Independent reflections 5769[R(int) = 0.0278] 
Data/restraints/parameters 5769/3/586 
Goodness-of-fit on F2 1.064 
Final R indexes [I>=2σ (I)] R1 = 0.0418, wR2 = 0.0903 
Final R indexes [all data] R1 = 0.0492, wR2 = 0.0950 
Largest diff. peak/hole / e Å-3 0.24/-0.30 
Flack parameter 0.59(7) 
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Crystal data and structure refinement for L4 
Empirical formula C14H19N4O4I 
Formula weight 434.23 
Temperature/K 99.97(11) 
Crystal system monoclinic 












Crystal size/mm3 0.17 × 0.06 × 0.04 
2Θ range for data collection 6.76 to 54.2° 
Index ranges -13 ≤ h ≤ 13, -9 ≤ k ≤ 9, -28 ≤ l ≤ 28 
Reflections collected 8263 
Independent reflections 3604[R(int) = 0.0537] 
Data/restraints/parameters 3604/6/225 
Goodness-of-fit on F2 1.016 
Final R indexes [I>=2σ (I)] R1 = 0.0424, wR2 = 0.0689 
Final R indexes [all data] R1 = 0.0668, wR2 = 0.0775 
Largest diff. peak/hole / e Å-3 0.85/-0.86 
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Crystal data and structure refinement for L6 
Empirical formula C23H20ClIN2 
Formula weight 486.76 
Temperature/K 99.98(10) 
Crystal system orthorhombic 












Crystal size/mm3 0.21 × 0.11 × 0.07 
2Θ range for data collection 6.5 to 56.56° 
Index ranges -14 ≤ h ≤ 9, -19 ≤ k ≤ 18, -33 ≤ l ≤ 27 
Reflections collected 13104 
Independent reflections 5081[R(int) = 0.0410] 
Data/restraints/parameters 5081/0/245 
Goodness-of-fit on F2 1.032 
Final R indexes [I>=2σ (I)] R1 = 0.0414, wR2 = 0.0820 
Final R indexes [all data] R1 = 0.0662, wR2 = 0.0924 
Largest diff. peak/hole / e Å-3 2.02/-1.09 
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Crystal data and structure refinement for L7 
Empirical formula C26H26N2ClI 
Formula weight 528.84 
Temperature/K 99.8(6) 
Crystal system triclinic 












Crystal size/mm3 0.28 × 0.16 × 0.11 
2Θ range for data collection 5.62 to 56.56° 
Index ranges -12 ≤ h ≤ 10, -9 ≤ k ≤ 14, -14 ≤ l ≤ 16 
Reflections collected 8893 
Independent reflections 5543[R(int) = 0.0353] 
Data/restraints/parameters 5543/0/300 
Goodness-of-fit on F2 1.049 
Final R indexes [I>=2σ (I)] R1 = 0.0362, wR2 = 0.0723 
Final R indexes [all data] R1 = 0.0450, wR2 = 0.0780 
Largest diff. peak/hole / e Å-3 0.73/-0.49 
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Crystal data and structure refinement for L8 
Empirical formula C24H22N2OCl1.26I0.74 
Formula weight 493.01 
Temperature/K 100.0(2) 
Crystal system triclinic 












Crystal size/mm3 0.26 × 0.14 × 0.1 
2Θ range for data collection 5.92 to 56.56° 
Index ranges -11 ≤ h ≤ 10, -13 ≤ k ≤ 14, -16 ≤ l ≤ 12 
Reflections collected 8180 
Independent reflections 5163[R(int) = 0.0315] 
Data/restraints/parameters 5163/2/270 
Goodness-of-fit on F2 1.240 
Final R indexes [I>=2σ (I)] R1 = 0.0585, wR2 = 0.1120 
Final R indexes [all data] R1 = 0.0679, wR2 = 0.1165 
Largest diff. peak/hole / e Å-3 1.14/-0.84 
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Crystal data and structure refinement for L9 
Empirical formula C23H20N2Cl2 
Formula weight 395.31 
Temperature/K 100.0(3) 
Crystal system monoclinic 












Crystal size/mm3 0.09 × 0.05 × 0.04 
2Θ range for data collection 10.32 to 133.04° 
Index ranges -9 ≤ h ≤ 6, -16 ≤ k ≤ 14, -10 ≤ l ≤ 9 
Reflections collected 3657 
Independent reflections 2561[R(int) = 0.0318] 
Data/restraints/parameters 2561/1/254 
Goodness-of-fit on F2 1.116 
Final R indexes [I>=2σ (I)] R1 = 0.0363, wR2 = 0.0864 
Final R indexes [all data] R1 = 0.0392, wR2 = 0.0875 
Largest diff. peak/hole / e Å-3 0.32/-0.19 
Flack parameter -0.001(16) 
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Crystal data and structure refinement for L10 
Empirical formula C25H24N2OCl2 
Formula weight 439.36 
Temperature/K 99.9(4) 
Crystal system orthorhombic 












Crystal size/mm3 0.31 × 0.2 × 0.15 
2Θ range for data collection 6.4 to 56.56° 
Index ranges -9 ≤ h ≤ 11, -14 ≤ k ≤ 26, -26 ≤ l ≤ 32 
Reflections collected 15101 
Independent reflections 5342[R(int) = 0.0497] 
Data/restraints/parameters 5342/3/277 
Goodness-of-fit on F2 1.029 
Final R indexes [I>=2σ (I)] R1 = 0.0479, wR2 = 0.0909 
Final R indexes [all data] R1 = 0.0727, wR2 = 0.1023 
Largest diff. peak/hole / e Å-3 0.37/-0.39 
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Crystal data and structure refinement for L12 
Empirical formula C29H26N2OCl2 
Formula weight 489.42 
Temperature/K 99.9(4) 
Crystal system monoclinic 












Crystal size/mm3 0.33 × 0.15 × 0.12 
2Θ range for data collection 6.58 to 56.56° 
Index ranges -14 ≤ h ≤ 14, -27 ≤ k ≤ 33, -10 ≤ l ≤ 13 
Reflections collected 11440 
Independent reflections 6126[R(int) = 0.0397] 
Data/restraints/parameters 6126/3/307 
Goodness-of-fit on F2 1.042 
Final R indexes [I>=2σ (I)] R1 = 0.0493, wR2 = 0.1045 
Final R indexes [all data] R1 = 0.0679, wR2 = 0.1174 
Largest diff. peak/hole / e Å-3 0.81/-0.43 
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Crystal data and structure refinement for L13 
Empirical formula C24H22Cl2N2O 
Formula weight 425.33 
Temperature/K 120.0(2) 
Crystal system triclinic 












Crystal size/mm3 0.11 × 0.06 × 0.03 
2Θ range for data collection 5.946 to 56.564° 
Index ranges -10 ≤ h ≤ 11, -14 ≤ k ≤ 14, -15 ≤ l ≤ 15 
Reflections collected 15179 
Independent reflections 4984[R(int) = 0.0403] 
Data/restraints/parameters 4984/0/282 
Goodness-of-fit on F2 1.039 
Final R indexes [I>=2σ (I)] R1 = 0.0439, wR2 = 0.0871 
Final R indexes [all data] R1 = 0.0616, wR2 = 0.0947 
Largest diff. peak/hole / e Å-3 0.39/-0.52 
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Crystal data and structure refinement for L18 
Empirical formula C24H23N2OCl 
Formula weight 390.89 
Temperature/K 120.15 
Crystal system monoclinic 












Crystal size/mm3 0.46 × 0.35 × 0.19 
2Θ range for data collection 6.558 to 56.564° 
Index ranges -16 ≤ h ≤ 12, -17 ≤ k ≤ 11, -16 ≤ l ≤ 15 
Reflections collected 9414 
Independent reflections 4908[R(int) = 0.0382] 
Data/restraints/parameters 4908/1/257 
Goodness-of-fit on F2 1.071 
Final R indexes [I>=2σ (I)] R1 = 0.0446, wR2 = 0.0972 
Final R indexes [all data] R1 = 0.0583, wR2 = 0.1096 
Largest diff. peak/hole / e Å-3 0.26/-0.27 
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Crystal data and structure refinement for PM3-L20 
Empirical formula C6H10N2O4S 
Formula weight 206.22 
Temperature/K 119.98(16) 
Crystal system orthorhombic 












Crystal size/mm3 0.25 × 0.11 × 0.3 
2Θ range for data collection 12.38 to 146.5° 
Index ranges -9 ≤ h ≤ 9, -8 ≤ k ≤ 13, -12 ≤ l ≤ 17 
Reflections collected 2054 
Independent reflections 1084[R(int) = 0.0356] 
Data/restraints/parameters 1084/0/119 
Goodness-of-fit on F2 1.048 
Final R indexes [I>=2σ (I)] R1 = 0.0496, wR2 = 0.1227 
Final R indexes [all data] R1 = 0.0674, wR2 = 0.1347 
Largest diff. peak/hole / e Å-3 0.30/-0.47 
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Crystal data and structure refinement for C1 
Empirical formula C11H19N4O6Ag 
Formula weight 411.17 
Temperature/K 100.00(10) 
Crystal system monoclinic 












Crystal size/mm3 0.18 × 0.16 × 0.08 
2Θ range for data collection 5.32 to 56.56° 
Index ranges -11 ≤ h ≤ 8, -6 ≤ k ≤ 8, -12 ≤ l ≤ 18 
Reflections collected 3462 
Independent reflections 1985[R(int) = 0.0260] 
Data/restraints/parameters 1985/6/149 
Goodness-of-fit on F2 1.035 
Final R indexes [I>=2σ (I)] R1 = 0.0279, wR2 = 0.0665 
Final R indexes [all data] R1 = 0.0310, wR2 = 0.0687 
Largest diff. peak/hole / e Å-3 0.67/-0.49 
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Crystal data and structure refinement for C1.Cu 
Empirical formula C18H24Cu2I2N8O4 
Formula weight 797.33 
Temperature/K 120.02(10) 
Crystal system triclinic 












Crystal size/mm3 0.18 × 0.15 × 0.03 
2Θ range for data collection 6.56 to 59.4° 
Index ranges -10 ≤ h ≤ 10, -10 ≤ k ≤ 11, -14 ≤ l ≤ 13 
Reflections collected 5468 
Independent reflections 2820[R(int) = 0.0457] 
Data/restraints/parameters 2820/0/158 
Goodness-of-fit on F2 1.055 
Final R indexes [I>=2σ (I)] R1 = 0.0470, wR2 = 0.0777 
Final R indexes [all data] R1 = 0.0672, wR2 = 0.0883 
Largest diff. peak/hole / e Å-3 1.37/-1.18 
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Crystal data and structure refinement for C2 
Empirical formula C28H44N8O9Ag2 
Formula weight 852.45 
Temperature/K 100.0(2) 
Crystal system triclinic 












Crystal size/mm3 0.21 × 0.1 × 0.03 
2Θ range for data collection 5.86 to 56.56° 
Index ranges -12 ≤ h ≤ 12, -12 ≤ k ≤ 12, -25 ≤ l ≤ 25 
Reflections collected 24918 
Independent reflections 8239[R(int) = 0.0369] 
Data/restraints/parameters 8239/0/395 
Goodness-of-fit on F2 1.022 
Final R indexes [I>=2σ (I)] R1 = 0.0331, wR2 = 0.0712 
Final R indexes [all data] R1 = 0.0447, wR2 = 0.0764 
Largest diff. peak/hole / e Å-3 1.22/-0.57 
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Crystal data and structure refinement for C2.Ru 
Empirical formula C25H30N4O2Cl2Ru 
Formula weight 590.50 
Temperature/K 293(2) 
Crystal system orthorhombic 












Crystal size/mm3 0.30 × 0.26 × 0.11 
2Θ range for data collection 5.38 to 63.82° 
Index ranges -10 ≤ h ≤ 9, -20 ≤ k ≤ 20, -39 ≤ l ≤ 39 
Reflections collected 30747 
Independent reflections 8440[R(int) = 0.0521] 
Data/restraints/parameters 8440/0/140 
Goodness-of-fit on F2 1.721 
Final R indexes [I>=2σ (I)] R1 = 0.0503, wR2 = 0.1598 
Final R indexes [all data] R1 = 0.0558, wR2 = 0.2092 
Largest diff. peak/hole / e Å-3 1.57/-2.09 
Flack parameter -0.10(5) 
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Crystal data and structure refinement for C3 
Empirical formula C17H19N4O4Ag 
Formula weight 451.23 
Temperature/K 200.15 
Crystal system triclinic 












Crystal size/mm3 0.24 × 0.08 × 0.05 
2Θ range for data collection 6.6 to 56.76° 
Index ranges -7 ≤ h ≤ 10, -12 ≤ k ≤ 12, -16 ≤ l ≤ 16 
Reflections collected 13274 
Independent reflections 4315[R(int) = 0.1124] 
Data/restraints/parameters 4315/0/240 
Goodness-of-fit on F2 1.061 
Final R indexes [I>=2σ (I)] R1 = 0.0774, wR2 = 0.1653 
Final R indexes [all data] R1 = 0.1181, wR2 = 0.1792 
Largest diff. peak/hole / e Å-3 1.86/-0.92 
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Crystal data and structure refinement for C3.Ru 
Empirical formula C25H30N4O2Cl2Ru 
Formula weight 590.50 
Temperature/K 120.00(10) 
Crystal system orthorhombic 












Crystal size/mm3 0.23 × 0.15 × 0.08 
2Θ range for data collection 6.46 to 59.42° 
Index ranges -9 ≤ h ≤ 7, -25 ≤ k ≤ 26, -21 ≤ l ≤ 27 
Reflections collected 16203 
Independent reflections 5939[R(int) = 0.1042] 
Data/restraints/parameters 5939/0/313 
Goodness-of-fit on F2 0.942 
Final R indexes [I>=2σ (I)] R1 = 0.0758, wR2 = 0.1578 
Final R indexes [all data] R1 = 0.1140, wR2 = 0.1837 
Largest diff. peak/hole / e Å-3 1.27/-1.10 
Flack parameter 0.05(7) 
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Crystal data and structure refinement for C4 
Empirical formula C16H17N4O4Ag 
Formula weight 437.21 
Temperature/K 99.9(5) 
Crystal system triclinic 












Crystal size/mm3 0.2 × 0.12 × 0.06 
2Θ range for data collection 6.34 to 56.56° 
Index ranges -11 ≤ h ≤ 11, -13 ≤ k ≤ 10, -9 ≤ l ≤ 13 
Reflections collected 6438 
Independent reflections 4023[R(int) = 0.0405] 
Data/restraints/parameters 4023/0/230 
Goodness-of-fit on F2 1.043 
Final R indexes [I>=2σ (I)] R1 = 0.0430, wR2 = 0.0756 
Final R indexes [all data] R1 = 0.0531, wR2 = 0.0836 
Largest diff. peak/hole / e Å-3 0.74/-0.78 
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Crystal data and structure refinement for C7 
Empirical formula C106.5H106N8Cl6Ag4I2 
Formula weight 2395.97 
Temperature/K 99.93(16) 
Crystal system monoclinic 












Crystal size/mm3 0.14 × 0.06 × 0.04 
2Θ range for data collection 6.56 to 113.84° 
Index ranges -20 ≤ h ≤ 19, -18 ≤ k ≤ 25, -26 ≤ l ≤ 21 
Reflections collected 27795 
Independent reflections 14093[R(int) = 0.1021] 
Data/restraints/parameters 14093/8/1160 
Goodness-of-fit on F2 0.976 
Final R indexes [I>=2σ (I)] R1 = 0.1000, wR2 = 0.2512 
Final R indexes [all data] R1 = 0.1859, wR2 = 0.3281 
Largest diff. peak/hole / e Å-3 1.92/-2.21 
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Crystal data and structure refinement for C13B 
Empirical formula C48H40AgCl3N4O2 
Formula weight 919.06 
Temperature/K 119.98(18) 
Crystal system monoclinic 












Crystal size/mm3 0.12 × 0.08 × 0.06 
2Θ range for data collection 6.14 to 50.06° 
Index ranges -24 ≤ h ≤ 25, -17 ≤ k ≤ 17, -16 ≤ l ≤ 16 
Reflections collected 13428 
Independent reflections 3919[R(int) = 0.0858] 
Data/restraints/parameters 3919/1/275 
Goodness-of-fit on F2 1.042 
Final R indexes [I>=2σ (I)] R1 = 0.1018, wR2 = 0.2844 
Final R indexes [all data] R1 = 0.1554, wR2 = 0.3228 
Largest diff. peak/hole / e Å-3 1.49/-0.64 
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Crystal data and structure refinement for C14 
Empirical formula C23H20N2ClAg 
Formula weight 467.73 
Temperature/K 110.01(10) 
Crystal system monoclinic 












Crystal size/mm3 0.41 × 0.16 × 0.14 
2Θ range for data collection 6.24 to 56.56° 
Index ranges -18 ≤ h ≤ 17, -9 ≤ k ≤ 13, -20 ≤ l ≤ 20 
Reflections collected 15088 
Independent reflections 4992[R(int) = 0.0523] 
Data/restraints/parameters 4992/0/245 
Goodness-of-fit on F2 1.253 
Final R indexes [I>=2σ (I)] R1 = 0.0757, wR2 = 0.1738 
Final R indexes [all data] R1 = 0.0850, wR2 = 0.1784 
Largest diff. peak/hole / e Å-3 4.70/-0.82 
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Crystal data and structure refinement for C15 
Empirical formula C25H22N2ClAg 
Formula weight 493.77 
Temperature/K 120.01(10) 
Crystal system monoclinic 












Crystal size/mm3 0.5 × 0.39 × 0.29 
2Θ range for data collection 5.92 to 61° 
Index ranges -8 ≤ h ≤ 10, -12 ≤ k ≤ 14, -19 ≤ l ≤ 19 
Reflections collected 10205 
Independent reflections 5255[R(int) = 0.0591] 
Data/restraints/parameters 5255/1/262 
Goodness-of-fit on F2 1.081 
Final R indexes [I>=2σ (I)] R1 = 0.0377, wR2 = 0.0926 
Final R indexes [all data] R1 = 0.0387, wR2 = 0.0939 
Largest diff. peak/hole / e Å-3 0.55/-0.69 
Flack parameter 0.00(3) 
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Crystal data and structure refinement for C17 
Empirical formula C58.75H49.5AgCl2.5N4O0.25 
Formula weight 1012.02 
Temperature/K 120.0(2) 
Crystal system monoclinic 












Crystal size/mm3 0.2166 × 0.1046 × 0.0771 
2Θ range for data collection 6.02 to 56.56° 
Index ranges -17 ≤ h ≤ 17, -23 ≤ k ≤ 25, -26 ≤ l ≤ 26 
Reflections collected 55175 
Independent reflections 12129[R(int) = 0.0473] 
Data/restraints/parameters 12129/2/620 
Goodness-of-fit on F2 1.051 
Final R indexes [I>=2σ (I)] R1 = 0.0564, wR2 = 0.1381 
Final R indexes [all data] R1 = 0.0728, wR2 = 0.1493 
Largest diff. peak/hole / e Å-3 1.21/-1.70 
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Crystal data and structure refinement for C28 
Empirical formula C7H9AgN2O2 
Formula weight 261.03 
Temperature/K 120.00(10) 
Crystal system monoclinic 












Crystal size/mm3 0.09 × 0.04 × 0.03 
2Θ range for data collection 6.08 to 52.74° 
Index ranges -11 ≤ h ≤ 10, -12 ≤ k ≤ 12, -11 ≤ l ≤ 9 
Reflections collected 4909 
Independent reflections 1719[R(int) = 0.0502] 
Data/restraints/parameters 1719/0/111 
Goodness-of-fit on F2 1.076 
Final R indexes [I>=2σ (I)] R1 = 0.0711, wR2 = 0.1356 
Final R indexes [all data] R1 = 0.1285, wR2 = 0.1620 
Largest diff. peak/hole / e Å-3 1.27/-2.00 
 
